

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPAL600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/Caplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/Caplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/Caplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	Caplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/Caplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/Caplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment

NEWS 35 JAN 28 MEDLINE and LMedLINE reloaded with enhancements
NEWS 36 FEB 08 STN Express, Version 8.3, now available

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:12:41 ON 14 FEB 2008

=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:12:55 ON 14 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6
DICTIONARY FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10577841.str



```

chain nodes :
14 15 16 17 18 19 20 21 26 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-14 2-18 3-19 5-21 6-20 7-17 15-16 15-17 15-21 15-26 26-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-12 7-8 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-6 1-14 2-3 2-18 3-4 3-19 4-5 5-6 5-21 6-20 7-17 15-16 15-17
15-21 15-26 26-27
normalized bonds :
7-12 7-8 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

```

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 26:CLASS 27:CLASS

```

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:13:30 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2 TO 124

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 12:13:33 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 21 TO ITERATE

100.0% PROCESSED 21 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=> fil stnguide

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'STNGUIDE' ENTERED AT 12:13:41 ON 14 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Feb 8, 2008 (20080208/UP).

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.06

178.63

FILE 'REGISTRY' ENTERED AT 12:14:21 ON 14 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6

DICTIONARY FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of

experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10577841.str



```
chain nodes :
14 15 16 17 18 19 20 21 26 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-14 2-18 3-19 5-21 6-20 7-17 15-16 15-17 15-21 15-26 26-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-12 7-8 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-6 1-14 2-3 2-18 3-4 3-19 4-5 5-6 5-21 6-20 7-17 15-16 15-17
15-21 15-26 26-27
normalized bonds :
7-12 7-8 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :
```

Match level :

```
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 26:CLASS 27:CLASS
```

L4 STRUCTURE UPLOADED

=> d

L4 HAS NO ANSWERS

L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 14

SAMPLE SEARCH INITIATED 12:14:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS 7 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 9 TO 360
PROJECTED ANSWERS: 7 TO 298

L5 7 SEA SSS SAM L4

=> s 14 full

FULL SEARCH INITIATED 12:14:47 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 253 TO ITERATE

100.0% PROCESSED 253 ITERATIONS 159 ANSWERS

SEARCH TIME: 00.00.01

L6 159 SEA SSS FUL L4

=> s 16 and caplus/lc
56059609 CAPLUS/LC

L7 119 L6 AND CAPLUS/LC

=> s 16 not 17


L8 40 L6 NOT L7

=> s 18 35-40
MISSING OPERATOR

=> d 18 35-40

LS ANSWER 35 OF 40 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 75484-59-2 REGISTRY
 ED Entered EFTN: 09 Oct 2004
 CN 2-Morpholinamethanol, m-[(2-methoxyphenyl)methyl]-m-phenyl-,
 (4R,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 R23 N O3
 CI OOH
 SA CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

LS ANSWER 36 OF 40 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 75740-98-0 REGISTRY
 ED Entered EFTN: 07 Oct 2004
 CN 2-Morpholinamethanol, m-[(2-methylphenyl)methyl]-m-phenyl-,
 (4R,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 R23 N O2
 CI OOH
 SA CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

LS ANSWER 37 OF 40 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 75570-01-3 REGISTRY
 ED Entered EFTN: 24 Sep 2004
 CN 2-Morpholinamethanol, m-[(2-methoxyphenyl)methyl]-m-phenyl-,
 (4R,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 R23 N O3
 CI OOH
 SA CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

LS ANSWER 38 OF 40 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 744156-20-1 REGISTRY
 ED Entered EFTN: 14 Sep 2004
 CN 2-Morpholinamethanol, m-[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-
 m-phenyl-, (4R,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 R24 F N O2
 CI OOH
 SA CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

LR NUMBER 39 OF 40 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 731913-60-7 REGISTRY
 ED Entered STM: 26 Aug 2004
 CN 2-Morpholinemetanol, *m*-[2-(1-methylethoxyphenyl)methyl]-*m*-phenyl-, (R₂,2S)- (CA INDEX NAME)
 FS STEREOBOND
 MF C12 R21 N O3
 CI OAH
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

LR NUMBER 40 OF 40 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 701907-86-0 REGISTRY
 ED Entered STM: 30 Jan 2004
 CN 2-Morpholinemetanol, *m*-([1,1'-bisphenyl]-2-ylmethyl)-*m*-phenyl-, (R₂,2S)- (CA INDEX NAME)
 FS STEREOBOND
 MF C24 R25 N O2
 CI OAH
 SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	195.97	374.60

FILE 'CAPLUS' ENTERED AT 12:15:15 ON 14 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Feb 2008 VOL 148 ISS 7
 FILE LAST UPDATED: 13 Feb 2008 (20080213/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 12:12:41 ON 14 FEB 2008)

FILE 'REGISTRY' ENTERED AT 12:12:55 ON 14 FEB 2008

L1	STRUCTURE UPLOADED
L2	0 S L1
L3	0 S L1 FULL

FILE 'STNGUIDE' ENTERED AT 12:13:41 ON 14 FEB 2008

FILE 'REGISTRY' ENTERED AT 12:14:21 ON 14 FEB 2008

L4	STRUCTURE UPLOADED
L5	7 S L4
L6	159 S L4 FULL
L7	119 S L6 AND CAPLUS/LC
L8	40 S L6 NOT L7

FILE 'CAPLUS' ENTERED AT 12:15:15 ON 14 FEB 2008

=> s l7

L9	10 L7
----	-------

=> d ibib abs hitstr 1-10

19 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 ACCESSION NUMBER: 2009;95116 CAPLUS
 TITLE: Biomarker-guided attention deficit-hyperactivity disorder (ADHD) treatment with selective norepinephrine reuptake inhibitors
 INVENTOR(S): Lawrence, Donald Gilbert
 PATENT ASSIGNER(S): USA
 SOURCE: U.S. Pat. Appl. Publ., App. 2006/008009 P
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2009020787	AL	20090214	US 2007-074909	20070730
PRIORITY APPL. INFO.			US 2006-788009 P	20060331

AB The invention provides methods for predicting patient responsiveness to treatment of attention-deficit/hyperactivity disorder (ADHD) with selective norepinephrine reuptake inhibitors identifying individuals requiring a higher than normal dose of atomoxetine for treating ADHD and predicting patient responsiveness to treatment of neuropsychiatric diseases or disorders responsive to treatment with selective norepinephrine reuptake inhibitors are provided. These methods are based on the identification of the variable number of tandem repeats (VNTR) polymorphism present in the 3'-untranslated region of the human dopamine transporter 1 (DAT 1) gene present in patient body fluid or tissue samples. Patients with a 10/10 VNTR genotype are considered poor responders to treatment with atomoxetine and other selective norepinephrine reuptake inhibitors for the indicated conditions.


IT 052376-02-9 052377-04-8 052377-04-09, salts
 RU PKC (Pharmacological activity); TMO (Therapeutic use); RIGS (Pharmacological study); URES (Uses)
 (Biomarker-guided attention deficit-hyperactivity disorder and neuropsychiatric disorder treatment with selective norepinephrine reuptake inhibitors)
 RU 052376-02-9 CAPLUS
 CN 2-Morpholinomethanol, α -[5-fluoro-2-methoxyphenylmethyl]- ω -[tetrahydro-2H-pyran-4-yl]-, hydrochloride (1:1), (4a,2b)-rel- (CA INDEX NAME)

Relative stereochemistry.


19 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 ACCESSION NUMBER: 2009;95116 CAPLUS
 TITLE: Biomarker-guided attention deficit-hyperactivity disorder (ADHD) treatment with selective norepinephrine reuptake inhibitors
 INVENTOR(S): Lawrence, Donald Gilbert
 PATENT ASSIGNER(S): USA
 SOURCE: U.S. Pat. Appl. Publ., App. 2006/008009 P
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2009020787	AL	20090214	US 2007-074909	20070730
PRIORITY APPL. INFO.			US 2006-788009 P	20060331

RU 052377-04-8 CAPLUS
 CN 2-Morpholinomethanol, α -[5-fluoro-2-methoxyphenylmethyl]- ω -[tetrahydro-2H-pyran-4-yl]-, (4a,2b)-rel- (CA INDEX NAME)
 Relative stereochemistry.



RU 052377-04-8 CAPLUS
 CN 2-Morpholinomethanol, α -[5-fluoro-2-methoxyphenylmethyl]- ω -[tetrahydro-2H-pyran-4-yl]-, (4a,2b)-rel- (CA INDEX NAME)
 Relative stereochemistry.



19 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)

19 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2008 ACS on STM
 ACCESSION NUMBER: 2009;131209 CAPLUS
 DOCUMENT NUMBER: 146123523
 TITLE: Synthesis of 11C-labelled (R)-OHMI and CPME and their evaluation as candidate radioligands for PET
 AUTHOR(S): Schen, Magnus; Fife, Victor W.; Savage, Judith; Walters, Balazs; Gallagher, Peter T.; Debono, David S.; Magnus W.; Roddy, Helene; Farde, Lars; Balldin, Christer
 CORPORATE SOURCE: Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital, Stockholm, S-17176, Swed.
 SOURCE: Bioorganic & Medicinal Chemistry (2007), 15(12), 616-625
 CODEN: BMCEEP; ISSN: 0968-0896
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CORDISACT 146123523

AB (R)-1-(10,11-Dihydro-silbenolol,fla)epine-5-yl-3-methylamino-propan-2-ol ((R)-OHMI) and (R)-2-epineptol-3-(5-fluoro-2-methoxy-phenyl)-2-morpholin-2-yl-ethanol (CPME) were synthesized and found to be potent inhibitors of norepinephrine reuptake. Each was labeled efficiently in its Me group with carbon-11 (t1/2 = 20.4 min) as a prospective radioligand for imaging brain norepinephrine transporters (NET) with positron emission tomography (PET). The uptake and distribution of radioactivity in brain following i.v. injection of each radioligand into synovectomized mice was examined in vivo with PET. After injection of (R)-[11C]OHMI, the maximal whole brain uptake of radioactivity was very low (1.1% of injected dose) i.d.). For occipital cortex, thalamus, lower brainstem, mammillary and cerebellum, radioactivity ratios to striatum at 93 min after radioligand injection were 1.35, 1.25, 1.2, 1.2 and 1.0, resp. After injection of [11C]CPME, radioactivity readily entered brain (1.5% i.d.). Ratios of radioactivity to cerebellum at 93 min for thalamus, occipital cortex, region of locus coeruleus, mesencephalon and striatum were 1.25, 1.7, 1.2 and 1.3, resp. Radioactive metabolites in plasma were measured by radio-HPLC. (R)-[11C]OHMI represented 73% of plasma radioactivity at 8 min after injection and 68 at 30 min. After injection of [11C]CPME, 68% of the radioactivity in plasma represented parent at 8 min and 20% at 30 min. Since the two new hydroxylated radioligands provide only modest regional differentiation in brain uptake and form potentially troublesome lipophilic radioactive metabolites, they are concluded to be inferior to existing radioligands, such as (S)-[11C]MAG3, (S)-[11C]MAG3-D2 and (S)-[11C]PEB-D4, for the study of brain NETs with PET in vivo.
 IT 952327-02-39
 RU RDN (Diagnostic use); PET (Pharmacokinetics); SW (Synthetic preparation); RIGS (Biological study); PREP (Preparation); URES (Uses)
 (Preparation of 11C-labeled (R)-OHMI and CPME as candidate radioligands for PET imaging of central norepinephrine transporters)



● 9C1

99 852236-29-4 CAPLUS
 CH 2-Morpholinomethanol, 4-methyl-4-[(5-fluoro-2-methoxyphenyl)methyl]-, hydrochloride (9C1) (CA INDEX NAME)




● 9C1

99 852236-31-8 CAPLUS
 CH 2-Morpholinomethanol, 4-ethyl-4-[(2-trifluoromethoxyphenyl)methyl]-, hydrochloride (9C1) (CA INDEX NAME)




● 9C1

99 852236-33-0 CAPLUS
 CH 2-Morpholinomethanol, 4-[[1,1'-biphenyl]-2-ylmethyl]-4-ethyl-, hydrochloride (9C1) (CA INDEX NAME)



99 852236-39-6 CAPLUS
 CH 2-Morpholinomethanol, 4-[(2-methoxyphenyl)methyl]-4-ethyl-, hydrochloride (9C1) (CA INDEX NAME)


Relative stereochemistry.



● 9C1

99 852236-40-3 CAPLUS
 CH 2-Morpholinomethanol, 4-[(2-methoxyphenyl)methyl]-4-ethyl-, hydrochloride (9C1) (CA INDEX NAME)

Relative stereochemistry.



● 9C1

99 852236-42-2 CAPLUS
 CH 2-Morpholinomethanol, 4-[(2-methoxyphenyl)methyl]-4-ethyl-, hydrochloride (9C1) (CA INDEX NAME)

Relative stereochemistry.



● 9C1


99 852236-35-2 CAPLUS
 CH 2-Morpholinomethanol, 4-[(5-fluoro-2-methoxyphenyl)methyl]-4-ethyl-, hydrochloride (9C1) (CA INDEX NAME)



● 9C1


99 852236-37-4 CAPLUS
 CH 2-Morpholinomethanol, 4-[(2-methoxyphenyl)methyl]-4-ethyl-, hydrochloride (9C1) (CA INDEX NAME)

Relative stereochemistry.




99 852236-38-5 CAPLUS
 CH 2-Morpholinomethanol, 4-[(2-methoxyphenyl)methyl]-4-ethyl-, hydrochloride (9C1) (CA INDEX NAME)

Relative stereochemistry.




99 852236-43-2 CAPLUS
 CH 2-Morpholinomethanol, 4-[(2-methoxyphenyl)methyl]-4-ethyl-, hydrochloride (9C1) (CA INDEX NAME)

Relative stereochemistry.



99 852236-44-3 CAPLUS
 CH 2-Morpholinomethanol, 4-[(2-methoxyphenyl)methyl]-4-ethyl-, hydrochloride (9C1) (CA INDEX NAME)


Relative stereochemistry.



● 9C1

99 852236-45-4 CAPLUS
 CH 2-Morpholinomethanol, 4-[(2-methoxyphenyl)methyl]-4-ethyl-, hydrochloride (9C1) (CA INDEX NAME)

Relative stereochemistry.



● RCI

852236-47-6 CAPLUS
 2-Morpholinemetanol, ω -[1-methylethyl]- ω -[2-(4-ethoxyphenyl)propyl]methyl-, hydrochloride (RCI) (CA INDEX NAME)




● RCI

852236-49-3 CAPLUS
 2-Morpholinemetanol, ω -[1,1'-biphenyl]-2-ylmethyl]- ω -[1-methylethyl]-, hydrochloride (RCI) (CA INDEX NAME)



● RCI

852236-51-2 CAPLUS
 2-Morpholinemetanol, ω -[4-fluoro[1,1'-biphenyl]-2-yl]methyl]- ω -[1-methylethyl]-, hydrochloride (RCI) (CA INDEX NAME)



852236-59-9 CAPLUS
 2-Morpholinemetanol, ω -[2-methylpropyl]- ω -[2-(4-ethoxyphenyl)propyl]methyl-, hydrochloride (RCI) (CA INDEX NAME)



● RCI

852236-62-3 CAPLUS
 2-Morpholinemetanol, ω -[1,1'-biphenyl]-2-ylmethyl]- ω -[2-methylpropyl]-, hydrochloride (RCI) (CA INDEX NAME)



852236-63-6 CAPLUS
 2-Morpholinemetanol, ω -[1,1'-biphenyl]-2-ylmethyl]- ω -[2-methylpropyl]-, hydrochloride (RCI) (CA INDEX NAME)



● RCI



● RCI


852236-53-4 CAPLUS
 2-Morpholinemetanol, ω -[5-fluoro-2-methoxyphenyl]methyl]- ω -[2-methylpropyl]-, hydrochloride (RCI) (CA INDEX NAME)



● RCI

852236-55-6 CAPLUS
 2-Morpholinemetanol, ω -[2-ethoxyphenyl]methyl]- ω -[2-methylpropyl]-, (4R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



852236-56-7 CAPLUS
 2-Morpholinemetanol, ω -[2-ethoxyphenyl]methyl]- ω -[2-methylpropyl]-, (4R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.

852236-65-8 CAPLUS
 2-Morpholinemetanol, ω -[4-fluoro[1,1'-biphenyl]-2-yl]methyl]- ω -[2-methylpropyl]-, hydrochloride (RCI) (CA INDEX NAME)



● RCI

852236-66-9 CAPLUS
 2-Morpholinemetanol, ω -[4-fluoro[1,1'-biphenyl]-2-yl]methyl]- ω -[2-methylpropyl]-, hydrochloride (RCI) (CA INDEX NAME)



852236-68-1 CAPLUS
 2-Morpholinemetanol, ω -cyclopentyl]- ω -[5-fluoro-2-methoxyphenyl]methyl]-, hydrochloride (RCI) (CA INDEX NAME)



● RCI

852236-70-5 CAPLUS
 2-Morpholinemetanol, ω -cyclopentyl]- ω -[2-ethoxyphenyl]methyl]-, hydrochloride (RCI) (CA INDEX NAME)



● HCl

RR 852336-72-7 CAPLOS
CN 2-Morpholinomethanol, 4-[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9C1) (CA INDEX NAME)



● HCl

RR 852336-74-9 CAPLOS
CN 2-Morpholinomethanol, 4-[[1,1'-biphenyl]-2-ylmethyl]-, hydrochloride (9C3) (CA INDEX NAME)



● HCl


RR 852336-76-1 CAPLOS

RR 852431-21-1 CAPLOS
CN 2-Morpholinomethanol, 4-[[1,1'-biphenyl]-2-ylmethyl]-, hydrochloride (CA INDEX NAME)



RR 854339-91-6 CAPLOS
CN 2-Morpholinomethanol, 4-[[4-fluoro[1,1'-biphenyl]-2-yl]methyl]-, hydrochloride, (4R,2S)-rel- (9C2) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RR 857642-38-7 CAPLOS
CN 2-Morpholinomethanol, 4-[[2-methoxyphenyl]methyl]-, hydrochloride, (4R,2S)-rel- (9C1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RR 857642-40-1 CAPLOS
CN 2-Morpholinomethanol, 4-[[2-methoxyphenyl]methyl]-, hydrochloride, (4R,2S)-rel- (9C1) (CA INDEX NAME)



● HCl

RR 852336-78-9 CAPLOS
CN 2-Morpholinomethanol, 4-[[5-fluoro-2-methoxyphenyl]methyl]-, hydrochloride (9C1) (CA INDEX NAME)




● HCl

RR 852336-84-1 CAPLOS
CN 2-Morpholinomethanol, 4-[[tetrahydro-2H-pyran-4-yl]-[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9C1) (CA INDEX NAME)



● HCl


Relative stereochemistry.



● HCl

RR 857642-41-2 CAPLOS
CN 2-Morpholinomethanol, 4-[[2-[1-methyl-2-phenyl-1-ethoxy]phenyl]methyl]-, hydrochloride, (4R,2S)-rel- (9C1) (CA INDEX NAME)


Relative stereochemistry.




● HCl

RR 857642-42-3 CAPLOS
CN 2-Morpholinomethanol, 4-[[2-methoxyphenyl]methyl]-, hydrochloride, (4R,2S)-rel- (9C1) (CA INDEX NAME)

Relative stereochemistry.






● RCI

RI 857442-43-4 CAPLUS
 CH 2-Morpholinomethyl, ω -phenyl- ω -[12-
 (trifluoromethyl)phenyl]methyl-, hydrochloride, (4R,2S)-rel- (PCI) (CA INDEX NAME)


Relative stereochemistry.



● RCI

RI 857442-44-5 CAPLUS
 CH 2-Morpholinomethyl, ω -[1,1'-biphenyl]-2-ylmethyl- ω -phenyl-,
 hydrochloride, (4R,2S)-rel- (PCI) (CA INDEX NAME)

Relative stereochemistry.



● RCI



● RCI

RI 857442-61-6 CAPLUS
 CH 2-Morpholinomethyl, ω -[5-fluoro-2-hydroxyphenyl]methyl- ω -
 phenyl-, (CA INDEX NAME)




RI 857442-62-7 CAPLUS
 CH 2-Morpholinomethyl, ω -[4'-methyl[1,1'-biphenyl]-2-yl]methyl-
 ω -phenyl-, (CA INDEX NAME)



RI 857442-63-8 CAPLUS
 CH 2-Morpholinomethyl, ω -[4'-chloro[1,1'-biphenyl]-2-yl]methyl-
 ω -phenyl-, (CA INDEX NAME)

RI 857442-52-5 CAPLUS
 CH 2-Morpholinomethyl, ω -[12-methylphenyl]methyl- ω -phenyl-,
 hydrochloride, (4R,2S)-rel- (PCI) (CA INDEX NAME)


Relative stereochemistry.



● RCI

RI 857442-59-2 CAPLUS
 CH 2-Morpholinomethyl, ω -[2'-chloro[1,1'-biphenyl]-2-yl]methyl-
 ω -phenyl-, hydrochloride, (4R,2S)-rel- (PCI) (CA INDEX NAME)

Relative stereochemistry.




● RCI

RI 857442-60-5 CAPLUS
 CH 2-Morpholinomethyl, ω -[5-fluoro-2-hydroxyphenyl]methyl- ω -
 phenyl-, hydrochloride (PCI) (CA INDEX NAME)



RI 857442-64-9 CAPLUS
 CH 2-Morpholinomethyl, ω -[4'-methoxy[1,1'-biphenyl]-2-yl]methyl-
 ω -phenyl-, (CA INDEX NAME)



RI 857442-65-0 CAPLUS
 CH 2-Morpholinomethyl, ω -[3'-fluoro[1,1'-biphenyl]-2-yl]methyl-
 ω -phenyl-, (CA INDEX NAME)



RI 857442-66-1 CAPLUS
 CH 2-Morpholinomethyl, ω -[3'-chloro[1,1'-biphenyl]-2-yl]methyl-
 ω -phenyl-, (CA INDEX NAME)




RII 857642-67-2 CAPLUS
CH 2-Morpholinomethyl, 4-([3'-methoxy[1,1'-biphenyl]-2-yl)methyl]-
-phenyl- (CA INDEX NAME)



RII 857642-68-3 CAPLUS
CH 2-Morpholinomethyl, 4-([3'-methyl[1,1'-biphenyl]-2-yl)methyl]-
-phenyl- (CA INDEX NAME)




RII 857642-69-4 CAPLUS
CH 2-Morpholinomethyl, 4-([3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]-
-phenyl- (CA INDEX NAME)



RII 857642-70-7 CAPLUS
CH 2-Morpholinomethyl, 4-([2',4'-dimethyl[1,1'-biphenyl]-2-yl)methyl]-
-phenyl- (CA INDEX NAME)



RII 857642-71-8 CAPLUS
CH 2-Morpholinomethyl, 4-([2',4'-dimethyl[1,1'-biphenyl]-2-yl)methyl)-
-phenyl- (CA INDEX NAME)




RII 857642-71-8 CAPLUS
CH 2-Morpholinomethyl, 4-([2',4'-dimethyl[1,1'-biphenyl]-2-yl)methyl)-
-phenyl- (CA INDEX NAME)

ACCESSION NUMBER: 2005153264 CAPLUS
DOCUMENT NUMBER: 14359831
TITLE: A preparation of aminopiperidine derivatives, useful for the treatment of cognitive failure
Hutfield, Alan Kramer; Synaster, Franklin; Barter, McKenzie, David Lee; Tucker, Tina Marie; Reaffaber, Kirk Matthew; Sumner, Calvin Russell; Torgerson, Paula Terese; Allen, Albert John; Easley, Douglas Kenneth; Nicholson, David; Gehlert, Donald Richard; Yang, Charles Benito
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 200 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
CODING: F10A02
FAMILY ACC. MEM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023662	A2	20050616	WO 2004-037719	20041124
US 2005023663	A3	20050811		
<p>W: AK, AG, AL, AM, AT, AU, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, DE, DK, DM, ES, EC, EE, EG, EP, FI, GB, GR, HU, IE, JP, KR, LK, LU, LV, MC, MD, ME, MG, MK, MN, MU, MX, MY, NZ, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, TJ, TM, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZW, ZY</p> <p>RI: BM, GB, GR, HK, IL, IN, JP, KR, RU, SD, SL, ST, TH, TR, UA, US, UZ, VC, VN, YU, ZA, ZW, ZY</p> <p>RE: ES, FI, FR, GB, GR, HU, IE, IT, LV, MC, NL, PL, PT, RO, RU, SI, SE, TR, UA, US, UZ, VC, VN, YU, ZA, ZW, ZY</p>				
PRIORITY APPL. INFO.:			US 2003-524409	P 20031124
			US 2003-524781	P 20031125

OTHER SOURCE(S): NABPAT 14359831
CI



AB The invention relates to a preparation of aminopiperidine deriva of
Formula 1
[wherein: x is 1-3; R1 is (un)substituted phenyl; R2 and R3 are
independently ar or alkyl; R3 is (cyclo)alkyl, alkyl, or
cycloalkylalkyl,

19 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 etc.; R4 is H, halogen, or OR, etc.; R5 is H, halogen, CH, or alkyl,
 etc.; useful for the treatment of cognitive failure. Selective
 norepinephrine reuptake inhibitors were used to treat cognitive failure.
 For instance, fumarate salt of amipipiperidine deriv. II was prep'd via
 imination of 2-fluoromethylpyridine by tert-Bu 4-[[2-
 methylpropyl]amino]piperidine-1-carboxylate, redb. of the obtained imine,
 and subsequent fumaric acid salt formation. The preferred in vivo
 comp'd. exhibit Ki values less than 500 nM at the norepinephrine
 transporter.

IT 664360-72-3P 664360-73-3P 664360-74-1P
 664360-75-2P 664360-76-3P 664360-77-4P
 664360-78-4P 664360-82-1P 664360-84-3P
 664360-88-7P 664360-89-8P 664360-92-6P
 664360-92-7P 664360-93-8P 664360-94-9P
 664360-95-0P 664360-96-1P 664360-97-2P
 664360-98-3P 664360-99-4P 664360-99-4P
 66440-01-1P 66440-04-8P
 R4: PNC (Pharmacological activity); STM (Synthetic preparation); TMD
 (Toxicological use); R10L (Biological study); PREP (Preparation); USES
 (Uses)
 [preparation of amipipiperidine deriva. useful for the treatment of
 cognitive failure]

RII 664360-72-3 CAPLUS
 CN 2-Morpholinemetanol, ω -[[2-methoxyphenyl]methyl]- ω -phenyl-,
 hydrochloride, (aB,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● RCI


RII 664360-73-0 CAPLUS
 CN 2-Morpholinemetanol, ω -[[2-ethoxyphenyl]methyl]- ω -phenyl-,
 hydrochloride, (aB,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

19 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)

RII 664360-74-3 CAPLUS
 CN 2-Morpholinemetanol, ω -phenyl- ω -[[2-(
 trifluoromethoxy)phenyl]methyl]-, hydrochloride, (aB,2S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



● RCI

RII 664360-77-4 CAPLUS
 CN 2-Morpholinemetanol, ω -[[1,1'-biphenyl]-2-ylmethyl]- ω -phenyl-,
 hydrochloride, (aB,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● RCI

RII 664360-79-6 CAPLUS
 CN 2-Morpholinemetanol, ω -[[5-fluoro-2-methoxyphenyl]methyl]- ω -
 phenyl-, hydrochloride, (aB,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


19 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



● RCI

RII 664360-74-1 CAPLUS
 CN 2-Morpholinemetanol, ω -[[2-(1-methyltetrahydropyridyl)methyl]- ω -
 phenyl-, hydrochloride, (aB,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● RCI


RII 664360-75-2 CAPLUS
 CN 2-Morpholinemetanol, ω -[[3-fluorophenyl]- ω -[[2-
 methoxyphenyl]methyl]-, hydrochloride, (aB,2S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



● RCI


19 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



● RCI


RII 664360-82-1 CAPLUS
 CN 2-Morpholinemetanol, ω -phenyl- ω -[[2-(
 trifluoromethyl)phenyl]methyl]-, (aB,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RII 664360-84-3 CAPLUS
 CN 2-Morpholinemetanol, ω -[[2-methylphenyl]methyl]- ω -phenyl-,
 hydrochloride, (aB,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● RCI

RII 664360-88-7 CAPLUS
 CN 2-Morpholinemetanol, ω -[[2'-chloro[1,1'-biphenyl]-2-ylmethyl]- ω -
 phenyl-, hydrochloride, (aB,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

HN 554139-92-6 CAPLUS
CN 2-Morpholinomethanol, ω -[4-chloro[1,1'-biphenyl]-2-yl)methyl]-
-phenyl-, hydrochloride, (aR,2S)-(9C1) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

HN 554139-92-6 CAPLUS
CN 2-Morpholinomethanol, ω -[4-fluoro[1,1'-biphenyl]-2-yl)methyl]-
-phenyl-, hydrochloride, (aR,2S)-(9C1) (CA INDEX NAME)

Relative stereochemistry.




● HCl




HN 554139-92-0 CAPLUS
CN 2-Morpholinomethanol, ω -[3'-fluoro[1,1'-biphenyl]-2-yl)methyl]-
-phenyl-, (aR,2S)-(9C1) (CA INDEX NAME)

Relative stereochemistry.



HN 554139-94-1 CAPLUS
CN 2-Morpholinomethanol, ω -[3'-chloro[1,1'-biphenyl]-2-yl)methyl]-
-phenyl-, (aR,2S)-(9C1) (CA INDEX NAME)

Relative stereochemistry.




HN 554139-97-2 CAPLUS
CN 2-Morpholinomethanol, ω -[3'-methoxy[1,1'-biphenyl]-2-yl)methyl]-
-phenyl-, (aR,2S)-(9C1) (CA INDEX NAME)

Relative stereochemistry.


HN 554139-92-7 CAPLUS
CN 2-Morpholinomethanol, ω -[4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-
-phenyl-, (aR,2S)-(9C1) (CA INDEX NAME)

Relative stereochemistry.




HN 554139-93-8 CAPLUS
CN 2-Morpholinomethanol, ω -[4'-chloro[1,1'-biphenyl]-2-yl)methyl]-
-phenyl-, (aR,2S)-(9C1) (CA INDEX NAME)

Relative stereochemistry.




HN 554139-94-9 CAPLUS
CN 2-Morpholinomethanol, ω -[4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-
-phenyl-, (aR,2S)-(9C1) (CA INDEX NAME)

Relative stereochemistry.




HN 554139-98-2 CAPLUS
CN 2-Morpholinomethanol, ω -[3'-methoxy[1,1'-biphenyl]-2-yl)methyl]-
-phenyl-, (aR,2S)-(9C1) (CA INDEX NAME)

Relative stereochemistry.




HN 554139-99-4 CAPLUS
CN 2-Morpholinomethanol, ω -[3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]-
-phenyl-, (aR,2S)-(9C1) (CA INDEX NAME)

Relative stereochemistry.



HN 554140-00-4 CAPLUS
CN 2-Morpholinomethanol, ω -[2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]-
-phenyl-, (aR,2S)-(9C1) (CA INDEX NAME)

Relative stereochemistry.



IT 852236-37-4P 852236-38-5P 852236-42-1P


852236-42-1P
 RU PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SFM (Synthetic preparation); THU (Therapeutic use); BIOG (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

[Preparation of morpholine derivs. as morphine/opioid reuptake

inhibitors]


RU 852236-37-4 CAPLUS
 CH 2-Morpholinomethanol, 4-[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, (4S,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RU 852236-38-5 CAPLUS
 CH 2-Morpholinomethanol, 4-[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, (4S,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RU 852237-02-6 CAPLUS
 CH 2-Morpholinomethanol, 4-[(1,1'-biphenyl)-2-ylmethyl]- α -(4,4'-trifluorophenyl)- (CA INDEX NAME)



RU 852237-05-9 CAPLUS
 CH 2-Morpholinomethanol, 4-[(2-methoxyphenyl)methyl]- α -(2-methoxyphenyl)methyl)- (CA INDEX NAME)




RU 852237-08-2 CAPLUS
 CH 2-Morpholinomethanol, 4-[(2-methoxyphenyl)methyl]- α -(2-methoxyphenyl)methyl)- (CA INDEX NAME)



RU 852237-12-7 CAPLUS
 CH 2-Morpholinomethanol, 4-[(1,1'-biphenyl)-2-ylmethyl]- α -cyclopropyl- (CA INDEX NAME)


RU 852236-42-1 CAPLUS
 CH 2-Morpholinomethanol, 4-[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, (4S,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RU 852236-42-2 CAPLUS
 CH 2-Morpholinomethanol, 4-[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, (4S,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 852236-42-3P 852236-47-4P 852237-02-6P
 852237-05-9P 852237-08-2P 852237-11-7P

RU PAC (Pharmacological activity); RCT (Reactant); SFM (Synthetic preparation); THU (Therapeutic use); BIOG (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

[Preparation of morpholine derivs. as morphine/opioid reuptake

inhibitors]

RU 852236-42-3 CAPLUS

CH 2-Morpholinomethanol, 4-[(1,1'-biphenyl)-2-ylmethyl]- α -(2-methylpropyl)- (CA INDEX NAME)



RU 852236-47-4 CAPLUS
 CH 2-Morpholinomethanol, 4-[(1,1'-biphenyl)-2-ylmethyl]- α -(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



IT 852236-27-2P 852236-28-4P 852236-31-8P

852236-33-0P 852236-35-2P 852236-37-4P

852236-40-9P 852236-44-2P 852236-45-4P

852236-47-4P 852236-48-0P 852236-49-2P

852236-53-4P 852236-55-6P 852236-56-7P

852236-58-9P 852236-62-4P 852236-65-8P

852236-68-1P 852236-70-5P 852236-72-7P

852236-74-9P 852236-76-1P 852236-78-3P

852236-84-1P 852236-86-3P 852236-90-9P

852236-93-2P 852236-95-4P 852236-97-6P

852236-98-8P 852237-01-5P 852237-04-4P

852237-07-1P 852237-10-6P 852237-14-0P

852237-21-0P 852237-23-1P 852237-25-7P

852237-54-8P

RU PAC (Pharmacological activity); SFM (Synthetic preparation); THU (Therapeutic use); BIOG (Biological study); PREP (Preparation); USES (Uses)

[Preparation of morpholine derivs. as morphine/opioid reuptake

inhibitors]

RU 852236-27-2 CAPLUS

CH 2-Morpholinomethanol, 4-[(1,1'-biphenyl)-2-ylmethyl]- α -methyl-, hydrochloride (9CI) (CA INDEX NAME)



RU 852236-28-4 CAPLUS
 CH 2-Morpholinomethanol, 4-ethyl- α -(5-fluoro-2-methoxyphenyl)methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

HN 852236-31-8 CAPLUS
CN 2-Morpholinemethanol, 4-ethyl-1-methyl-1-phenyl-2-(1-methyl-2-methoxyphenyl)ethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


HN 852236-33-0 CAPLUS
CN 2-Morpholinemethanol, 4-([1,1'-biphenyl]-2-ylmethyl)-4-ethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

HN 852236-35-2 CAPLUS
CN 2-Morpholinemethanol, 4-([5-fluoro-2-methoxyphenyl)methyl]-4-1-methylethyl-, hydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

HN 852236-43-4 CAPLUS
CN 2-Morpholinemethanol, 4-([2-ethoxyphenyl)methyl]-4-1-methylethyl-, hydrochloride, (4R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

HN 852236-47-4 CAPLUS
CN 2-Morpholinemethanol, 4-([1-methylethyl]-4-([2-(1-fluoro-2-methoxyphenyl)methyl]-4-1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl



● HCl

HN 852236-39-6 CAPLUS
CN 2-Morpholinemethanol, 4-([2-methoxyphenyl)methyl]-4-1-methylethyl-, hydrochloride, (4R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

HN 852236-40-9 CAPLUS
CN 2-Morpholinemethanol, 4-([2-methoxyphenyl)methyl]-4-1-methylethyl-, hydrochloride, (4R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

HN 852236-44-3 CAPLUS
CN 2-Morpholinemethanol, 4-([2-ethoxyphenyl)methyl]-4-1-methylethyl-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

HN 852236-51-2 CAPLUS
CN 2-Morpholinemethanol, 4-([4-fluoro[1,1'-biphenyl]-2-yl)methyl]-4-1-methylethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


HN 852236-53-4 CAPLUS
CN 2-Morpholinemethanol, 4-([5-fluoro-2-methoxyphenyl)methyl]-4-1-methylethyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

HN 852236-55-6 CAPLUS
CN 2-Morpholinemethanol, 4-([2-ethoxyphenyl)methyl]-4-1-methylethyl-, hydrochloride, (4R,2R)-rel- (CA INDEX NAME)

19 ANSWER 5 OF 10 CAPLOS COPYRIGHT 2008 ACS on STM (Continued)
Relative stereochemistry.



HN 852274-14-7 CAPLOS
CN 2-Morpholinomethanol, 4-((2-ethoxyphenyl)methyl)-4-(2-methylpropyl)-, (1R,2S)-, (CA INDEX NAME)
Relative stereochemistry.



HN 852274-53-9 CAPLOS
CN 2-Morpholinomethanol, 4-((2-methylpropyl)-4-((2-(1,1,1-trifluoroethoxy)phenyl)methyl))-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

HN 852274-63-6 CAPLOS
CN 2-Morpholinomethanol, 4-((1,1'-biphenyl)-2-ylmethyl)-4-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)

19 ANSWER 5 OF 10 CAPLOS COPYRIGHT 2008 ACS on STM (Continued)



● HCl

HN 852274-72-7 CAPLOS
CN 2-Morpholinomethanol, 4-cyclopentyl-4-((2-(1,1,1-trifluoroethoxy)phenyl)methyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

HN 852274-74-9 CAPLOS
CN 2-Morpholinomethanol, 4-((1,1'-biphenyl)-2-ylmethyl)-4-cyclopentyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

HN 852274-74-3 CAPLOS
CN 2-Morpholinomethanol, 4-cyclopentyl-4-((4-fluoro-1,1'-

19 ANSWER 5 OF 10 CAPLOS COPYRIGHT 2008 ACS on STM (Continued)



● HCl

HN 852274-65-8 CAPLOS
CN 2-Morpholinomethanol, 4-((4-fluoro-1,1'-biphenyl)-2-ylmethyl)-4-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

HN 852274-65-1 CAPLOS
CN 2-Morpholinomethanol, 4-cyclopentyl-4-((5-fluoro-2-methoxyphenyl)methyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

HN 852274-70-5 CAPLOS
CN 2-Morpholinomethanol, 4-cyclopentyl-4-((2-ethoxyphenyl)methyl)-, hydrochloride (9CI) (CA INDEX NAME)

19 ANSWER 5 OF 10 CAPLOS COPYRIGHT 2008 ACS on STM (Continued)
biphenyl)-2-ylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

HN 852274-75-3 CAPLOS
CN 2-Morpholinomethanol, 4-((5-fluoro-2-methoxyphenyl)methyl)-4-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

HN 852274-84-1 CAPLOS
CN 2-Morpholinomethanol, 4-(tetrahydro-2H-pyran-4-yl)-4-((2-(1,1,1-trifluoroethoxy)phenyl)methyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

1.9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 RN 852376-86-3 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -tetrahydro-2H-pyran-6-yl)-, hydrochloride (PCL) (CA INDEX NAME)



● PCL

RN 852376-90-9 CAPLUS
 CN 2-Morpholinemethanol, α -([3'-fluoro[1,1'-biphenyl]-2-yl)methyl)- α -(tetrahydro-2H-pyran-6-yl)-, hydrochloride (PCL) (CA INDEX NAME)




● PCL

RN 852376-90-2 CAPLUS
 CN 2-Morpholinemethanol, α -([1-fluoro-2-methoxyphenyl)methyl)- α -([3,3,3-trifluoropropyl)-, hydrochloride (PCL) (CA INDEX NAME)



1.9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



● PCL

RN 852377-01-5 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -(4,4,4-trifluorobutyl)-, hydrochloride (PCL) (CA INDEX NAME)



● PCL


RN 852377-04-8 CAPLUS
 CN 2-Morpholinemethanol, α -cyclopropyl- α -([2-methoxyphenyl)methyl]-, hydrochloride (PCL) (CA INDEX NAME)



● PCL


RN 852377-07-1 CAPLUS
 CN 2-Morpholinemethanol, α -cyclopropyl- α -([2-methoxyphenyl)methyl]-, hydrochloride (PCL) (CA INDEX NAME)

1.9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)




● PCL

RN 852376-90-4 CAPLUS
 CN 2-Morpholinemethanol, α -([2-(trifluoromethoxy)phenyl)methyl)- α -(3,3,3-trifluoropropyl)-, hydrochloride (PCL) (CA INDEX NAME)



● PCL

RN 852376-97-4 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -(3,3,3-trifluoropropyl)-, hydrochloride (PCL) (CA INDEX NAME)



● PCL

RN 852376-99-8 CAPLUS
 CN 2-Morpholinemethanol, α -([5-fluoro-2-methoxyphenyl)methyl)- α -(4,4,4-trifluorobutyl)-, hydrochloride (PCL) (CA INDEX NAME)

1.9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)




● PCL

RN 852377-10-6 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -cyclopropyl-, hydrochloride (PCL) (CA INDEX NAME)



● PCL

RN 852377-14-0 CAPLUS
 CN 2-Morpholinemethanol, α -bis-([2-methoxyphenyl)methyl]-, hydrochloride (PCL) (CA INDEX NAME)




● PCL

RN 852377-23-9 CAPLUS
 CN 2-Morpholinemethanol, α -butyl- α -([2-methoxyphenyl)methyl]-, hydrochloride (PCL) (CA INDEX NAME)

1,9 ANSWER 6 OF 10 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 CN 2-Morpholinemetanol, ω -[2-methoxyphenylmethyl]- α -phenyl-, hydrochloride, (ef,25)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-73-0 CAPLOS
 CN 2-Morpholinemetanol, ω -[2-ethoxyphenylmethyl]- α -phenyl-, hydrochloride, (ef,25)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 664360-74-3 CAPLOS
 CN 2-Morpholinemetanol, ω -[2-[1-methylethoxyphenylmethyl]- α -phenyl]-, hydrochloride, (ef,28)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


1,9 ANSWER 6 OF 10 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 664360-79-6 CAPLOS
 CN 2-Morpholinemetanol, ω -[5-fluoro-2-methoxyphenylmethyl]- α -phenyl-, hydrochloride, (ef,28)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-82-1 CAPLOS
 CN 2-Morpholinemetanol, ω -phenyl- ω -[3-[trifluoromethyl]phenylmethyl]-, (ef,28)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664360-84-3 CAPLOS
 CN 2-Morpholinemetanol, ω -[2-methylphenylmethyl]- α -phenyl-, hydrochloride, (ef,25)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

1,9 ANSWER 6 OF 10 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
 RN 664360-75-2 CAPLOS
 CN 2-Morpholinemetanol, ω -[2-(3-chlorophenyl)- α -[2-methoxyphenylmethyl]-, hydrochloride, (ef,25)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-76-3 CAPLOS
 CN 2-Morpholinemetanol, ω -phenyl- ω -[2-(trifluoromethylphenylmethyl)-, hydrochloride, (ef,25)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-77-4 CAPLOS
 CN 2-Morpholinemetanol, ω -[1,3'-biphenyl]-2-ylmethyl)- α -phenyl-, hydrochloride, (ef,28)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




1,9 ANSWER 6 OF 10 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 664360-88-7 CAPLOS
 CN 2-Morpholinemetanol, ω -[2'-chloro[1,3'-biphenyl]-2-ylmethyl)- α -phenyl-, hydrochloride, (ef,28)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-89-8 CAPLOS
 CN 2-Morpholinemetanol, ω -[5-fluoro-2-hydroxyphenylmethyl]- α -phenyl-, hydrochloride, (ef,28)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


19 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 RN 664360-96-7 CAPLUS
 CN 2-Morpholinemetanol, ω -[4-fluoro[1,1'-biphenyl]-2-yl)methyl]-
 ω -phenyl-, hydrochloride, (aR,2S)- (SC1) (CA INDEX NAME)

Absolute stereochemistry.



RN 664360-97-8 CAPLUS
 CN 2-Morpholinemetanol, ω -[4-methyl[1,1'-biphenyl]-2-yl)methyl]-
 ω -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664360-98-9 CAPLUS
 CN 2-Morpholinemetanol, ω -[4'-chloro[1,1'-biphenyl]-2-yl)methyl]-
 ω -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.


19 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Absolute stereochemistry.




RN 664361-02-8 CAPLUS
 CN 2-Morpholinemetanol, ω -[3'-methoxy[1,1'-biphenyl]-2-yl)methyl]-
 ω -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-03-9 CAPLUS
 CN 2-Morpholinemetanol, ω -[3'-methyl[1,1'-biphenyl]-2-yl)methyl]-
 ω -phenyl-, (aR,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 664361-04-0 CAPLUS
 CN 2-Morpholinemetanol, ω -[3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]-
 ω -phenyl-, (aR,2S)- (CA INDEX NAME)


Absolute stereochemistry.

19 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 664360-99-0 CAPLUS
 CN 2-Morpholinemetanol, ω -[4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-
 ω -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-00-6 CAPLUS
 CN 2-Morpholinemetanol, ω -[3'-fluoro[1,1'-biphenyl]-2-yl)methyl]-
 ω -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-01-7 CAPLUS
 CN 2-Morpholinemetanol, ω -[3'-chloro[1,1'-biphenyl]-2-yl)methyl]-
 ω -phenyl-, (aR,2S)- (CA INDEX NAME)

19 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 664361-00-1 CAPLUS
 CN 2-Morpholinemetanol, ω -[2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]-
 ω -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-06-2 CAPLUS
 CN 2-Morpholinemetanol, ω -[2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]-
 ω -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-09-5 CAPLUS
 CN 2-Morpholinemetanol, ω -[3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]-
 ω -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.



320 664361-42-6 CAPLUS
CN 2-Morpholinomethanol, 1-([2-(2-chlorophenyl)ethyl]-4-phenyl-, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



An effective anti-4 selective norepinephrine reuptake inhibitor. The invention discloses the use of atomoxetine, racemic roboseline, (R,S)-roboseline, and compounds of formula I (wherein X = alkylthio and Y = alkyl; as described in U.S. patent No. 5,281,624), as well as their pharmaceutically acceptable salts, as the norepinephrine reuptake inhibitors described for treatment purposes. The invention further discloses the prep. of addn. heterocyclic deriv. (as well as their pharmaceutically acceptable salts) that possess ability to serve as norepinephrine reuptake inhibitors. For instance, morpholine deriv. (I) (X = H = O) was prep. via alkylation of (4-phenyl)morpholine-2-yl phenylmethanols by 2-chloro-6-fluorobenzylmagnesium chloride and subsequent *m*-debenzylation of the obtained salt. I (R = H). The preferred


invention comds. exhibited Ki values of less than 500 nM at the norepinephrine transporter (antitoxification proximity assay).

IT 664360-71-9 664360-71-9 664360-74-13
664360-75-2 664360-76-3 664360-77-4P
664360-78-4 664360-81-2 664360-84-7P
664360-88-7P 664360-89-8P 664360-96-7P
664360-97-9 664360-99-5P 664360-99-5P
664361-00-4P 664361-01-7P 664361-02-8P
664361-03-9P 664361-04-0P 664361-05-3P
664361-06-2P 664361-05-3P 664361-42-6P

Ki: PAC (Pharmacological activity); SR (Synthetic preparation); TBO (Therapeutic use); BCG (Biological study); PREP (Preparation); USES (Uses).
[Preparation of heterocyclic comds. useful as norepinephrine reuptake inhibitors]

320 664360-72-9 CAPLUS
CN 2-Morpholinomethanol, 1-([2-(methoxyphenyl)ethyl]-4-phenyl-, hydrochloride, (4S,2S)- (PCT) (CA INDEX NAME)

Absolute stereochemistry.



● RCL


320 664360-73-0 CAPLUS
CN 2-Morpholinomethanol, 1-([2-(methoxyphenyl)ethyl]-4-phenyl-, hydrochloride, (4S,2S)- (PCT) (CA INDEX NAME)

Absolute stereochemistry.


ACCESSION NUMBER: 2005-216440 CAPLUS
DOCUMENT NUMBER: 1421291415
TITLE: Treatment of pervasive development disorders employing norepinephrine reuptake inhibitors
INVENTOR(S): Allen, Albert John; Melany, Douglas Kenneth
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 300 pp.
COUNTRY: PCT/US
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2005024976	A2	20050310	MO 2004-0525593	20040505	
WO 2005024976	A3	20050616			
WI	AE, AG, AL, AM, AT, AU, BA, BB, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, FI, GB, GR, GU, HK, HN, HU, IL, IN, JP, KE, KG, KH, KR, KZ, LA, LB, LG, LI, LT, LU, LV, MA, MD, ME, MG, MK, MN, MU, MW, MY, NA, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, SL, SM, SN, SV, TH, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
WI	BA, BG, BR, BY, BZ, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, FI, GB, GR, GU, HK, HN, HU, IL, IN, JP, KE, KG, KH, KR, KZ, LA, LB, LG, LI, LT, LU, LV, MA, MD, ME, MG, MK, MN, MU, MW, MY, NA, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, SL, SM, SN, SV, TH, TJ, TM, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
CA 2576161	A1	20050310	CA 2004-2576161	20040505	
EP 1410265	A2	20050310	EP 2004-703470	20050310	
FR	AT, BE, BG, BR, BY, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, FI, GB, GR, GU, HK, HN, HU, IL, IN, JP, KE, KG, KH, KR, KZ, LA, LB, LG, LI, LT, LU, LV, MA, MD, ME, MG, MK, MN, MU, MW, MY, NA, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, SL, SM, SN, SV, TH, TJ, TM, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
US	2006243188	A1	20061006	US 2006-243188	20060214
PRIORITY CLAIM, INFO.			US 2003-430146P	F 20030827	
			MO 2004-0525593	W 20040505	

OTHER SOURCE(S): CASREACT 1421291415; MARPAT 1421291415
OI




AB Provided are methods and medications for treating a pervasive development disorder, comprising administering to a patient in need of such treatment



● RCL

320 664360-74-1 CAPLUS
CN 2-Morpholinomethanol, 1-([2-(1-methoxyphenyl)ethyl]-4-phenyl-, hydrochloride, (4S,2S)- (PCT) (CA INDEX NAME)


Absolute stereochemistry.



● RCL

320 664360-75-1 CAPLUS
CN 2-Morpholinomethanol, 1-([2-(3-fluorophenyl)ethyl]-4-phenyl-, hydrochloride, (4S,2S)- (PCT) (CA INDEX NAME)


Absolute stereochemistry.



● RCL

HN 664360-76-3 CAPLUS
CN 2-Morpholinemetanol, α -phenyl- α -[2-(trifluoromethyl)phenyl]methyl-, hydrochloride, (aR,2S)- (PC1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

HN 664360-77-4 CAPLUS
CN 2-Morpholinemetanol, α -[1,1'-biphenyl]-2-ylmethyl]- α -phenyl-, hydrochloride, (aR,2S)- (PC2) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

HN 664360-79-6 CAPLUS
CN 2-Morpholinemetanol, α -[5-fluoro-2-methoxyphenyl]methyl]- α -phenyl-, hydrochloride, (aR,2S)- (PC3) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


HN 664360-82-1 CAPLUS
CN 2-Morpholinemetanol, α -phenyl- α -[2-(trifluoromethyl)phenyl]methyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.



HN 664360-84-3 CAPLUS
CN 2-Morpholinemetanol, α -[2-methylphenyl]methyl]- α -phenyl-, hydrochloride, (aR,2S)- (PC1) (CA INDEX NAME)



Absolute stereochemistry.



● HCl

HN 664360-85-1 CAPLUS
CN 2-Morpholinemetanol, α -[2'-chloro[1,1'-biphenyl]-2-ylmethyl]- α -phenyl-, hydrochloride, (aR,2S)- (PC1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

HN 664360-89-8 CAPLUS
CN 2-Morpholinemetanol, α -[5-fluoro-2-hydroxyphenyl]methyl]- α -phenyl-, hydrochloride, (aR,2S)- (PC1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

HN 664360-94-7 CAPLUS
CN 2-Morpholinemetanol, α -[4-fluoro[1,1'-biphenyl]-2-ylmethyl]- α -phenyl-, hydrochloride, (aR,2S)- (PC1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


HN 664360-97-8 CAPLUS
CN 2-Morpholinemetanol, α -[4'-methyl[1,1'-biphenyl]-2-ylmethyl]- α -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




HN 664360-98-9 CAPLUS
CN 2-Morpholinemetanol, α -[4'-chloro[1,1'-biphenyl]-2-ylmethyl]- α -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




HN 664360-99-0 CAPLUS
CN 2-Morpholinemetanol, α -[4'-methoxy[1,1'-biphenyl]-2-ylmethyl]- α -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




20 664761-00-6 CAPLUS
CN 2-Morpholinomethyl-1,1'-biphenyl-2-ylmethyl-4-phenyl-, (4b,25)- (CA INDEX NAME)

Absolute stereochemistry.




20 664761-01-7 CAPLUS
CN 2-Morpholinomethyl-1,1'-biphenyl-2-ylmethyl-4-phenyl-, (4b,25)- (CA INDEX NAME)

Absolute stereochemistry.




20 664761-01-8 CAPLUS
CN 2-Morpholinomethyl-1,1'-biphenyl-2-ylmethyl-4-phenyl-, (4b,25)- (CA INDEX NAME)

Absolute stereochemistry.




20 664761-04-2 CAPLUS
CN 2-Morpholinomethyl-1,1'-biphenyl-2-ylmethyl-4-phenyl-, (4b,25)- (CA INDEX NAME)

Absolute stereochemistry.




20 664761-09-3 CAPLUS
CN 2-Morpholinomethyl-1,1'-biphenyl-2-ylmethyl-4-phenyl-, (4b,28)- (CA INDEX NAME)

Absolute stereochemistry.




20 664761-42-6 CAPLUS




20 664761-03-9 CAPLUS
CN 2-Morpholinomethyl-1,1'-biphenyl-2-ylmethyl-4-phenyl-, (4b,25)- (CA INDEX NAME)

Absolute stereochemistry.



20 664761-04-0 CAPLUS
CN 2-Morpholinomethyl-1,1'-biphenyl-2-ylmethyl-4-phenyl-, (4b,25)- (CA INDEX NAME)

Absolute stereochemistry.




20 664761-05-1 CAPLUS
CN 2-Morpholinomethyl-1,1'-biphenyl-2-ylmethyl-4-phenyl-, (4b,25)- (CA INDEX NAME)

Absolute stereochemistry.

20 664761-06-2 CAPLUS
CN 2-Morpholinomethyl-1,1'-biphenyl-2-ylmethyl-4-phenyl-, (4b,25)- (CA INDEX NAME)

Absolute stereochemistry.



19 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)
 ACCESSION NUMBER: 2005:216659 CAPLUS
 DOCUMENT NUMBER: 142259414
 TITLE: Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
 INVENTOR(S): Sumner, Calvin Russell
 PATENT ASSIGNER(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 204 pp.
 CURRENT PRIORITY: Patent
 DOCUMENT TYPE: English
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020970	A2	20050310	WO 2004-022592	20040805
WO 2005020970	A3	20050802		
US 6,643,820	A1	20050310	US 2004-022592	20040805
US 6,643,820	A2	20050802		
US 6,643,820	A3	20050802		
US 6,643,820	A4	20050802		
US 6,643,820	A5	20050802		
US 6,643,820	A6	20050802		
US 6,643,820	A7	20050802		
US 6,643,820	A8	20050802		
US 6,643,820	A9	20050802		
US 6,643,820	A10	20050802		
US 6,643,820	A11	20050802		
US 6,643,820	A12	20050802		
US 6,643,820	A13	20050802		
US 6,643,820	A14	20050802		
US 6,643,820	A15	20050802		
US 6,643,820	A16	20050802		
US 6,643,820	A17	20050802		
US 6,643,820	A18	20050802		
US 6,643,820	A19	20050802		
US 6,643,820	A20	20050802		
US 6,643,820	A21	20050802		
US 6,643,820	A22	20050802		
US 6,643,820	A23	20050802		
US 6,643,820	A24	20050802		
US 6,643,820	A25	20050802		
US 6,643,820	A26	20050802		
US 6,643,820	A27	20050802		
US 6,643,820	A28	20050802		
US 6,643,820	A29	20050802		
US 6,643,820	A30	20050802		
US 6,643,820	A31	20050802		
US 6,643,820	A32	20050802		
US 6,643,820	A33	20050802		
US 6,643,820	A34	20050802		
US 6,643,820	A35	20050802		
US 6,643,820	A36	20050802		
US 6,643,820	A37	20050802		
US 6,643,820	A38	20050802		
US 6,643,820	A39	20050802		
US 6,643,820	A40	20050802		
US 6,643,820	A41	20050802		
US 6,643,820	A42	20050802		
US 6,643,820	A43	20050802		
US 6,643,820	A44	20050802		
US 6,643,820	A45	20050802		
US 6,643,820	A46	20050802		
US 6,643,820	A47	20050802		
US 6,643,820	A48	20050802		
US 6,643,820	A49	20050802		
US 6,643,820	A50	20050802		
US 6,643,820	A51	20050802		
US 6,643,820	A52	20050802		
US 6,643,820	A53	20050802		
US 6,643,820	A54	20050802		
US 6,643,820	A55	20050802		
US 6,643,820	A56	20050802		
US 6,643,820	A57	20050802		
US 6,643,820	A58	20050802		
US 6,643,820	A59	20050802		
US 6,643,820	A60	20050802		
US 6,643,820	A61	20050802		
US 6,643,820	A62	20050802		
US 6,643,820	A63	20050802		
US 6,643,820	A64	20050802		
US 6,643,820	A65	20050802		
US 6,643,820	A66	20050802		
US 6,643,820	A67	20050802		
US 6,643,820	A68	20050802		
US 6,643,820	A69	20050802		
US 6,643,820	A70	20050802		
US 6,643,820	A71	20050802		
US 6,643,820	A72	20050802		
US 6,643,820	A73	20050802		
US 6,643,820	A74	20050802		
US 6,643,820	A75	20050802		
US 6,643,820	A76	20050802		
US 6,643,820	A77	20050802		
US 6,643,820	A78	20050802		
US 6,643,820	A79	20050802		
US 6,643,820	A80	20050802		
US 6,643,820	A81	20050802		
US 6,643,820	A82	20050802		
US 6,643,820	A83	20050802		
US 6,643,820	A84	20050802		
US 6,643,820	A85	20050802		
US 6,643,820	A86	20050802		
US 6,643,820	A87	20050802		
US 6,643,820	A88	20050802		
US 6,643,820	A89	20050802		
US 6,643,820	A90	20050802		
US 6,643,820	A91	20050802		
US 6,643,820	A92	20050802		
US 6,643,820	A93	20050802		
US 6,643,820	A94	20050802		
US 6,643,820	A95	20050802		
US 6,643,820	A96	20050802		
US 6,643,820	A97	20050802		
US 6,643,820	A98	20050802		
US 6,643,820	A99	20050802		
US 6,643,820	A100	20050802		

OTHER SOURCE(S):
 GI

19 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)




AB Provided are methods and medicaments for treating a learning disability or a motor skills disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor. The invention discloses the use of atomoxetine, atomoxetine, 1,7-reboxetine, and compounds of formula I wherein X = isopropyl and Y = alkyl as described in U.S. Patent Number 5,351,624), as well as their pharmaceutically acceptable salts, for the norepinephrine reuptake inhibitors described for treatment purposes. The invention further discloses the preparation of solid, heterocyclic derivative, (as well as their pharmaceutically acceptable salts) that possess ability to serve as norepinephrine reuptake inhibitors. For instance, morpholine derivative II (HCl) was prepared via alkylation of (S)-methylmorpholine-2-yl (phenyl)methanone with 2-chloro-4-(fluoromethyl)phenol hydrochloride and subsequent N-debenzoylation. The preferred invention compounds exhibited Ki values of less than 500 nM at the norepinephrine transporter (scintillation proximity assay).
 IT 6643820-70 6643820-71 6643820-72 6643820-73 6643820-74 6643820-75 6643820-76 6643820-77 6643820-78 6643820-79 6643820-80 6643820-81 6643820-82 6643820-83 6643820-84 6643820-85 6643820-86 6643820-87 6643820-88 6643820-89 6643820-90 6643820-91 6643820-92 6643820-93 6643820-94 6643820-95 6643820-96 6643820-97 6643820-98 6643820-99 6643820-100 6643820-101 6643820-102 6643820-103 6643820-104 6643820-105 6643820-106 6643820-107 6643820-108 6643820-109 6643820-110 6643820-111 6643820-112 6643820-113 6643820-114 6643820-115 6643820-116 6643820-117 6643820-118 6643820-119 6643820-120 6643820-121 6643820-122 6643820-123 6643820-124 6643820-125 6643820-126 6643820-127 6643820-128 6643820-129 6643820-130 6643820-131 6643820-132 6643820-133 6643820-134 6643820-135 6643820-136 6643820-137 6643820-138 6643820-139 6643820-140 6643820-141 6643820-142 6643820-143 6643820-144 6643820-145 6643820-146 6643820-147 6643820-148 6643820-149 6643820-150 6643820-151 6643820-152 6643820-153 6643820-154 6643820-155 6643820-156 6643820-157 6643820-158 6643820-159 6643820-160 6643820-161 6643820-162 6643820-163 6643820-164 6643820-165 6643820-166 6643820-167 6643820-168 6643820-169 6643820-170 6643820-171 6643820-172 6643820-173 6643820-174 6643820-175 6643820-176 6643820-177 6643820-178 6643820-179 6643820-180 6643820-181 6643820-182 6643820-183 6643820-184 6643820-185 6643820-186 6643820-187 6643820-188 6643820-189 6643820-190 6643820-191 6643820-192 6643820-193 6643820-194 6643820-195 6643820-196 6643820-197 6643820-198 6643820-199 6643820-200 6643820-201 6643820-202 6643820-203 6643820-204 6643820-205 6643820-206 6643820-207 6643820-208 6643820-209 6643820-210 6643820-211 6643820-212 6643820-213 6643820-214 6643820-215 6643820-216 6643820-217 6643820-218 6643820-219 6643820-220 6643820-221 6643820-222 6643820-223 6643820-224 6643820-225 6643820-226 6643820-227 6643820-228 6643820-229 6643820-230 6643820-231 6643820-232 6643820-233 6643820-234 6643820-235 6643820-236 6643820-237 6643820-238 6643820-239 6643820-240 6643820-241 6643820-242 6643820-243 6643820-244 6643820-245 6643820-246 6643820-247 6643820-248 6643820-249 6643820-250 6643820-251 6643820-252 6643820-253 6643820-254 6643820-255 6643820-256 6643820-257 6643820-258 6643820-259 6643820-260 6643820-261 6643820-262 6643820-263 6643820-264 6643820-265 6643820-266 6643820-267 6643820-268 6643820-269 6643820-270 6643820-271 6643820-272 6643820-273 6643820-274 6643820-275 6643820-276 6643820-277 6643820-278 6643820-279 6643820-280 6643820-281 6643820-282 6643820-283 6643820-284 6643820-285 6643820-286 6643820-287 6643820-288 6643820-289 6643820-290 6643820-291 6643820-292 6643820-293 6643820-294 6643820-295 6643820-296 6643820-297 6643820-298 6643820-299 6643820-300 6643820-301 6643820-302 6643820-303 6643820-304 6643820-305 6643820-306 6643820-307 6643820-308 6643820-309 6643820-310 6643820-311 6643820-312 6643820-313 6643820-314 6643820-315 6643820-316 6643820-317 6643820-318 6643820-319 6643820-320 6643820-321 6643820-322 6643820-323 6643820-324 6643820-325 6643820-326 6643820-327 6643820-328 6643820-329 6643820-330 6643820-331 6643820-332 6643820-333 6643820-334 6643820-335 6643820-336 6643820-337 6643820-338 6643820-339 6643820-340 6643820-341 6643820-342 6643820-343 6643820-344 6643820-345 6643820-346 6643820-347 6643820-348 6643820-349 6643820-350 6643820-351 6643820-352 6643820-353 6643820-354 6643820-355 6643820-356 6643820-357 6643820-358 6643820-359 6643820-360 6643820-361 6643820-362 6643820-363 6643820-364 6643820-365 6643820-366 6643820-367 6643820-368 6643820-369 6643820-370 6643820-371 6643820-372 6643820-373 6643820-374 6643820-375 6643820-376 6643820-377 6643820-378 6643820-379 6643820-380 6643820-381 6643820-382 6643820-383 6643820-384 6643820-385 6643820-386 6643820-387 6643820-388 6643820-389 6643820-390 6643820-391 6643820-392 6643820-393 6643820-394 6643820-395 6643820-396 6643820-397 6643820-398 6643820-399 6643820-400 6643820-401 6643820-402 6643820-403 6643820-404 6643820-405 6643820-406 6643820-407 6643820-408 6643820-409 6643820-410 6643820-411 6643820-412 6643820-413 6643820-414 6643820-415 6643820-416 6643820-417 6643820-418 6643820-419 6643820-420 6643820-421 6643820-422 6643820-423 6643820-424 6643820-425 6643820-426 6643820-427 6643820-428 6643820-429 6643820-430 6643820-431 6643820-432 6643820-433 6643820-434 6643820-435 6643820-436 6643820-437 6643820-438 6643820-439 6643820-440 6643820-441 6643820-442 6643820-443 6643820-444 6643820-445 6643820-446 6643820-447 6643820-448 6643820-449 6643820-450 6643820-451 6643820-452 6643820-453 6643820-454 6643820-455 6643820-456 6643820-457 6643820-458 6643820-459 6643820-460 6643820-461 6643820-462 6643820-463 6643820-464 6643820-465 6643820-466 6643820-467 6643820-468 6643820-469 6643820-470 6643820-471 6643820-472 6643820-473 6643820-474 6643820-475 6643820-476 6643820-477 6643820-478 6643820-479 6643820-480 6643820-481 6643820-482 6643820-483 6643820-484 6643820-485 6643820-486 6643820-487 6643820-488 6643820-489 6643820-490 6643820-491 6643820-492 6643820-493 6643820-494 6643820-495 6643820-496 6643820-497 6643820-498 6643820-499 6643820-500 6643820-501 6643820-502 6643820-503 6643820-504 6643820-505 6643820-506 6643820-507 6643820-508 6643820-509 6643820-510 6643820-511 6643820-512 6643820-513 6643820-514 6643820-515 6643820-516 6643820-517 6643820-518 6643820-519 6643820-520 6643820-521 6643820-522 6643820-523 6643820-524 6643820-525 6643820-526 6643820-527 6643820-528 6643820-529 6643820-530 6643820-531 6643820-532 6643820-533 6643820-534 6643820-535 6643820-536 6643820-537 6643820-538 6643820-539 6643820-540 6643820-541 6643820-542 6643820-543 6643820-544 6643820-545 664



● RCI

HN 664360-79-6 CAPLUS
CN 2-Morpholinomethanol, 4-fluoro-2-methoxyphenylmethyl-α-phenyl-, hydrochloride, (4S,2S)- (RCI) (CA INDEX NAME)


Absolute stereochemistry.



● RCI

HN 664360-82-1 CAPLUS
CN 2-Morpholinomethanol, 4-phenyl-4-[[2-(trifluoromethyl)phenyl]methyl]-, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.




HN 664360-84-1 CAPLUS
CN 2-Morpholinomethanol, 4-[[2-(2-methylphenyl)methyl]-α-phenyl-, hydrochloride, (4S,2S)- (RCI) (CA INDEX NAME)

Absolute stereochemistry.

HN 664360-86-7 CAPLUS
CN 2-Morpholinomethanol, 4-[[4-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, hydrochloride, (4S,2S)- (RCI) (CA INDEX NAME)


Absolute stereochemistry.



● RCI


HN 664360-87-8 CAPLUS
CN 2-Morpholinomethanol, 4-[[4-methyl[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



HN 664360-89-9 CAPLUS
CN 2-Morpholinomethanol, 4-[[4'-chloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (4S,2S)- (CA INDEX NAME)


Absolute stereochemistry.



● RCI

HN 664360-88-7 CAPLUS
CN 2-Morpholinomethanol, 4-[[2'-chloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, hydrochloride, (4S,2S)- (RCI) (CA INDEX NAME)


Absolute stereochemistry.




● RCI

HN 664360-89-8 CAPLUS
CN 2-Morpholinomethanol, 4-[[5-fluoro-2-hydroxyphenyl)methyl]-α-phenyl-, hydrochloride, (4S,2S)- (RCI) (CA INDEX NAME)

Absolute stereochemistry.




● RCI




HN 664360-89-0 CAPLUS
CN 2-Morpholinomethanol, 4-[[4-methyl[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



HN 664361-00-6 CAPLUS
CN 2-Morpholinomethanol, 4-[[3'-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.




HN 664361-01-7 CAPLUS
CN 2-Morpholinomethanol, 4-[[3'-chloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (4S,2S)- (CA INDEX NAME)

L9 ANSWER 9 OF 10 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

HN 664360-73-0 CAPLOS
CN 2-Morpholinemetanol, ω -[2-(2-methoxyphenyl)methyl]- ω -phenyl-, hydrochloride, (4*S*,2*S*)- (ICI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

HN 664360-74-1 CAPLOS
CN 2-Morpholinemetanol, ω -[2-(1-methylethoxyphenyl)methyl]- ω -phenyl-, hydrochloride, (4*S*,2*S*)- (ICI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

HN 664360-76-3 CAPLOS
CN 2-Morpholinemetanol, ω -phenyl- ω -[2-(trifluoromethoxyphenyl)methyl]-, hydrochloride, (4*S*,2*S*)- (ICI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


L9 ANSWER 10 OF 10 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




HN 664360-84-3 CAPLOS
CN 2-Morpholinemetanol, ω -[2-methylphenyl)methyl]- ω -phenyl-, hydrochloride, (4*S*,2*S*)- (ICI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


L9 ANSWER 9 OF 10 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

HN 664360-77-4 CAPLOS
CN 2-Morpholinemetanol, ω -[1,1'-biphenyl]-2-ylmethyl)- ω -phenyl-, hydrochloride, (4*S*,2*S*)- (ICI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

HN 664360-79-6 CAPLOS
CN 2-Morpholinemetanol, ω -[5-fluoro-2-methoxyphenyl)methyl]- ω -phenyl-, hydrochloride, (4*S*,2*S*)- (ICI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


HN 664360-82-1 CAPLOS
CN 2-Morpholinemetanol, ω -phenyl- ω -[2-(trifluoromethylphenyl)methyl]-, (4*S*,2*S*)- (CA INDEX NAME)

L9 ANSWER 10 OF 10 CAPLOS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 200418085
DOCUMENT NUMBER: 140217649
TITLE: Preparation of aryl and heteroaryl morpholine derivatives as nociceptin receptor antagonists
INVENTOR(S): Cline-Thomas, Manuel; Jansky, Mark; Lounsbury, James-Patrick; Carlos, Owens; Mahadevan, Sivi; Matyas, John; Joseph, Sumendra; Nalla, George; Rudy, Helene; Catherine, Eugenio; Walter, Magnus; Wilhelm, Eli Lilly and Company, USA
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: ECT Int. Appl., E2 pp.
CDBH: FICOLD
LANGUAGE: English
FAMILY ACC. NUM. COUNTRY: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018441	A1	20040304	WO 2003-052320	20030618
W1	AK, AG, AL, AM, AT, AU, BE, BG, BR, BY, CA, CH, CN, CO, CU, CY, DE, DK, DM, EE, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, KZ, LI, LU, LV, LT, MD, ME, MG, MK, MN, MU, NL, NO, NZ, PL, PT, PY, RO, RU, SC, SE, SI, SK, SV, TH, TR, TT, UA, US, VC, VE, YU, ZA			
W4	GB, GR, HU, IE, IL, IN, JP, KR, KZ, LI, LU, LV, LT, MD, ME, MG, MK, MN, MU, NL, NO, NZ, PL, PT, PY, RO, RU, SC, SE, SI, SK, SV, TH, TR, TT, UA, US, VC, VE, YU, ZA			
AC 2003248624	A1	20040311	EP 2003-248624	20030818
EP 1534694	A1	20050601	EP 2003-248624	20030818
US 2004003598	A1	20040305	US 2003-248624	20030818
PRIORITY AFFIL. INFO.:				
US 2002-415303P	P	20020101		
WO 2003-052320	W	20030618		

OTHER SOURCE(S): MARCH 140217649
OI



AS Morpholine derivs. of formula 1 [R = independently H, alkyl, R1 = H, alkyl; Y = OR, alkoxy; Ar1, Ar2 = (substituted) Ph, (substituted) heterocycle] are prepared. The compds. are selective inhibitors of the reuptake of norepinephrine. Thus, II-8C3 was prepared from 4-benzylmorpholine-2-yl]-phenylmethanone (preparation given) and 2-trifluoromethylbenzyl bromide. The compds. had Ki values less than 500 nM at the norepinephrine transporter in a solubilization proximity assay.


IT 664360-91-8P 664360-98-9P 664360-99-0P
664361-01-0P 664361-01-7P 664361-02-0P
664361-02-3P 664361-04-0P 664361-05-1P
664361-06-2P 664361-08-9P

RI: CHN (Combustional preparation); PAC (Pharmacological activity); TDD (Therapeutic use); RLD (Biological study); CM1 (Combinatorial study); TADP (Preparation); TDD (Use)
[preparation of aryl and heterocyclic morpholine derivs. as reuptake inhibitors]

RI 664360-91-8 CAPLUS

CH 2-Morpholinemetanone, ω -[4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (4a, 2S)- (CA INDEX NAME)

Absolute stereochemistry.




RI 664360-98-9 CAPLUS

CH 2-Morpholinemetanone, ω -[4'-chloro[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (4a, 2S)- (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.



RI 664361-02-8 CAPLUS

CH 2-Morpholinemetanone, ω -[3'-methoxy[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (4a, 2S)- (CA INDEX NAME)


Absolute stereochemistry.



RI 664361-03-8 CAPLUS

CH 2-Morpholinemetanone, ω -[3'-methoxy[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (4a, 2S)- (CA INDEX NAME)

Absolute stereochemistry.



RI 664361-04-0 CAPLUS

CH 2-Morpholinemetanone, ω -[3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (4a, 2S)- (CA INDEX NAME)


Absolute stereochemistry.



RI 664360-99-0 CAPLUS

CH 2-Morpholinemetanone, ω -[4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (4a, 2S)- (CA INDEX NAME)


Absolute stereochemistry.



RI 664361-02-6 CAPLUS

CH 2-Morpholinemetanone, ω -[3'-fluoro[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (4a, 2S)- (CA INDEX NAME)


Absolute stereochemistry.



RI 664361-01-7 CAPLUS

CH 2-Morpholinemetanone, ω -[3'-chloro[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (4a, 2S)- (CA INDEX NAME)


Absolute stereochemistry.



RI 664361-02-1 CAPLUS

CH 2-Morpholinemetanone, ω -[2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (4a, 2S)- (CA INDEX NAME)


Absolute stereochemistry.



RI 664361-06-2 CAPLUS

CH 2-Morpholinemetanone, ω -[2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (4a, 2S)- (CA INDEX NAME)


Absolute stereochemistry.



RI 664361-09-5 CAPLUS


CH 2-Morpholinemetanone, ω -[3',4'-dichloro[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (4a, 2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 664361-41-9
 RI PAC (Pharmacological activity); PEP (Physical, engineering or chemical); PEP (Physical process); SPW (Synthetic preparation); THU (Therapeutic use); RIOL (Biological study); PEP (Preparation); URES (Uses)
 (Preparation of aryl and heterocyclic morpholine derivs. as norepinephrine reuptake inhibitors)
 RI 664361-41-5 CAPLUS
 CH 2-Morpholinemethanol, ω -phenyl- ω -[[2-(trifluoromethyl)phenyl]methyl]-, (4*S*,2*S*)-rel- (CA INDEX NAME)

Relative stereochemistry.




IT 664360-52-1P
 RI PAC (Pharmacological activity); PUR (Purification or recovery); SPW (Synthetic preparation); THU (Therapeutic use); RIOL (Biological study); PEP (Preparation); URES (Uses)
 (Preparation of aryl and heterocyclic morpholine derivs. as norepinephrine reuptake inhibitors)
 RI 664360-52-1 CAPLUS
 CH 2-Morpholinemethanol, ω -phenyl- ω -[[2-(trifluoromethyl)phenyl]methyl]-, (4*S*,2*S*)- (CA INDEX NAME)

Absolute stereochemistry.

664361-39-1P 664361-40-4P

RI PAC (Pharmacological activity); SPW (Synthetic preparation); THU (Therapeutic use); RIOL (Biological study); PEP (Preparation); URES (Uses)
 (Prep. of aryl and heterocyclic morpholine derivs. as norepinephrine reuptake inhibitors)
 RI 664360-72-3 CAPLUS
 CH 2-Morpholinemethanol, ω -[[2-methoxyphenyl]methyl]- ω -phenyl-, hydrochloride, (4*S*,2*S*)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● RCI

RI 664360-73-0 CAPLUS
 CH 2-Morpholinemethanol, ω -[[2-methoxyphenyl]methyl]- ω -phenyl-, hydrochloride, (4*S*,2*S*)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● RCI


RI 664360-74-1 CAPLUS
 CH 2-Morpholinemethanol, ω -[[2-(1-methylethoxy)phenyl]methyl]- ω -phenyl-, hydrochloride, (4*S*,2*S*)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.



IT 664360-79-4P 664361-42-4P
 RI PAC (Pharmacological activity); RCT (Reaction); SPW (Synthetic preparation); THU (Therapeutic use); RIOL (Biological study); PEP (Preparation); RACT (Reactant or reagent); URES (Uses)
 (Preparation of aryl and heterocyclic morpholine derivs. as norepinephrine reuptake inhibitors)
 RI 664360-79-6 CAPLUS
 CH 2-Morpholinemethanol, ω -[[5-fluoro-2-methoxyphenyl]methyl]- ω -phenyl-, hydrochloride, (4*S*,2*S*)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.




● RCI

RI 664361-42-6 CAPLUS
 CH 2-Morpholinemethanol, ω -[[5-fluoro-2-methoxyphenyl]methyl]- ω -phenyl-, hydrochloride, (4*S*,2*S*)- (CA INDEX NAME)

Absolute stereochemistry.




IT 664360-72-3P 664360-73-4P 664360-74-3P
 664360-75-2P 664360-76-3P 664360-77-4P
 664360-84-3P 664360-86-7P 664360-88-9P
 664360-96-7P 664361-37-9P 664361-38-0P



● RCI

RI 664360-75-2 CAPLUS
 CH 2-Morpholinemethanol, ω -[[3-fluorophenyl]- ω -[[2-methoxyphenyl]methyl]-, hydrochloride, (4*S*,2*S*)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● RCI

RI 664360-76-3 CAPLUS
 CH 2-Morpholinemethanol, ω -phenyl- ω -[[2-(trifluoromethyl)phenyl]methyl]-, hydrochloride, (4*S*,2*S*)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

XX 664360-77-4 CAPLUS
CH 2-Morpholinomethanol, α -[1,1'-biphenyl]-2-ylmethyl]- α -phenyl-, hydrochloride, (4R,2S)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


XX 664360-84-3 CAPLUS
CH 2-Morpholinomethanol, α -[2-methylphenylmethyl]- α -phenyl-, hydrochloride, (4R,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

XX 664360-88-7 CAPLUS
CH 2-Morpholinomethanol, α -[2'-chloro[1,1'-biphenyl]-2-ylmethyl]- α -phenyl-, hydrochloride, (4R,2S)- (PCI) (CA INDEX NAME)




● HCl

XX 664361-37-9 CAPLUS
CH 2-Morpholinomethanol, α -phenyl- α -[2-(trifluoromethyl)phenylmethyl]- (CA INDEX NAME)



XX 664361-38-0 CAPLUS
CH 2-Morpholinomethanol, α -phenyl- α -[2-(trifluoromethyl)phenylmethyl]-, (4R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



XX 664361-39-1 CAPLUS
CH 2-Morpholinomethanol, α -[5-fluoro-2-methoxyphenylmethyl]- α -phenyl-, (CA INDEX NAME)




Absolute stereochemistry.



● HCl

XX 664360-89-5 CAPLUS
CH 2-Morpholinomethanol, α -[5-fluoro-2-hydroxyphenylmethyl]- α -phenyl-, hydrochloride, (4R,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

XX 664360-96-7 CAPLUS
CH 2-Morpholinomethanol, α -[4-fluoro[1,1'-biphenyl]-2-ylmethyl]- α -phenyl-, hydrochloride, (4R,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.

XX 664361-40-4 CAPLUS
CH 2-Morpholinomethanol, α -[5-fluoro-2-methoxyphenylmethyl]- α -phenyl-, (4R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	54.98	429.58
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-8.00	-8.00

FILE 'REGISTRY' ENTERED AT 12:15:50 ON 14 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6
 DICTIONARY FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of

```

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-12 7-8 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-6 1-14 2-3 2-18 3-4 3-19 4-5 5-6 5-21 6-20 7-17 15-16 15-17
15-21 15-26 26-27
normalized bonds :
7-12 7-8 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

```

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 26:CLASS 27:CLASS

```

L10 STRUCTURE UPLOADED



=> d

L10 HAS NO ANSWERS

L10 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.



```

chain nodes :
14 15 16 17 18 19 20 21 26 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-14 2-18 3-19 5-21 6-20 7-17 15-16 15-17 15-21 15-26 26-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-12 7-8 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-6 1-14 2-3 2-18 3-4 3-19 4-5 5-6 5-21 6-20 7-17 15-16 15-17
15-21 15-26 26-27
normalized bonds :
7-12 7-8 8-9 9-10 10-11 11-12

```

=> s l13 full
FULL SEARCH INITIATED 12:20:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 18294 TO ITERATE

100.0% PROCESSED 18294 ITERATIONS
SEARCH TIME: 00.00.01

28 ANSWERS


L15 28 SEA SSS FUL L13

=> s l15 and caplus/lc
56059609 CAPLUS/LC
L16 23 L15 AND CAPLUS/LC

=> s l15 not l16
L17 5 L15 NOT L16

=> d l17 1-5

117 ANWEX 1 OF 5 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 851431-23-3 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemetanol, α -(tetrahydro-2H-pyran-4-yl)- ω -[12-
 (4-((1-fluoro- ω -heptyl)phenyl)methyl)]- (CA INDEX NAME)
 MF C19 H24 F2 N O4
 CI COH
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

117 ANWEX 2 OF 5 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-22-2 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemetanol, α -cyclopentyl- ω -[14-fluoro[1,1'-
 biphenyl]-2-yl)methyl]- (CA INDEX NAME)
 MF C25 H23 F N O2
 CI COH
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

117 ANWEX 3 OF 5 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-20-0 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemetanol, α -cyclopentyl- ω -[12-
 (4-((1-fluoro- ω -heptyl)phenyl)methyl)]- (CA INDEX NAME)
 MF C19 H24 F2 N O2
 CI COH
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

117 ANWEX 4 OF 5 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-19-7 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemetanol, α -cyclopentyl- ω -[12-ethoxyphenyl)methyl]-
 (CA INDEX NAME)
 MF C19 H23 N O2
 CI COH
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	374.63	804.21
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-8.00

FILE 'CAPLUS' ENTERED AT 12:20:45 ON 14 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Feb 2008 VOL 148 ISS 7
 FILE LAST UPDATED: 13 Feb 2008 (20080213/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 12:12:41 ON 14 FEB 2008)

FILE 'REGISTRY' ENTERED AT 12:12:55 ON 14 FEB 2008

L1 STRUCTURE UPLOADED
 L2 0 S L1
 L3 0 S L1 FULL

FILE 'STNGUIDE' ENTERED AT 12:13:41 ON 14 FEB 2008

FILE 'REGISTRY' ENTERED AT 12:14:21 ON 14 FEB 2008

L4 STRUCTURE UPLOADED
 L5 7 S L4
 L6 159 S L4 FULL
 L7 119 S L6 AND CAPLUS/LC
 L8 40 S L6 NOT L7

FILE 'CAPLUS' ENTERED AT 12:15:15 ON 14 FEB 2008

L9 10 S L7

FILE 'REGISTRY' ENTERED AT 12:15:50 ON 14 FEB 2008

L10 STRUCTURE UPLOADED
 L11 1 S L10

L12 28 S L10 FULL
L13 STRUCTURE UPLOADED
L14 1 S L13
L15 28 S L13 FULL
L16 23 S L15 AND CAPLUS/LC
L17 5 S L15 NOT L16

FILE 'CAPLUS' ENTERED AT 12:20:45 ON 14 FEB 2008

=> s l16

L18 4 L16

=> d ibib abs hitstr 1-4

118 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)
 ACCESSION NUMBER: 2009:95116 CAPLUS
 TITLE: Biomarker-guided attention deficit-hyperactivity disorder (ADHD) treatment with selective norepinephrine reuptake inhibitors
 INVENTOR(S): Lawrence, Donald Gilbert
 PATENT ASSIGNER(S): USA
 SOURCE: U.S. Pat. Appl. Publ., App. 2008:0080000
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2009020787	AL	20090214	US 2007-674999	20070330
PRIORITY APPL. INFO.			US 2006-788009	P 20060331


AB The invention provides methods for predicting patient responsiveness to treatment of attention-deficit/hyperactivity disorder (ADHD) with selective norepinephrine reuptake inhibitors identifying individuals requiring a higher than normal dose of atomoxetine for treating ADHD and predicting patient responsiveness to treatment of neuropsychiatric diseases or disorders responsive to treatment with selective norepinephrine reuptake inhibitors are provided. These methods are based on the identification of the variable number of tandem repeats (VNTR) polymorphism present in the 3'-untranslated region of the human dopamine transporter 1 (DAT 1) gene present in patient body fluid or tissue samples. Patients with a 10/10 VNTR genotype are considered poor responders to treatment with atomoxetine and other selective norepinephrine reuptake inhibitors for the indicated conditions.

IT 852376-82-9 852377-54-8 852377-54-8b, salts
 RX PKC (Pharmacological activity); TRD (Therapeutic use); RIGS (Pharmacological study); URES (Uses)
 (Biomarker-guided attention deficit-hyperactivity disorder and neuropsychiatric disorder treatment with selective norepinephrine reuptake inhibitors)

RU 852376-82-9 CAPLUS
 CN 2-Morpholinomethanol, α -[5-fluoro-2-methoxyphenylmethyl]- ω -[tetrahydro-2H-pyran-4-yl]-, hydrochloride (1:1), (4a,2b)-rel- (CA INDEX NAME)

Relative stereochemistry.


118 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)



● RCI


RU 852377-54-8 CAPLUS
 CN 2-Morpholinomethanol, α -[5-fluoro-2-methoxyphenylmethyl]- ω -[tetrahydro-2H-pyran-4-yl]-, (4a,2b)-rel- (CA INDEX NAME)

Relative stereochemistry.



RU 852377-54-8 CAPLUS
 CN 2-Morpholinomethanol, α -[5-fluoro-2-methoxyphenylmethyl]- ω -[tetrahydro-2H-pyran-4-yl]-, (4a,2b)-rel- (CA INDEX NAME)

Relative stereochemistry.



118 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)

118 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS ON STM
 ACCESSION NUMBER: 2006:1331209 CAPLUS
 DOCUMENT NUMBER: 146:223523

TITLE: Synthesis of ¹¹C-labelled (R)-ORMD and CPMD and their evaluation as candidate radioligands for


Imaging central norepinephrine transporters with PET
 AUTHOR(S): Schen, Magnus; Fife, Victor W.; Savage, Judith; Walters, Balazs; Gallagher, Peter T.; Debono, David S.; Magnus M.; Roddy, Helene; Farde, Lars; Balldin, Christer
 CORPORATE SOURCE: Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital, Stockholm, S-17176, Swed.
 SOURCE: Bioorganic & Medicinal Chemistry (2007), 15(12), 616-625
 COUNTRY: SWEDEN; ISSN: 0968-0896
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CORDISACT 146:223523

AB (R)-1-(10,11-Dihydro-silbenolol,flaressin-5-yl)-3-methylamino-propan-2-ol ((R)-ORMD) and (R)-2-(1-cyclopentyl-3-(5-fluoro-2-methoxy-phenyl)-2-morpholin-2-yl)-ethanol (CPMD) were synthesized and found to be potent inhibitors of norepinephrine reuptake. Each was labeled efficiently in its Me group with carbon-11 (t_{1/2} = 20.4 min) as a prospective radioligand

for imaging brain norepinephrine transporters (NET) with positron emission tomography (PET). The uptake and distribution of radioactivity in brain following i.v. injection of each radioligand into synovectomized mice was examined *in vivo* with PET. After injection of (R)-[¹¹C]ORMD, the maximal whole brain uptake of radioactivity was very low (1.1% of injected dose) 1.D.). For occipital cortex, thalamus, lower brainstem, mammillary and cerebellum, radioactivity ratios to striatum at 93 min after radioligand injection were 1.35, 1.25, 1.2, 1.2 and 1.0, resp. After injection of [11C]CPMD, radioactivity readily entered brain (1.5% 1.D.). Ratios of radioactivity to cerebellum at 93 min for thalamus, occipital cortex, region of locus coeruleus, mammillary and striatum were 1.25, 1.7, 1.2 and 1.3, resp.

1.2 and 1.3, resp. Radioactive metabolites in plasma were measured by radio-HPLC. (R)-[¹¹C]ORMD represented 73% of plasma radioactivity at 8 min after injection and 68 at 30 min. After injection of [11C]CPMD, 68% of the radioactivity in plasma represented parent at 8 min and 20% at 30 min. Since the two new hydroxylated radioligands provide only modest regional differentiation in brain uptake and form potentially troublesome lipophilic radioactive metabolites, they are concluded to be inferior to existing radioligands, such as (S,S)-[11C]MAG, (S,S)-[11C]MAGNE-32 and (S,S)-[11C]PBE-34, for the study of brain NETs with PET *in vivo*.

IT 923227-42-39
 RU RDN (Diagnostic use); PET (Pharmacokinetics); SW (Synthetic preparation); RIG (Biological study); PREP (Preparation); URES (Uses)
 (Preparation of ¹¹C-labelled (R)-ORMD and CPMD as candidate radioligands for PET imaging of central norepinephrine transporters)



● RCI

IT 852236-81-4P 852237-05-5P 852237-08-2P
852237-11-7P
Rx: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THO (Therapeutic use); RGS (Biological study); PREP (Preparation); RACT (Reactant or reagent); USGS (Uses)
[Preparation of morpholine derivs. as xeropsaphrine reuptake inhibitors]

RN 852236-81-4 CAPLUS
CN 2-Morpholinemetanol, α -[1,1'-biphenyl]-2-ylmethyl]- α -(4-tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 852237-05-9 CAPLUS
CN 2-Morpholinemetanol, α -cyclopropyl]- α -[12-methoxyphenyl]methyl]- (CA INDEX NAME)



RN 852237-08-2 CAPLUS
CN 2-Morpholinemetanol, α -cyclopropyl]- α -[12-methoxyphenyl]methyl]- (CA INDEX NAME)

118 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS ON STM (Continued)
CN 2-Morpholinemetanol, α -cyclopropyl]- α -[12-methoxyphenyl]methyl]-, hydrochloride (PCL) (CA INDEX NAME)



● RCI

RN 852236-72-7 CAPLUS
CN 2-Morpholinemetanol, α -cyclopentyl]- α -[12-(trifluoromethyl)phenyl]methyl]-, hydrochloride (PCL) (CA INDEX NAME)



● RCI

RN 852236-74-9 CAPLUS
CN 2-Morpholinemetanol, α -[1,1'-biphenyl]-2-ylmethyl]- α -cyclopentyl]-, hydrochloride (PCL) (CA INDEX NAME)



● RCI



RN 852237-11-7 CAPLUS
CN 2-Morpholinemetanol, α -[1,1'-biphenyl]-2-ylmethyl]- α -cyclopropyl]- (CA INDEX NAME)



IT 852236-68-1P 852236-70-1P 852236-72-1P
852236-74-9P 852236-76-1P 852236-78-1P
852236-84-1P 852236-86-1P 852236-90-1P
852237-04-9P 852237-07-1P 852237-10-9P
852237-53-7P 852237-54-8P
Rx: PAC (Pharmacological activity); RSN (Synthetic preparation); THO (Therapeutic use); RGS (Biological study); PREP (Preparation); USGS (Uses)
[Preparation of morpholine derivs. as xeropsaphrine reuptake inhibitors]

RN 852236-68-1 CAPLUS
CN 2-Morpholinemetanol, α -cyclopentyl]- α -[15-fluoro-2-methoxyphenyl]methyl]-, hydrochloride (PCL) (CA INDEX NAME)



● RCI

RN 852236-70-5 CAPLUS

RN 852236-76-1 CAPLUS
CN 2-Morpholinemetanol, α -cyclopentyl]- α -[14-fluoro-1,1'-biphenyl]-2-ylmethyl]-, hydrochloride (PCL) (CA INDEX NAME)




● RCI

RN 852236-78-3 CAPLUS
CN 2-Morpholinemetanol, α -[15-fluoro-2-methoxyphenyl]methyl]- α -(tetrahydro-2H-pyran-4-yl)-, hydrochloride (PCL) (CA INDEX NAME)



● RCI

RN 852236-84-1 CAPLUS
CN 2-Morpholinemetanol, α -(tetrahydro-2H-pyran-4-yl)- α -[12-(trifluoromethyl)phenyl]methyl]-, hydrochloride (PCL) (CA INDEX NAME)



● PC1

RN 852236-86-3 CAPLUS
CN 2-Morpholinemethanol, 4-((1,1'-biphenyl)-2-ylmethyl)-
-tetrahydro-2H-pyran-4-yl)-, hydrochloride (PC1) (CA INDEX NAME)



● PC1

RN 852236-89-9 CAPLUS
CN 2-Morpholinemethanol, 4-((5-fluoro[1,1'-biphenyl]-2-yl)methyl)-
-tetrahydro-2H-pyran-4-yl)-, hydrochloride (PC1) (CA INDEX NAME)



● PC1

RN 852237-04-8 CAPLUS
CN 2-Morpholinemethanol, 4-cyclopropyl-4-((2-



● PC1

RN 852237-07-3 CAPLUS
CN 2-Morpholinemethanol, 4-cyclopropyl-4-((2-methoxyphenyl)methyl)-
-hydrochloride (PC1) (CA INDEX NAME)



● PC1

RN 852237-10-6 CAPLUS
CN 2-Morpholinemethanol, 4-((1,1'-biphenyl)-2-ylmethyl)-4-
-cyclopropyl-, hydrochloride (PC1) (CA INDEX NAME)




● PC1

RN 852237-53-7 CAPLUS
CN 2-Morpholinemethanol, 4-((5-fluoro-2-methoxyphenyl)methyl)-4-
-tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 852237-54-8 CAPLUS
CN 2-Morpholinemethanol, 4-((5-fluoro-2-methoxyphenyl)methyl)-4-
-tetrahydro-2H-pyran-4-yl)-, (4S,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 852236-91-0P
SL PC1 (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of morpholine deriv. as norepinephrine reuptake
inhibitor)

RN 852236-91-0 CAPLUS
CN 2-Morpholinemethanol, 4-((3'-fluoro[1,1'-biphenyl]-2-yl)methyl)-
-tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	22.76	826.97
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.20	-11.20

FILE 'REGISTRY' ENTERED AT 12:21:40 ON 14 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6
 DICTIONARY FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of

```

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-12 7-8 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-6 1-14 2-3 2-18 3-4 3-19 4-5 5-6 5-21 6-20 7-17 15-16 15-17
15-21 15-26 26-27
normalized bonds :
7-12 7-8 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

```

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 26:CLASS 27:CLASS

```

L19 STRUCTURE UPLOADED

=> d

L19 HAS NO ANSWERS

L19 STR



FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 16524 TO 20156
PROJECTED ANSWERS: 8 TO 329

L20 8 SEA SSS SAM L19

=> s l19 full
FULL SEARCH INITIATED 12:22:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 18294 TO ITERATE

100.0% PROCESSED 18294 ITERATIONS
SEARCH TIME: 00.00.01

196 ANSWERS

L21 196 SEA SSS FUL L19

=> s l21 and caplus
0 CAPLUS
L22 0 L21 AND CAPLUS


=> s l21 and caplus/lc
56059609 CAPLUS/LC
L23 136 L21 AND CAPLUS/LC

=> s l21 not l23
L24 60 L21 NOT L23

=> d l24 1-60

124 ANSWER 1 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 884511-43-2 REGISTRY
 ED Entered STN: 15 May 2006
 CN 2-Morpholinemetanol, *m*-(3-chlorophenyl)-*m*-(4-methoxybutyl)-,
 (4*R*,2*S*)-rel- (CA INDEX NAME)
 FS STEREOBOND
 MF C16 H24 Cl N O2
 CI OOH
 SN CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 2 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-26-1 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemetanol, *m*-[(2'-chloro[1,1'-biphenyl]-2-yl)methyl]-
m-phenyl-, (4*R*,2*S*)-rel- (CA INDEX NAME)
 FS STEREOBOND
 MF C24 H24 Cl N O2
 CI OOH
 SN CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 3 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-25-0 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemetanol, *m*-[2-(4-fluorophenyl)methyl]-*m*-phenyl-,
 (4*R*,2*S*)-rel- (CA INDEX NAME)
 FS STEREOBOND
 MF C18 H20 F N O2
 CI OOH
 SN CA

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 4 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-24-9 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemetanol, *m*-phenyl-*m*-(phenylmethyl)-,
 (4*R*,2*S*)-rel- (CA INDEX NAME)
 FS STEREOBOND
 MF C18 H22 N O2
 CI OOH
 SN CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 5 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 857729-23-8 REGISTRY
 ED Entered STM: 31 Jul 2005
 CN 2-Morpholinemetanabol, s-[(2-methylphenyl)methyl]-s-phenyl-,
 (8R,2S)-rel- (CA INDEX NAME)
 FS STEREOCENERS
 MF C18 R23 N O2
 CI OOH
 SN CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 6 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 857729-22-7 REGISTRY
 ED Entered STM: 31 Jul 2005
 CN 2-Morpholinemetanabol, s-[(2-chlorophenyl)methyl]-s-(3-fluorophenyl)-, (8R,2S)-rel- (CA INDEX NAME)
 FS STEREOCENERS
 MF C18 R19 Cl F N O2
 CI OOH
 SN CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 7 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 857729-21-6 REGISTRY
 ED Entered STM: 31 Jul 2005
 CN 2-Morpholinemetanabol, s-[(5-fluoro-2-methoxyphenyl)methyl]-s-phenyl-, (8R,2S)-rel- (CA INDEX NAME)
 FS STEREOCENERS
 MF C18 R22 F N O3
 CI OOH
 SN CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 8 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 857729-20-5 REGISTRY
 ED Entered STM: 31 Jul 2005
 CN 2-Morpholinemetanabol, s-[(2-chlorophenyl)methyl]-s-phenyl-, (8R,2S)-rel- (CA INDEX NAME)
 FS STEREOCENERS
 MF C18 R20 Cl N O2
 CI OOH
 SN CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 9 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-19-2 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemetanol, *e*-{[1'-(*n*-phenyl)-2-ylmethyl]-*e*-phenyl}-
 , (4*R*,2*S*)-rel- (CA INDEX NAME)
 FS STEREOISOMER
 MF C24 H25 N O2
 CI COH
 SA CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 10 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-18-1 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemetanol, *e*-phenyl-*e*-{[2-(trifluoromethoxy)phenyl]methyl}-, (4*R*,2*S*)-rel- (CA INDEX NAME)
 FS STEREOISOMER
 MF C19 H19 F3 N O2
 CI COH
 SA CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 11 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-17-0 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemetanol, *e*-{3-[4-oxocyclohexyl]-*e*-{[2-methoxyphenyl]methyl}-, (4*R*,2*S*)-rel- (CA INDEX NAME)
 FS STEREOISOMER
 MF C18 H22 F N O3
 CI COH
 SA CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 12 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-16-9 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemetanol, *e*-{[2-(1-methylethoxy)phenyl]methyl]-*e*-phenyl}-, (4*R*,2*S*)-rel- (CA INDEX NAME)
 FS STEREOISOMER
 MF C21 H27 N O2
 CI COH
 SA CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 13 OF 40 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 85729-15-8 REGISTRY
 ED Entered STM: 21 Jul 2005
 CN 2-Morpholinomethanol, α -(2-methoxyphenyl)methyl- α -phenyl-,
 (R₂,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 R25 N O2
 CI COM
 SA CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 14 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 85729-14-7 REGISTRY
 ED Entered STM: 21 Jul 2005
 CN 2-Morpholinomethanol, α -(2-methoxyphenyl)methyl- α -phenyl-,
 (R₂,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 R23 N O2
 CI COM
 SA CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 13 OF 40 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 85742-47-8 REGISTRY
 ED Entered STM: 23 Jul 2005
 CN 2-Morpholinomethanol, α -phenyl- α -[2-
 (trifluoromethyl)thio]phenyl)methyl-, (R₂,2S)-rel- (CA INDEX
 NAME)
 FS STEREOSEARCH
 MF C19 R25 P3 N O2 S
 CI COM
 SA CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 16 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 854302-51-5 REGISTRY
 ED Entered STM: 10 Jul 2005
 CN 2-Morpholinomethanol, α -[4-fluoro[3,1'-biphenyl]-2-yl)methyl]-
 α -phenyl-, (R₂,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 R24 F N O2
 CI COM
 SA CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 17 OF 40 REGISTRY COPYRIGHT 2008 ACS on STN
 EN 854302-50-4 REGISTRY
 ED Entered STN: 10 Jul 2005
 CN 2-Morpholinamethanol, *m*-[(2,5-difluorophenyl)methyl]-*n*-phenyl-
 , (4*S*,2*S*)-rel- (CA INDEX NAME)
 FS STEREOBOND
 MF C18 R19 F2 N O2
 CI CON
 SN CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 18 OF 40 REGISTRY COPYRIGHT 2008 ACS on STN
 EN 854302-49-1 REGISTRY
 ED Entered STN: 10 Jul 2005
 CN 2-Morpholinamethanol, *m*-[(2,5-dichlorophenyl)methyl]-*n*-phenyl-
 , (4*S*,2*S*)-rel- (CA INDEX NAME)
 FS STEREOBOND
 MF C18 R19 C12 N O2
 CI CON
 SN CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 19 OF 40 REGISTRY COPYRIGHT 2008 ACS on STN
 EN 854302-49-0 REGISTRY
 ED Entered STN: 10 Jul 2005
 CN 2-Morpholinamethanol, *m*-[(2,6-dichlorophenyl)methyl]-*n*-phenyl-
 , (4*S*,2*S*)-rel- (CA INDEX NAME)
 FS STEREOBOND
 MF C18 R19 C12 N O2
 CI CON
 SN CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 20 OF 40 REGISTRY COPYRIGHT 2008 ACS on STN
 EN 854302-47-9 REGISTRY
 ED Entered STN: 10 Jul 2005
 CN 2-Morpholinamethanol, *m*-[(2,4-difluorophenyl)methyl]-*n*-phenyl-
 , (4*S*,2*S*)-rel- (CA INDEX NAME)
 FS STEREOBOND
 MF C18 R19 F2 N O2
 CI CON
 SN CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 21 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 854302-46-3 REGISTRY
 ED Entered STN: 12 Jul 2005
 CN 2-Morpholinometanohol, α -[(2,5-dimethoxyphenyl)methyl]- α -phenyl-
 , (4S,12)-rel- (CA INDEX NAME)
 FS 5753252A3CH
 MF C18 H25 N O4
 CI COH
 SR CA


Relative stereochemistry:



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 22 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 854302-45-7 REGISTRY
 ED Entered STN: 12 Jul 2005
 CN 2-Morpholinometanohol, α -[(2-chloro-6-fluorophenyl)methyl]- α -
 phenyl-, (4S,2S)-rel- (CA INDEX NAME)
 FS 5753252A3CH
 MF C18 H19 Cl F N O2
 CI COH
 SR CA

Relative stereochemistry:



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 23 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-32-3 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinometanohol, α -[(2-chlorophenyl)methyl]- α -(2-
 methylpropyl)- (CA INDEX NAME)
 MF C14 H24 Cl N O2
 CI COH
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 24 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-32-4 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinometanohol, α -[(2-chloro-6-fluorophenyl)methyl]- α -(2-
 methylpropyl)- (CA INDEX NAME)
 MF C16 H23 Cl F N O2
 CI COH
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 25 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-31-3 REGISTRY
 ED Entered EFTN: 17 Jun 2005
 CN 2-Morpholinomethyl, *n*-{[1,1'-bis(phenyl)-2-ylmethyl]-*n*-butyl}-
 (CA INDEX NAME)
 MF C23 H29 N O2
 CI COH
 SR CA




***PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

124 ANSWER 26 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-30-2 REGISTRY
 ED Entered EFTN: 17 Jun 2005
 CN 2-Morpholinomethyl, *n*-butyl-*n*-{[2-methoxyphenyl)methyl]-
 (CA INDEX NAME)
 MF C17 H27 N O2
 CI COH
 SR CA




***PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

124 ANSWER 27 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-28-8 REGISTRY
 ED Entered EFTN: 17 Jun 2005
 CN 2-Morpholinomethyl, *n*,*n*-bis{[2-methoxyphenyl)methyl]- (CA
 INDEX NAME)
 MF C21 H27 N O4
 CI COH
 SR CA



***PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

124 ANSWER 28 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-27-7 REGISTRY
 ED Entered EFTN: 17 Jun 2005
 CN 2-Morpholinomethyl, *n*-{[5-*l*-isocro-2-methoxyphenyl)methyl]-*n*-
 (4,4,4-trifluorobutyl)- (CA INDEX NAME)
 MF C17 H23 F4 N O2
 CI COH
 SR CA




***PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

124 NUMBER 29 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-26-6 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemetanol, ω -[1,1'-biphenyl]-2-ylmethyl)- ω -[3,3'-
 trifiuoropropyl)- (CA INDEX NAME)
 MF C17 H24 F3 N O2
 CI COH
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 NUMBER 30 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-25-5 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemetanol, ω -[2-(trifluoromethoxy)phenyl]methyl)- ω -
 [3,3'-trifiuoropropyl)- (CA INDEX NAME)
 MF C16 H19 F3 N O2
 CI COH
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 NUMBER 32 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-24-4 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemetanol, ω -[5-fluoro-2-methoxyphenyl]methyl)- ω -
 [3,3'-trifiuoropropyl)- (CA INDEX NAME)
 MF C17 H21 F4 N O2
 CI COH
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 NUMBER 33 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-17-5 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemetanol, ω -[2-methylpropyl)- ω -[2-(
 trifluoromethoxy)phenyl]methyl)- (CA INDEX NAME)
 MF C17 H24 F3 N O2
 CI COH
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 33 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-16-4 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinometanol, *o*-{[5-fluoro-2-methoxyphenyl]methyl}-*o*-
 [2-methylbutyl]- (CA INDEX NAME)
 MF C15 H26 F N O3
 CI COH
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 34 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-15-2 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinometanol, *o*-{[4-fluoro[1,1'-biphenyl]-2-yl]methyl}-
o-[1-methylbutyl]- (CA INDEX NAME)
 MF C21 H28 F N O2
 CI COH
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 35 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-14-2 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinometanol, *o*-{[1,1'-biphenyl]-2-ylmethyl}-*o*-[1-
 methylbutyl]- (CA INDEX NAME)
 MF C21 H27 N O2
 CI COH
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 36 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-13-1 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinometanol, *o*-{[2-(trifluoromethyl)phenyl]methyl}-
 [2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)
 MF C16 H22 F3 N O2
 CI COH
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 37 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 851431-12-6 REGISTRY
 ED Entered STM: 17-Jun-2005
 CN 2-Morpholinometanol, ω -[5-fluoro-2-methoxyphenylmethyl]- ω -
 [1-methyl-ethyl]- (CA INDEX NAME)
 MF C14 H14 F N O2
 CI COM
 SS CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 38 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 851431-11-9 REGISTRY
 ED Entered STM: 17-Jun-2005
 CN 2-Morpholinometanol, ω -[1,1'-bisphenyl]-2-ylmethyl)- ω -ethyl-
 (CA INDEX NAME)
 MF C20 H25 N O2
 CI COM
 SS CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 39 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 851431-10-8 REGISTRY
 ED Entered STM: 17-Jun-2005
 CN 2-Morpholinometanol, ω -ethyl)- ω -[12-
 (trifluoromethoxy)phenylmethyl]- (CA INDEX NAME)
 MF C15 H20 F3 N O2
 CI COM
 SS CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 40 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 851431-09-5 REGISTRY
 ED Entered STM: 17-Jun-2005
 CN 2-Morpholinometanol, ω -ethyl)- ω -[5-fluoro-2-
 methoxyphenylmethyl]- (CA INDEX NAME)
 MF C15 H22 F N O2
 CI COM
 SS CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


124 ANSWER 41 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 851431-68-4 REGISTRY
 ED Entered STN: 17-Dec-2005
 CN 2-Morpholinometan-ol, α -([1,1'-biphenyl]-2-ylmethyl)- α -methyl-
 (CA INDEX NAME)
 MF C19 H21 N O2
 CI COH
 SS CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 42 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 793646-65-6 REGISTRY
 ED Entered STN: 07-Dec-2004
 CN 2-Morpholinometan-ol, α -([2-chlorophenyl)methyl]- α -phenyl-,
 (4R,2S)- (CA INDEX NAME)
 FE STEREOSKARCH
 MF C18 H20 Cl N O2
 CI COH
 SS CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 43 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 796207-20-4 REGISTRY
 ED Entered STN: 23-Nov-2004
 CN 2-Morpholinometan-ol, α -([2-chlorophenyl)methyl]- α -([3-fluorophenyl]-,
 (4R,2S)- (CA INDEX NAME)
 FE STEREOSKARCH
 MF C18 H19 Cl F N O2
 CI COH
 SS CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 44 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 788156-38-7 REGISTRY
 ED Entered STN: 35-Nov-2004
 CN 2-Morpholinometan-ol, α -([3-fluorophenyl]- α -([2-methoxyphenyl)methyl]-,
 (4R,2S)- (CA INDEX NAME)
 FE STEREOSKARCH
 MF C19 H22 F N O3
 CI COH
 SS CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 45 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 785041-43-0 REGISTRY
 ED Entered STN: 21 Nov 2004
 CN 2-Morpholinemetanol, α -[(2,6-dichlorophenyl)methyl]- α -phenyl-
 , (4S,2S)- (CA INDEX NAME)
 FS STEREOISOMER
 MF C18 H19 Cl2 N O2
 CI COH
 SM CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 46 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 760944-34-1 REGISTRY
 ED Entered STN: 12 Oct 2004
 CN 2-Morpholinemetanol, α -[(2-Ethoxyphenyl)methyl]- α -phenyl-,
 (4S,2S)- (CA INDEX NAME)
 FS STEREOISOMER
 MF C18 H20 F N O2
 CI COH
 SM CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 41 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 760172-63-2 REGISTRY
 ED Entered STN: 11 Oct 2004
 CN 2-Morpholinemetanol, α -[(2'-ethoxy[1,1'-biphenyl]-2-yl)methyl]-
 α -phenyl-, (4S,2S)- (CA INDEX NAME)
 FS STEREOISOMER
 MF C24 H24 Cl N O2
 CI COH
 SM CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 48 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 758694-59-2 REGISTRY
 ED Entered STN: 08 Oct 2004
 CN 2-Morpholinemetanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-,
 (4S,2S)- (CA INDEX NAME)
 FS STEREOISOMER
 MF C20 H23 N O2
 CI COH
 SM CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 49 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 757940-98-6 REGISTRY
 ED Entered STN: 97 Oct 2004
 CN 2-Morpholinemetanol, *m*-[(2-methylphenyl)methyl]-*n*-phenyl-,
 (R₁,2S)- (CA INDEX NAME)
 FS STEREOSOURCE
 MF C18 R13 N O2
 CI COM
 SA CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 50 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 756475-53-3 REGISTRY
 ED Entered STN: 94 Oct 2004
 CN 2-Morpholinemetanol, *m*-[(2,4-difluorophenyl)methyl]-*n*-phenyl-,
 (R₁,2S)- (CA INDEX NAME)
 FS STEREOSOURCE
 MF C18 R19 F2 N O2
 CI COM
 SA CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 51 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 752982-94-8 REGISTRY
 ED Entered STN: 25 Sep 2004
 CN 2-Morpholinemetanol, *m*-[(2,5-dichlorophenyl)methyl]-*n*-phenyl-,
 (R₁,2S)- (CA INDEX NAME)
 FS STEREOSOURCE
 MF C18 R19 Cl2 N O2
 CI COM
 SA CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 52 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 752203-49-3 REGISTRY
 ED Entered STN: 27 Sep 2004
 CN 2-Morpholinemetanol, *m*-[(2,5-dimethoxyphenyl)methyl]-*n*-phenyl-,
 (R₁,2S)- (CA INDEX NAME)
 FS STEREOSOURCE
 MF C20 R23 N O4
 CI COM
 SA CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 53 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 756170-01-5 REGISTRY
 ED Entered STM: 24 Sep 2004
 CN 2-Morpholinemetanol, *e*-[(2-methoxyphenyl)methyl]-*e*-phenyl-,
 (R₁,2S)- (CA INDEX NAME)
 FS STEREOISOMER
 MF C19 H21 N O3
 CI COH
 SA CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 54 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 747409-00-1 REGISTRY
 ED Entered STM: 19 Sep 2004
 CN 2-Morpholinemetanol, *e*-phenyl-*e*-(phenylmethyl)-,
 (R₁,2S)- (CA INDEX NAME)
 FS STEREOISOMER
 MF C18 H21 N O2
 CI COH
 SA CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 53 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 746190-00-1 REGISTRY
 ED Entered STM: 14 Sep 2004
 CN 2-Morpholinemetanol, *e*-[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-
e-phenyl-, (R₁,2S)- (CA INDEX NAME)
 FS STEREOISOMER
 MF C14 H14 F N O2
 CI COH
 SA CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANWEX 55 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 74618-05-7 REGISTRY
 ED Entered STM: 13 Sep 2004
 CN 2-Morpholinemetanol, *e*-[(2,5-difluorophenyl)methyl]-*e*-phenyl-,
 (R₁,2S)- (CA INDEX NAME)
 FS STEREOISOMER
 MF C18 H19 F2 N O2
 CI COH
 SA CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 57 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 736942-30-6 REGISTRY
 ED Entered STM: 02 Sep 2004
 CN 2-Morpholinemetanol, α -[(2-chloro-6-[isocyclohexyl]methyl)- α -phenyl]-, (4*S*,2*S*)- (CA INDEX NAME)
 FS STEREOBOND
 MP C18 R19 C1 F N O2
 CI CON
 SN CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 58 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 732983-60-7 REGISTRY
 ED Entered STM: 18 Aug 2004
 CN 2-Morpholinemetanol, α -[[2-(1-methylethoxy)phenyl]methyl]- α -phenyl-, (4*S*,2*S*)- (CA INDEX NAME)
 FS STEREOBOND
 MP C21 R27 N O3
 CI CON
 SN CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 19 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 701907-80-0 REGISTRY
 ED Entered STM: 30 Jun 2004
 CN 2-Morpholinemetanol, α -[[1-(4-phenyl)-2-ylmethyl]- α -phenyl]-, (4*S*,2*S*)- (CA INDEX NAME)
 FS STEREOBOND
 MP C14 R15 N O2
 CI CON
 SN CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

124 ANSWER 83 OF 60 REGISTRY COPYRIGHT 2008 ACS on STM
 RN 864360-80-9 REGISTRY
 ED Entered STM: 18 Mar 2004
 CN 2-Morpholinemetanol, α -phenyl- α -[[2-(trifluoromethyl)thiophenyl]methyl]-, (4*S*,2*S*)- (CA INDEX NAME)
 FS STEREOBOND
 MP C19 R20 F3 N O2 S
 CI CON
 SN CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
309.58	1136.55

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-11.20

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 12:23:15 ON 14 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Feb 2008 VOL 148 ISS 7
FILE LAST UPDATED: 13 Feb 2008 (20080213/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.

L12 28 S L10 FULL
L13 STRUCTURE UPLOADED
L14 1 S L13
L15 28 S L13 FULL
L16 23 S L15 AND CAPLUS/LC
L17 5 S L15 NOT L16

FILE 'CAPLUS' ENTERED AT 12:20:45 ON 14 FEB 2008
L18 4 S L16

FILE 'REGISTRY' ENTERED AT 12:21:40 ON 14 FEB 2008
L19 STRUCTURE UPLOADED
L20 8 S L19
L21 196 S L19 FULL
L22 0 S L21 AND CAPLUS
L23 136 S L21 AND CAPLUS/LC
L24 60 S L21 NOT L23


FILE 'CAPLUS' ENTERED AT 12:23:15 ON 14 FEB 2008

=> s l23
L25 14 L23

=> d ibib abs hitstr 1-14

125 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2004 ACS on STM (Continued)
 ACCESSION NUMBER: 2004:365001 CAPLUS
 DOCUMENT NUMBER: 144432692
 TITLE: Preparation of diaminoalkanes, particularly N-1-antagonist-2-ylpiperidine-1-carboxamides, as aspartic protease inhibitors
 INVENTOR(S): Balderis, John J.; Clareson, David A.; Thew, Colin; Constant, Salvatore; D'Silva, Lawrence M.; Ishchenko, Alexey V.; Tsao, Jang; Xu, Shengrong; Molecules
 Gerardi: Shao, Wei; Simpson, Robert D.; Singh, Buresh S.; Vlahovity, Patricia T.; Werry, Jean-Francoise
 PATENT ASSIGNOR(S): Vitas Pharmaceuticals, Inc, USA
 SOURCE: PCT Int. Appl., 755 pp.
 COUNTRY: FR3002
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACQ. INFO. COMMT: 1
 PATENT INFORMATION: 1

125 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2004 ACS on STM (Continued)



AB The invention is related to diaminoalkanes of formula R¹-N-(CR²)²-Y-A-Q-N(R³)-L- (I) R¹ = haloalkyl/cycloalkyl, (un)substituted Ph, naphthyl, heteroaryl, etc.; Y = independently CR² or a single bond; R² = (un)substituted alkyl/enyl, alkoalkyl, (un)substituted iminoalkyl, aminoalkyl/iminoalkyl, etc.; R³ = H, alkyl, CR and derivative, alkylamino/iminoalkyl, (un)substituted phenylamino, heteroarylaminoyl A

= (un)substituted (un)substituted 6- to 7-membered ring, which is optionally modified by CR² in Y via bonds to 2 members of said ring A and Y are attached to C or N atoms in ring A in a 1,2 or 1,3 or 1,4 relationship; Q = divalent radical selected from CO, C=S, SO₂, CO-OR, CO-CR, etc.; a = 1-3; Y = H or haloalkyl/cycloalkyl; L = (un)substituted linear (CR²-CR²)_n chain when C = CR, CR, NR, NR², NR³, NR⁴, NR⁵, NR⁶, NR⁷, NR⁸, NR⁹, NR¹⁰, NR¹¹, NR¹², NR¹³, NR¹⁴, NR¹⁵, NR¹⁶, NR¹⁷, NR¹⁸, NR¹⁹, NR²⁰, NR²¹, NR²², NR²³, NR²⁴, NR²⁵, NR²⁶, NR²⁷, NR²⁸, NR²⁹, NR³⁰, NR³¹, NR³², NR³³, NR³⁴, NR³⁵, NR³⁶, NR³⁷, NR³⁸, NR³⁹, NR⁴⁰, NR⁴¹, NR⁴², NR⁴³, NR⁴⁴, NR⁴⁵, NR⁴⁶, NR⁴⁷, NR⁴⁸, NR⁴⁹, NR⁵⁰, NR⁵¹, NR⁵², NR⁵³, NR⁵⁴, NR⁵⁵, NR⁵⁶, NR⁵⁷, NR⁵⁸, NR⁵⁹, NR⁶⁰, NR⁶¹, NR⁶², NR⁶³, NR⁶⁴, NR⁶⁵, NR⁶⁶, NR⁶⁷, NR⁶⁸, NR⁶⁹, NR⁷⁰, NR⁷¹, NR⁷², NR⁷³, NR⁷⁴, NR⁷⁵, NR⁷⁶, NR⁷⁷, NR⁷⁸, NR⁷⁹, NR⁸⁰, NR⁸¹, NR⁸², NR⁸³, NR⁸⁴, NR⁸⁵, NR⁸⁶, NR⁸⁷, NR⁸⁸, NR⁸⁹, NR⁹⁰, NR⁹¹, NR⁹², NR⁹³, NR⁹⁴, NR⁹⁵, NR⁹⁶, NR⁹⁷, NR⁹⁸, NR⁹⁹, NR¹⁰⁰, NR¹⁰¹, NR¹⁰², NR¹⁰³, NR¹⁰⁴, NR¹⁰⁵, NR¹⁰⁶, NR¹⁰⁷, NR¹⁰⁸, NR¹⁰⁹, NR¹¹⁰, NR¹¹¹, NR¹¹², NR¹¹³, NR¹¹⁴, NR¹¹⁵, NR¹¹⁶, NR¹¹⁷, NR¹¹⁸, NR¹¹⁹, NR¹²⁰, NR¹²¹, NR¹²², NR¹²³, NR¹²⁴, NR¹²⁵, NR¹²⁶, NR¹²⁷, NR¹²⁸, NR¹²⁹, NR¹³⁰, NR¹³¹, NR¹³², NR¹³³, NR¹³⁴, NR¹³⁵, NR¹³⁶, NR¹³⁷, NR¹³⁸, NR¹³⁹, NR¹⁴⁰, NR¹⁴¹, NR¹⁴², NR¹⁴³, NR¹⁴⁴, NR¹⁴⁵, NR¹⁴⁶, NR¹⁴⁷, NR¹⁴⁸, NR¹⁴⁹, NR¹⁵⁰, NR¹⁵¹, NR¹⁵², NR¹⁵³, NR¹⁵⁴, NR¹⁵⁵, NR¹⁵⁶, NR¹⁵⁷, NR¹⁵⁸, NR¹⁵⁹, NR¹⁶⁰, NR¹⁶¹, NR¹⁶², NR¹⁶³, NR¹⁶⁴, NR¹⁶⁵, NR¹⁶⁶, NR¹⁶⁷, NR¹⁶⁸, NR¹⁶⁹, NR¹⁷⁰, NR¹⁷¹, NR¹⁷², NR¹⁷³, NR¹⁷⁴, NR¹⁷⁵, NR¹⁷⁶, NR¹⁷⁷, NR¹⁷⁸, NR¹⁷⁹, NR¹⁸⁰, NR¹⁸¹, NR¹⁸², NR¹⁸³, NR¹⁸⁴, NR¹⁸⁵, NR¹⁸⁶, NR¹⁸⁷, NR¹⁸⁸, NR¹⁸⁹, NR¹⁹⁰, NR¹⁹¹, NR¹⁹², NR¹⁹³, NR¹⁹⁴, NR¹⁹⁵, NR¹⁹⁶, NR¹⁹⁷, NR¹⁹⁸, NR¹⁹⁹, NR²⁰⁰, NR²⁰¹, NR²⁰², NR²⁰³, NR²⁰⁴, NR²⁰⁵, NR²⁰⁶, NR²⁰⁷, NR²⁰⁸, NR²⁰⁹, NR²¹⁰, NR²¹¹, NR²¹², NR²¹³, NR²¹⁴, NR²¹⁵, NR²¹⁶, NR²¹⁷, NR²¹⁸, NR²¹⁹, NR²²⁰, NR²²¹, NR²²², NR²²³, NR²²⁴, NR²²⁵, NR²²⁶, NR²²⁷, NR²²⁸, NR²²⁹, NR²³⁰, NR²³¹, NR²³², NR²³³, NR²³⁴, NR²³⁵, NR²³⁶, NR²³⁷, NR²³⁸, NR²³⁹, NR²⁴⁰, NR²⁴¹, NR²⁴², NR²⁴³, NR²⁴⁴, NR²⁴⁵, NR²⁴⁶, NR²⁴⁷, NR²⁴⁸, NR²⁴⁹, NR²⁵⁰, NR²⁵¹, NR²⁵², NR²⁵³, NR²⁵⁴, NR²⁵⁵, NR²⁵⁶, NR²⁵⁷, NR²⁵⁸, NR²⁵⁹, NR²⁶⁰, NR²⁶¹, NR²⁶², NR²⁶³, NR²⁶⁴, NR²⁶⁵, NR²⁶⁶, NR²⁶⁷, NR²⁶⁸, NR²⁶⁹, NR²⁷⁰, NR²⁷¹, NR²⁷², NR²⁷³, NR²⁷⁴, NR²⁷⁵, NR²⁷⁶, NR²⁷⁷, NR²⁷⁸, NR²⁷⁹, NR²⁸⁰, NR²⁸¹, NR²⁸², NR²⁸³, NR²⁸⁴, NR²⁸⁵, NR²⁸⁶, NR²⁸⁷, NR²⁸⁸, NR²⁸⁹, NR²⁹⁰, NR²⁹¹, NR²⁹², NR²⁹³, NR²⁹⁴, NR²⁹⁵, NR²⁹⁶, NR²⁹⁷, NR²⁹⁸, NR²⁹⁹, NR³⁰⁰, NR³⁰¹, NR³⁰², NR³⁰³, NR³⁰⁴, NR³⁰⁵, NR³⁰⁶, NR³⁰⁷, NR³⁰⁸, NR³⁰⁹, NR³¹⁰, NR³¹¹, NR³¹², NR³¹³, NR³¹⁴, NR³¹⁵, NR³¹⁶, NR³¹⁷, NR³¹⁸, NR³¹⁹, NR³²⁰, NR³²¹, NR³²², NR³²³, NR³²⁴, NR³²⁵, NR³²⁶, NR³²⁷, NR³²⁸, NR³²⁹, NR³³⁰, NR³³¹, NR³³², NR³³³, NR³³⁴, NR³³⁵, NR³³⁶, NR³³⁷, NR³³⁸, NR³³⁹, NR³⁴⁰, NR³⁴¹, NR³⁴², NR³⁴³, NR³⁴⁴, NR³⁴⁵, NR³⁴⁶, NR³⁴⁷, NR³⁴⁸, NR³⁴⁹, NR³⁵⁰, NR³⁵¹, NR³⁵², NR³⁵³, NR³⁵⁴, NR³⁵⁵, NR³⁵⁶, NR³⁵⁷, NR³⁵⁸, NR³⁵⁹, NR³⁶⁰, NR³⁶¹, NR³⁶², NR³⁶³, NR³⁶⁴, NR³⁶⁵, NR³⁶⁶, NR³⁶⁷, NR³⁶⁸, NR³⁶⁹, NR³⁷⁰, NR³⁷¹, NR³⁷², NR³⁷³, NR³⁷⁴, NR³⁷⁵, NR³⁷⁶, NR³⁷⁷, NR³⁷⁸, NR³⁷⁹, NR³⁸⁰, NR³⁸¹, NR³⁸², NR³⁸³, NR³⁸⁴, NR³⁸⁵, NR³⁸⁶, NR³⁸⁷, NR³⁸⁸, NR³⁸⁹, NR³⁹⁰, NR³⁹¹, NR³⁹², NR³⁹³, NR³⁹⁴, NR³⁹⁵, NR³⁹⁶, NR³⁹⁷, NR³⁹⁸, NR³⁹⁹, NR⁴⁰⁰, NR⁴⁰¹, NR⁴⁰², NR⁴⁰³, NR⁴⁰⁴, NR⁴⁰⁵, NR⁴⁰⁶, NR⁴⁰⁷, NR⁴⁰⁸, NR⁴⁰⁹, NR⁴¹⁰, NR⁴¹¹, NR⁴¹², NR⁴¹³, NR⁴¹⁴, NR⁴¹⁵, NR⁴¹⁶, NR⁴¹⁷, NR⁴¹⁸, NR⁴¹⁹, NR⁴²⁰, NR⁴²¹, NR⁴²², NR⁴²³, NR⁴²⁴, NR⁴²⁵, NR⁴²⁶, NR⁴²⁷, NR⁴²⁸, NR⁴²⁹, NR⁴³⁰, NR⁴³¹, NR⁴³², NR⁴³³, NR⁴³⁴, NR⁴³⁵, NR⁴³⁶, NR⁴³⁷, NR⁴³⁸, NR⁴³⁹, NR⁴⁴⁰, NR⁴⁴¹, NR⁴⁴², NR⁴⁴³, NR⁴⁴⁴, NR⁴⁴⁵, NR⁴⁴⁶, NR⁴⁴⁷, NR⁴⁴⁸, NR⁴⁴⁹, NR⁴⁵⁰, NR⁴⁵¹, NR⁴⁵², NR⁴⁵³, NR⁴⁵⁴, NR⁴⁵⁵, NR⁴⁵⁶, NR⁴⁵⁷, NR⁴⁵⁸, NR⁴⁵⁹, NR⁴⁶⁰, NR⁴⁶¹, NR⁴⁶², NR⁴⁶³, NR⁴⁶⁴, NR⁴⁶⁵, NR⁴⁶⁶, NR⁴⁶⁷, NR⁴⁶⁸, NR⁴⁶⁹, NR⁴⁷⁰, NR⁴⁷¹, NR⁴⁷², NR⁴⁷³, NR⁴⁷⁴, NR⁴⁷⁵, NR⁴⁷⁶, NR⁴⁷⁷, NR⁴⁷⁸, NR⁴⁷⁹, NR⁴⁸⁰, NR⁴⁸¹, NR⁴⁸², NR⁴⁸³, NR⁴⁸⁴, NR⁴⁸⁵, NR⁴⁸⁶, NR⁴⁸⁷, NR⁴⁸⁸, NR⁴⁸⁹, NR⁴⁹⁰, NR⁴⁹¹, NR⁴⁹², NR⁴⁹³, NR⁴⁹⁴, NR⁴⁹⁵, NR⁴⁹⁶, NR⁴⁹⁷, NR⁴⁹⁸, NR⁴⁹⁹, NR⁵⁰⁰, NR⁵⁰¹, NR⁵⁰², NR⁵⁰³, NR⁵⁰⁴, NR⁵⁰⁵, NR⁵⁰⁶, NR⁵⁰⁷, NR⁵⁰⁸, NR⁵⁰⁹, NR⁵¹⁰, NR⁵¹¹, NR⁵¹², NR⁵¹³, NR⁵¹⁴, NR⁵¹⁵, NR⁵¹⁶, NR⁵¹⁷, NR⁵¹⁸, NR⁵¹⁹, NR⁵²⁰, NR⁵²¹, NR⁵²², NR⁵²³, NR⁵²⁴, NR⁵²⁵, NR⁵²⁶, NR⁵²⁷, NR⁵²⁸, NR⁵²⁹, NR⁵³⁰, NR⁵³¹, NR⁵³², NR⁵³³, NR⁵³⁴, NR⁵³⁵, NR⁵³⁶, NR⁵³⁷, NR⁵³⁸, NR⁵³⁹, NR⁵⁴⁰, NR⁵⁴¹, NR⁵⁴², NR⁵⁴³, NR⁵⁴⁴, NR⁵⁴⁵, NR⁵⁴⁶, NR⁵⁴⁷, NR⁵⁴⁸, NR⁵⁴⁹, NR⁵⁵⁰, NR⁵⁵¹, NR⁵⁵², NR⁵⁵³, NR⁵⁵⁴, NR⁵⁵⁵, NR⁵⁵⁶, NR⁵⁵⁷, NR⁵⁵⁸, NR⁵⁵⁹, NR⁵⁶⁰, NR⁵⁶¹, NR⁵⁶², NR⁵⁶³, NR⁵⁶⁴, NR⁵⁶⁵, NR⁵⁶⁶, NR⁵⁶⁷, NR⁵⁶⁸, NR⁵⁶⁹, NR⁵⁷⁰, NR⁵⁷¹, NR⁵⁷², NR⁵⁷³, NR⁵⁷⁴, NR⁵⁷⁵, NR⁵⁷⁶, NR⁵⁷⁷, NR⁵⁷⁸, NR⁵⁷⁹, NR⁵⁸⁰, NR⁵⁸¹, NR⁵⁸², NR⁵⁸³, NR⁵⁸⁴, NR⁵⁸⁵, NR⁵⁸⁶, NR⁵⁸⁷, NR⁵⁸⁸, NR⁵⁸⁹, NR⁵⁹⁰, NR⁵⁹¹, NR⁵⁹², NR⁵⁹³, NR⁵⁹⁴, NR⁵⁹⁵, NR⁵⁹⁶, NR⁵⁹⁷, NR⁵⁹⁸, NR⁵⁹⁹, NR⁶⁰⁰, NR⁶⁰¹, NR⁶⁰², NR⁶⁰³, NR⁶⁰⁴, NR⁶⁰⁵, NR⁶⁰⁶, NR⁶⁰⁷, NR⁶⁰⁸, NR⁶⁰⁹, NR⁶¹⁰, NR⁶¹¹, NR⁶¹², NR⁶¹³, NR⁶¹⁴, NR⁶¹⁵, NR⁶¹⁶, NR⁶¹⁷, NR⁶¹⁸, NR⁶¹⁹, NR⁶²⁰, NR⁶²¹, NR⁶²², NR⁶²³, NR⁶²⁴, NR⁶²⁵, NR⁶²⁶, NR⁶²⁷, NR⁶²⁸, NR⁶²⁹, NR⁶³⁰, NR⁶³¹, NR⁶³², NR⁶³³, NR⁶³⁴, NR⁶³⁵, NR⁶³⁶, NR⁶³⁷, NR⁶³⁸, NR⁶³⁹, NR⁶⁴⁰, NR⁶⁴¹, NR⁶⁴², NR⁶⁴³, NR⁶⁴⁴, NR⁶⁴⁵, NR⁶⁴⁶, NR⁶⁴⁷, NR⁶⁴⁸, NR⁶⁴⁹, NR⁶⁵⁰, NR⁶⁵¹, NR⁶⁵², NR⁶⁵³, NR⁶⁵⁴, NR⁶⁵⁵, NR⁶⁵⁶, NR⁶⁵⁷, NR⁶⁵⁸, NR⁶⁵⁹, NR⁶⁶⁰, NR⁶⁶¹, NR⁶⁶², NR⁶⁶³, NR⁶⁶⁴, NR⁶⁶⁵, NR⁶⁶⁶, NR⁶⁶⁷, NR⁶⁶⁸, NR⁶⁶⁹, NR⁶⁷⁰, NR⁶⁷¹, NR⁶⁷², NR⁶⁷³, NR⁶⁷⁴, NR⁶⁷⁵, NR⁶⁷⁶, NR⁶⁷⁷, NR⁶⁷⁸, NR⁶⁷⁹, NR⁶⁸⁰, NR⁶⁸¹, NR⁶⁸², NR⁶⁸³, NR⁶⁸⁴, NR⁶⁸⁵, NR⁶⁸⁶, NR⁶⁸⁷, NR⁶⁸⁸, NR⁶⁸⁹, NR⁶⁹⁰, NR⁶⁹¹, NR⁶⁹², NR⁶⁹³, NR⁶⁹⁴, NR⁶⁹⁵, NR⁶⁹⁶, NR⁶⁹⁷, NR⁶⁹⁸, NR⁶⁹⁹, NR⁷⁰⁰, NR⁷⁰¹, NR⁷⁰², NR⁷⁰³, NR⁷⁰⁴, NR⁷⁰⁵, NR⁷⁰⁶, NR⁷⁰⁷, NR⁷⁰⁸, NR⁷⁰⁹, NR⁷¹⁰, NR⁷¹¹, NR⁷¹², NR⁷¹³, NR⁷¹⁴, NR⁷¹⁵, NR⁷¹⁶, NR⁷¹⁷, NR⁷¹⁸, NR⁷¹⁹, NR⁷²⁰, NR⁷²¹, NR⁷²², NR⁷²³, NR⁷²⁴, NR⁷²⁵, NR⁷²⁶, NR⁷²⁷, NR⁷²⁸, NR⁷²⁹, NR⁷³⁰, NR⁷³¹, NR⁷³², NR⁷³³, NR⁷³⁴, NR⁷³⁵, NR⁷³⁶, NR⁷³⁷, NR⁷³⁸, NR⁷³⁹, NR⁷⁴⁰, NR⁷⁴¹, NR⁷⁴², NR⁷⁴³, NR⁷⁴⁴, NR⁷⁴⁵, NR⁷⁴⁶, NR⁷⁴⁷, NR⁷⁴⁸, NR⁷⁴⁹, NR⁷⁵⁰, NR⁷⁵¹, NR⁷⁵², NR⁷⁵³, NR⁷⁵⁴, NR⁷⁵⁵, NR⁷⁵⁶, NR⁷⁵⁷, NR⁷⁵⁸, NR⁷⁵⁹, NR⁷⁶⁰, NR⁷⁶¹, NR⁷⁶², NR⁷⁶³, NR⁷⁶⁴, NR⁷⁶⁵, NR⁷⁶⁶, NR⁷⁶⁷, NR⁷⁶⁸, NR⁷⁶⁹, NR⁷⁷⁰, NR⁷⁷¹, NR⁷⁷², NR⁷⁷³, NR⁷⁷⁴, NR⁷⁷⁵, NR⁷⁷⁶, NR⁷⁷⁷, NR⁷⁷⁸, NR⁷⁷⁹, NR⁷⁸⁰, NR⁷⁸¹, NR⁷⁸², NR⁷⁸³, NR⁷⁸⁴, NR⁷⁸⁵, NR⁷⁸⁶, NR⁷⁸⁷, NR⁷⁸⁸, NR⁷⁸⁹, NR⁷⁹⁰, NR⁷⁹¹, NR⁷⁹², NR⁷⁹³, NR⁷⁹⁴, NR⁷⁹⁵, NR⁷⁹⁶, NR⁷⁹⁷, NR⁷⁹⁸, NR⁷⁹⁹, NR⁸⁰⁰, NR⁸⁰¹, NR⁸⁰², NR⁸⁰³, NR⁸⁰⁴, NR⁸⁰⁵, NR⁸⁰⁶, NR⁸⁰⁷, NR⁸⁰⁸, NR⁸⁰⁹, NR⁸¹⁰, NR⁸¹¹, NR⁸¹², NR⁸¹³, NR⁸¹⁴, NR⁸¹⁵, NR⁸¹⁶, NR⁸¹⁷, NR⁸¹⁸, NR⁸¹⁹, NR⁸²⁰, NR⁸²¹, NR⁸²², NR⁸²³, NR⁸²⁴, NR⁸²⁵, NR⁸²⁶, NR⁸²⁷, NR⁸²⁸, NR⁸²⁹, NR⁸³⁰, NR⁸³¹, NR⁸³², NR⁸³³, NR⁸³⁴, NR⁸³⁵, NR⁸³⁶, NR⁸³⁷, NR⁸³⁸, NR⁸³⁹, NR⁸⁴⁰, NR⁸⁴¹, NR⁸⁴², NR⁸⁴³, NR⁸⁴⁴, NR⁸⁴⁵, NR⁸⁴⁶, NR⁸⁴⁷, NR⁸⁴⁸, NR⁸⁴⁹, NR⁸⁵⁰, NR⁸⁵¹, NR⁸⁵², NR⁸⁵³, NR⁸⁵⁴, NR⁸⁵⁵, NR⁸⁵⁶, NR⁸⁵⁷, NR⁸⁵⁸, NR⁸⁵⁹, NR⁸⁶⁰, NR⁸⁶¹, NR⁸⁶², NR⁸⁶³, NR⁸⁶⁴, NR⁸⁶⁵, NR⁸⁶⁶, NR⁸⁶⁷, NR⁸⁶⁸, NR⁸⁶⁹, NR⁸⁷⁰, NR⁸⁷¹, NR⁸⁷², NR⁸⁷³, NR⁸⁷⁴, NR⁸⁷⁵, NR⁸⁷⁶, NR⁸⁷⁷, NR⁸⁷⁸, NR⁸⁷⁹, NR⁸⁸⁰, NR⁸⁸¹, NR⁸⁸², NR⁸⁸³, NR⁸⁸⁴, NR⁸⁸⁵, NR⁸⁸⁶, NR⁸⁸⁷, NR⁸⁸⁸, NR⁸⁸⁹, NR⁸⁹⁰, NR⁸⁹¹, NR⁸⁹², NR⁸⁹³, NR⁸⁹⁴, NR⁸⁹⁵, NR⁸⁹⁶, NR⁸⁹⁷, NR⁸⁹⁸, NR⁸⁹⁹, NR⁹⁰⁰, NR⁹⁰¹, NR⁹⁰², NR⁹⁰³, NR⁹⁰⁴, NR⁹⁰⁵, NR⁹⁰⁶, NR⁹⁰⁷, NR⁹⁰⁸, NR⁹⁰⁹, NR⁹¹⁰, NR⁹¹¹, NR⁹¹², NR⁹¹³, NR⁹¹⁴, NR⁹¹⁵, NR⁹¹⁶, NR⁹¹⁷, NR⁹¹⁸, NR⁹¹⁹, NR⁹²⁰, NR⁹²¹, NR⁹²², NR⁹²³, NR⁹²⁴, NR⁹²⁵, NR⁹²⁶, NR⁹²⁷, NR⁹²⁸, NR⁹²⁹, NR⁹³⁰, NR⁹³¹, NR⁹³², NR⁹³³, NR⁹³⁴, NR⁹³⁵, NR⁹³⁶, NR⁹³⁷, NR⁹³⁸, NR⁹³⁹, NR⁹⁴⁰, NR⁹⁴¹, NR⁹⁴², NR⁹⁴³, NR⁹⁴⁴, NR⁹⁴⁵, NR⁹⁴⁶, NR⁹⁴⁷, NR⁹⁴⁸, NR⁹⁴⁹, NR⁹⁵⁰, NR⁹⁵¹, NR⁹⁵², NR⁹⁵³, NR⁹⁵⁴, NR⁹⁵⁵, NR⁹⁵⁶, NR⁹⁵⁷, NR⁹⁵⁸, NR⁹⁵⁹, NR⁹⁶⁰, NR⁹⁶¹, NR⁹⁶², NR⁹⁶³, NR⁹⁶⁴, NR⁹⁶⁵, NR⁹⁶⁶, NR⁹⁶⁷, NR⁹⁶⁸, NR⁹⁶⁹, NR⁹⁷⁰, NR⁹⁷¹, NR⁹⁷², NR⁹⁷³, NR⁹⁷⁴, NR⁹⁷⁵, NR⁹⁷⁶, NR⁹⁷⁷, NR⁹⁷⁸, NR⁹⁷⁹, NR⁹⁸⁰, NR⁹⁸¹, NR⁹⁸², NR⁹⁸³, NR⁹⁸⁴, NR⁹⁸⁵, NR⁹⁸⁶, NR⁹⁸⁷, NR⁹⁸⁸, NR⁹⁸⁹, NR⁹⁹⁰, NR⁹⁹¹, NR⁹⁹², NR⁹⁹³, NR⁹⁹⁴, NR⁹⁹⁵, NR⁹⁹⁶, NR⁹⁹⁷, NR⁹⁹⁸, NR⁹⁹⁹, NR¹⁰⁰⁰, NR¹⁰⁰¹, NR¹⁰⁰², NR¹⁰⁰³, NR¹⁰⁰⁴, NR¹⁰⁰⁵, NR¹⁰⁰⁶, NR¹⁰⁰⁷, NR¹⁰⁰⁸, NR¹⁰⁰⁹, NR¹⁰¹⁰, NR¹⁰¹¹, NR¹⁰¹², NR¹⁰¹³, NR¹⁰¹⁴, NR¹⁰¹⁵, NR¹⁰¹⁶, NR¹⁰¹⁷, NR¹⁰¹⁸, NR¹⁰¹⁹, NR¹⁰²⁰, NR¹⁰²¹, NR¹⁰²², NR¹⁰²³, NR¹⁰²⁴, NR¹⁰²⁵, NR¹⁰²⁶, NR¹⁰²⁷, NR¹⁰²⁸, NR¹⁰²⁹, NR¹⁰³⁰, NR¹⁰³¹, NR¹⁰³², NR¹⁰³³, NR¹⁰³⁴, NR¹⁰³⁵, NR¹⁰³⁶, NR¹⁰³⁷, NR¹⁰³⁸, NR¹⁰³⁹, NR¹⁰⁴⁰, NR¹⁰⁴¹, NR¹⁰⁴², NR¹⁰⁴³, NR¹⁰⁴⁴, NR¹⁰⁴⁵, NR¹⁰⁴⁶, NR¹⁰⁴⁷, NR¹⁰⁴⁸, NR¹⁰⁴⁹, NR¹⁰⁵⁰, NR¹⁰⁵¹, NR¹⁰⁵², NR¹⁰⁵³, NR¹⁰⁵⁴, NR¹⁰⁵⁵, NR¹⁰⁵⁶, NR¹⁰⁵⁷, NR¹⁰⁵⁸, NR¹⁰⁵⁹, NR¹⁰⁶⁰, NR¹⁰⁶¹, NR¹⁰⁶², NR¹⁰⁶³, NR¹⁰⁶⁴, NR¹⁰⁶⁵, NR¹⁰⁶⁶, NR¹⁰⁶⁷, NR¹⁰⁶⁸, NR¹⁰⁶⁹, NR¹⁰⁷⁰, NR¹⁰⁷¹, NR¹⁰⁷², NR¹⁰⁷³, NR¹⁰⁷⁴, NR¹⁰⁷⁵, NR¹⁰⁷⁶, NR¹⁰⁷⁷, NR¹⁰⁷⁸, NR¹⁰⁷⁹, NR¹⁰⁸⁰, NR¹⁰⁸¹, NR¹⁰⁸², NR¹⁰⁸³, NR¹⁰⁸⁴, NR¹⁰⁸⁵, NR¹⁰⁸⁶, NR¹⁰⁸⁷, NR¹⁰⁸⁸, NR¹⁰⁸⁹, NR¹⁰⁹⁰, NR¹⁰⁹¹, NR¹⁰⁹², NR¹⁰⁹³, NR¹⁰⁹⁴, NR¹⁰⁹⁵, NR¹⁰⁹⁶, NR¹⁰⁹⁷, NR¹⁰⁹⁸, NR¹⁰⁹⁹, NR¹¹⁰⁰, NR¹¹⁰¹, NR¹¹⁰², NR¹¹⁰³, NR¹¹⁰⁴, NR¹¹⁰⁵, NR¹¹⁰⁶, NR¹¹⁰⁷, NR¹¹⁰⁸, NR¹¹⁰⁹, NR¹¹¹⁰, NR¹¹¹¹, NR¹¹¹², NR¹¹¹³, NR¹¹¹⁴, NR¹¹¹⁵, NR¹¹¹⁶, NR¹¹¹⁷, NR¹¹¹⁸, NR¹¹¹⁹, NR¹¹²⁰, NR¹¹²¹, NR¹¹²², NR¹¹²³, NR¹¹²⁴, NR¹¹²⁵, NR¹¹²⁶, NR¹¹²⁷, NR¹¹²⁸, NR¹¹²⁹, NR¹¹³⁰, NR¹¹³¹, NR¹¹³², NR¹¹³³, NR¹¹³⁴, NR¹¹³⁵, NR¹¹³⁶, NR¹¹³⁷, NR¹¹³⁸, NR¹¹³⁹, NR¹¹⁴⁰, NR<



● HCl


HN 852236-35-2 CAPLUS
CN 2-Morpholinomethanol, α -[2-ethoxyphenyl]methyl]- α -[1-methylethyl]-, hydrochloride (HCl) (CA INDEX NAME)



● HCl


HN 852236-37-4 CAPLUS
CN 2-Morpholinomethanol, α -[2-methoxyphenyl]methyl]- α -[1-methylethyl]-, (4*S*,2*S*)-rel- (CA INDEX NAME)

Relative stereochemistry.




HN 852236-38-5 CAPLUS
CN 2-Morpholinomethanol, α -[2-methoxyphenyl]methyl]- α -[1-methylethyl]-, (4*S*,2*S*)-rel- (CA INDEX NAME)

Relative stereochemistry.




HN 852236-43-2 CAPLUS
CN 2-Morpholinomethanol, α -[2-ethoxyphenyl]methyl]- α -[1-methylethyl]-, (4*S*,2*S*)-rel- (CA INDEX NAME)

Relative stereochemistry.



HN 852236-44-3 CAPLUS
CN 2-Morpholinomethanol, α -[2-ethoxyphenyl]methyl]- α -[1-methylethyl]-, hydrochloride, (4*S*,2*S*)-rel- (HCl) (CA INDEX NAME)


Relative stereochemistry.



● HCl


HN 852236-45-4 CAPLUS
CN 2-Morpholinomethanol, α -[2-ethoxyphenyl]methyl]- α -[1-methylethyl]-, hydrochloride, (4*S*,2*S*)-rel- (HCl) (CA INDEX NAME)

Relative stereochemistry.



HN 852236-39-4 CAPLUS
CN 2-Morpholinomethanol, α -[2-methoxyphenyl]methyl]- α -[1-methylethyl]-, hydrochloride, (4*S*,2*S*)-rel- (HCl) (CA INDEX NAME)


Relative stereochemistry.



● HCl

HN 852236-40-9 CAPLUS
CN 2-Morpholinomethanol, α -[2-methoxyphenyl]methyl]- α -[1-methylethyl]-, hydrochloride, (4*S*,2*S*)-rel- (HCl) (CA INDEX NAME)


Relative stereochemistry.



● HCl

HN 852236-42-1 CAPLUS
CN 2-Morpholinomethanol, α -[2-ethoxyphenyl]methyl]- α -[1-methylethyl]-, (4*S*,2*S*)-rel- (CA INDEX NAME)

Relative stereochemistry.




● HCl

HN 852236-47-6 CAPLUS
CN 2-Morpholinomethanol, α -[2-methylethyl]- α -[2-(trifluoromethyl)phenyl]methyl]-, hydrochloride (HCl) (CA INDEX NAME)



● HCl

HN 852236-48-8 CAPLUS
CN 2-Morpholinomethanol, α -[1,1'-biphenyl]-2-yl)methyl]- α -[1-methylethyl]-, hydrochloride (HCl) (CA INDEX NAME)



● HCl

HN 852236-51-2 CAPLUS
CN 2-Morpholinomethanol, α -[4-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -[1-methylethyl]-, hydrochloride (HCl) (CA INDEX NAME)




● 9CI

HN 852236-53-4 CAPLUS
CN 2-Morpholinomethanol, α-[(5-fluoro-2-methoxyphenyl)methyl]-α-[(2-methylpropyl)-], hydrochloride (9CI) (CA INDEX NAME)



● 9CI

HN 852236-60-3 CAPLUS
CN 2-Morpholinomethanol, α-[(2-ethoxyphenyl)methyl]-α-[(2-methylpropyl)-], (4S,2S)-rel- (CA INDEX NAME)
Relative stereochemistry.



HN 852236-56-7 CAPLUS
CN 2-Morpholinomethanol, α-[(2-ethoxyphenyl)methyl]-α-[(2-methylpropyl)-], (4S,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.

HN 852236-63-8 CAPLUS
CN 2-Morpholinomethanol, α-[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-[(2-methylpropyl)-], hydrochloride (9CI) (CA INDEX NAME)




● 9CI

HN 852236-66-9 CAPLUS
CN 2-Morpholinomethanol, α-[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-[(2-methylpropyl)-], hydrochloride (9CI) (CA INDEX NAME)




HN 854139-85-8 CAPLUS
CN 2-Morpholinomethanol, α-[(2-chloro-6-fluorophenyl)methyl]-α-phenyl-, hydrochloride, (4S,2S)-rel- (9CI) (CA INDEX NAME)
Relative stereochemistry.



● 9CI

HN 854139-86-9 CAPLUS
CN 2-Morpholinomethanol, α-[(2,5-dimethoxyphenyl)methyl]-α-phenyl-, hydrochloride, (4S,2S)-rel- (9CI) (CA INDEX NAME)



HN 852236-58-9 CAPLUS
CN 2-Morpholinomethanol, α-[(2-methylpropyl)-α-[(2-(trifluoromethoxy)phenyl)methyl]-], hydrochloride (9CI) (CA INDEX NAME)



● 9CI

HN 852236-60-3 CAPLUS
CN 2-Morpholinomethanol, α-[(1,1'-biphenyl)-2-ylmethyl]-α-[(2-methylpropyl)-] (CA INDEX NAME)




HN 852236-63-6 CAPLUS
CN 2-Morpholinomethanol, α-[(1,1'-biphenyl)-2-ylmethyl]-α-[(2-methylpropyl)-], hydrochloride (9CI) (CA INDEX NAME)




● 9CI

Relative stereochemistry.




● 9CI

HN 854139-87-0 CAPLUS
CN 2-Morpholinomethanol, α-[(2,4-difluorophenyl)methyl]-α-phenyl-, hydrochloride, (4S,2S)-rel- (9CI) (CA INDEX NAME)
Relative stereochemistry.



● 9CI

HN 854139-88-1 CAPLUS
CN 2-Morpholinomethanol, α-[(2,6-dichlorophenyl)methyl]-α-phenyl-, hydrochloride, (4S,2S)-rel- (9CI) (CA INDEX NAME)




● 9CI

125 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

HN 854139-89-2 CAPLUS
CN 2-Morpholinemetanol, ω -[(2,5-dichlorophenyl)methyl]- α -phenyl-, hydrochloride, (aR,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

HN 854139-90-5 CAPLUS
CN 2-Morpholinemetanol, ω -[(2,5-difluorophenyl)methyl]- α -phenyl-, hydrochloride, (aR,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


HN 854139-91-6 CAPLUS
CN 2-Morpholinemetanol, ω -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (aR,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



125 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


Relative stereochemistry.



● HCl

HN 857642-42-3 CAPLUS
CN 2-Morpholinemetanol, ω -[(3-fluorophenyl)- α -(2-methoxyphenyl)methyl]-, hydrochloride, (aR,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

HN 857642-43-4 CAPLUS
CN 2-Morpholinemetanol, ω -phenyl- α -[[2-(trifluoromethyl)thio]phenyl]methyl]-, hydrochloride, (aR,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




125 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

HN 857642-38-7 CAPLUS
CN 2-Morpholinemetanol, ω -[[2-methoxyphenyl]methyl]- α -phenyl-, hydrochloride, (aR,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

HN 857642-40-1 CAPLUS
CN 2-Morpholinemetanol, ω -[[2-ethoxyphenyl]methyl]- α -phenyl-, hydrochloride, (aR,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

HN 857642-41-2 CAPLUS
CN 2-Morpholinemetanol, ω -[[2-(3-methylethoxyphenyl)methyl]- α -phenyl]-, hydrochloride, (aR,2S)-rel- (9CI) (CA INDEX NAME)


125 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

HN 857642-44-5 CAPLUS
CN 2-Morpholinemetanol, ω -[[1,1'-biphenyl]-2-ylmethyl]- α -phenyl-, hydrochloride, (aR,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

HN 857642-45-6 CAPLUS
CN 2-Morpholinemetanol, ω -[[2-chlorophenyl]methyl]- α -phenyl-, hydrochloride, (aR,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

HN 857642-48-9 CAPLUS
CN 2-Morpholinemetanol, ω -phenyl- α -[[2-[[trifluoromethyl]thio]phenyl]methyl]-, (aR,2S)-rel-, acetate (salt) (9CI) (CA INDEX NAME)

CH 3

CH 857642-17-8
CH C19 B20 F3 N O2 S

Relative stereochemistry.




CH 2

CH 857642-19-7
CH C2 B4 O2



CH 857642-51-4 CAPLOS
CH 2-Morpholinomethanol, 4-phenyl-1-phenylmethyl-, hydrochloride, (4S,2S)-rel- (PCI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


CH 857642-52-5 CAPLOS
CH 2-Morpholinomethanol, 4-phenyl-1-phenylmethyl-, hydrochloride, (4S,2S)-rel- (PCI) (CA INDEX NAME)

Relative stereochemistry.




CH 857642-53-2 CAPLOS
CH 2-Morpholinomethanol, 4-phenyl-1-phenylmethyl-, hydrochloride, (4S,2S)-rel- (PCI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

CH 857642-60-5 CAPLOS
CH 2-Morpholinomethanol, 4-phenyl-1-phenylmethyl-, hydrochloride (PCI) (CA INDEX NAME)



● HCl


CH 857642-61-6 CAPLOS
CH 2-Morpholinomethanol, 4-phenyl-1-phenylmethyl-, hydrochloride (PCI) (CA INDEX NAME)



● HCl

CH 857642-54-7 CAPLOS
CH 2-Morpholinomethanol, 4-phenyl-1-phenylmethyl-, hydrochloride, (4S,2S)-rel- (PCI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

CH 857642-56-3 CAPLOS
CH 2-Morpholinomethanol, 4-phenyl-1-phenylmethyl-, hydrochloride, (4S,2S)-rel- (PCI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

CH 857642-57-0 CAPLOS
CH 2-Morpholinomethanol, 4-phenyl-1-phenylmethyl-, hydrochloride, (4S,2S)-rel- (CA INDEX NAME)




CH 857642-62-7 CAPLOS
CH 2-Morpholinomethanol, 4-phenyl-1-phenylmethyl-, hydrochloride, (4S,2S)-rel- (CA INDEX NAME)



CH 857642-63-8 CAPLOS
CH 2-Morpholinomethanol, 4-phenyl-1-phenylmethyl-, hydrochloride, (4S,2S)-rel- (CA INDEX NAME)



CH 857642-64-9 CAPLOS
CH 2-Morpholinomethanol, 4-phenyl-1-phenylmethyl-, hydrochloride, (4S,2S)-rel- (CA INDEX NAME)



RII 857642-65-0 CAPLUS
 CH 2-Morpholinomethanol, 4-phenyl-1-methoxy-2-ylmethyl-1-phenyl- (CA INDEX NAME)




RII 857642-66-1 CAPLUS
 CH 2-Morpholinomethanol, 4-phenyl-1-chloro-2-ylmethyl-1-phenyl- (CA INDEX NAME)



RII 857642-67-2 CAPLUS
 CH 2-Morpholinomethanol, 4-phenyl-1-methoxy-2-ylmethyl-1-phenyl- (CA INDEX NAME)




RII 857642-71-8 CAPLUS
 CH 2-Morpholinomethanol, 4-phenyl-1-methoxy-2-ylmethyl-1-phenyl- (CA INDEX NAME)



RII 857642-72-9 CAPLUS
 CH 2-Morpholinomethanol, 4-phenyl-1-methoxy-2-ylmethyl-1-phenyl- (CA INDEX NAME)




RII 857642-73-0 CAPLUS
 CH 2-Morpholinomethanol, 4-phenyl-1-methoxy-2-ylmethyl-1-phenyl- (CA INDEX NAME)



RII 857642-68-3 CAPLUS
 CH 2-Morpholinomethanol, 4-phenyl-1-methoxy-2-ylmethyl-1-phenyl- (CA INDEX NAME)





RII 857642-69-4 CAPLUS
 CH 2-Morpholinomethanol, 4-phenyl-1-methoxy-2-ylmethyl-1-phenyl- (CA INDEX NAME)



RII 857642-70-7 CAPLUS
 CH 2-Morpholinomethanol, 4-phenyl-1-methoxy-2-ylmethyl-1-phenyl- (CA INDEX NAME)

RII 857642-74-1 CAPLUS
 CH 2-Morpholinomethanol, 4-phenyl-1-methoxy-2-ylmethyl-1-phenyl- (CA INDEX NAME)






● HCl

HN 664360-79-6 CAPLUS
CN 2-Morpholinomethanol, 4-phenyl-1-[(2S)-2-methoxyphenylmethyl]-1-phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl



HN 664360-81-2 CAPLUS
CN 2-Morpholinomethanol, 4-phenyl-1-[(2S)-2-methoxyphenylmethyl]-1-phenyl-, acetate (salt) (PCI) (CA INDEX NAME)

CN 1

CHN 664360-80-9

CMF C19 H25 F3 N O2 S


Absolute stereochemistry.



● HCl

HN 664360-81-4 CAPLUS
CN 2-Morpholinomethanol, 4-phenyl-1-[(2S)-2-methoxyphenylmethyl]-1-phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

HN 664360-84-5 CAPLUS
CN 2-Morpholinomethanol, 4-phenyl-1-[(2S)-2-methoxyphenylmethyl]-1-phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


HN 664360-87-6 CAPLUS
CN 2-Morpholinomethanol, 4-phenyl-1-[(2S)-2-methoxyphenylmethyl]-1-phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)

CHN 64-19-7
CMF C2 H4 O2




HN 664360-82-1 CAPLUS
CN 2-Morpholinomethanol, 4-phenyl-1-[(2S)-2-methoxyphenylmethyl]-1-phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.



HN 664360-83-2 CAPLUS
CN 2-Morpholinomethanol, 4-phenyl-1-[(2S)-2-methoxyphenylmethyl]-1-phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


HN 664360-84-3 CAPLUS
CN 2-Morpholinomethanol, 4-phenyl-1-[(2S)-2-methoxyphenylmethyl]-1-phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.



HN 664360-88-7 CAPLUS
CN 2-Morpholinomethanol, 4-phenyl-1-[(2S)-2-methoxyphenylmethyl]-1-phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

HN 664360-89-8 CAPLUS
CN 2-Morpholinomethanol, 4-phenyl-1-[(2S)-2-methoxyphenylmethyl]-1-phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

HN 854339-85-8 CAPLUS
CN 2-Morpholinomethanol, 4-phenyl-1-[(2S)-2-methoxyphenylmethyl]-1-phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

HN 854139-84-9 CAPLUS
CN 2-Morpholinomethanol, α -[12,5-dimethoxyphenylmethyl]- ω -phenyl-, hydrochloride, (4*S*,2*S*)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




● HCl

HN 854139-87-0 CAPLUS
CN 2-Morpholinomethanol, α -[12,4-difluorophenylmethyl]- ω -phenyl-, hydrochloride, (4*S*,2*S*)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl



● HCl

HN 854139-91-6 CAPLUS
CN 2-Morpholinomethanol, α -[4'-fluoro[1,1'-biphenyl]-2-ylmethyl]- ω -phenyl-, hydrochloride, (4*S*,2*S*)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

HN 854139-92-7 CAPLUS
CN 2-Morpholinomethanol, α -[4'-methyl[1,1'-biphenyl]-2-ylmethyl]- ω -phenyl-, (4*S*,2*S*)-rel- (CA INDEX NAME)


Relative stereochemistry.



HN 854139-93-8 CAPLUS

HN 854139-88-1 CAPLUS
CN 2-Morpholinomethanol, α -[12,6-dichlorophenylmethyl]- ω -phenyl-, hydrochloride, (4*S*,2*S*)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

HN 854139-89-2 CAPLUS
CN 2-Morpholinomethanol, α -[12,5-dichlorophenylmethyl]- ω -phenyl-, hydrochloride, (4*S*,2*S*)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

HN 854139-90-5 CAPLUS
CN 2-Morpholinomethanol, α -[12,5-difluorophenylmethyl]- ω -phenyl-, hydrochloride, (4*S*,2*S*)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

Relative stereochemistry.




HN 854139-94-3 CAPLUS
CN 2-Morpholinomethanol, α -[4'-methoxy[1,1'-biphenyl]-2-ylmethyl]- ω -phenyl-, (4*S*,2*S*)-rel- (CA INDEX NAME)

Relative stereochemistry.



HN 854139-95-0 CAPLUS
CN 2-Morpholinomethanol, α -[3'-fluoro[1,1'-biphenyl]-2-ylmethyl]- ω -phenyl-, (4*S*,2*S*)-rel- (CA INDEX NAME)


Relative stereochemistry.



125 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)


RN 854139-96-2 CAPLUS
CN 2-Morpholinemetanediol, ω -[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (4*S*,2*S*)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 854139-97-2 CAPLUS
CN 2-Morpholinemetanediol, ω -[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (4*S*,2*S*)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 854139-98-3 CAPLUS
CN 2-Morpholinemetanediol, ω -[(3'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (4*S*,2*S*)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 854139-99-4 CAPLUS

125 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)


RN 854140-01-6 CAPLUS
CN 2-Morpholinemetanediol, ω -phenyl- ω -[[2-(3-pyridinyl)phenyl]methyl]-, (4*S*,2*S*)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 854140-03-7 CAPLUS
CN 2-Morpholinemetanediol, ω -phenyl- ω -[[2-(3-thienyl)phenyl]methyl]-, (4*S*,2*S*)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 854140-04-8 CAPLUS
CN 2-Morpholinemetanediol, ω -[(3',4'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (4*S*,2*S*)-rel- (CA INDEX NAME)

Relative stereochemistry.




IT 444361-42-6P

KL: KCT (Isotant); SYN (Synthetic preparation); PREP (Preparation); RACT

125 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)


CN 2-Morpholinemetanediol, ω -[(3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (4*S*,2*S*)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 854140-00-4 CAPLUS
CN 2-Morpholinemetanediol, ω -[(2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (4*S*,2*S*)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 854140-01-5 CAPLUS
CN 2-Morpholinemetanediol, ω -[(2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (4*S*,2*S*)-rel- (CA INDEX NAME)


Relative stereochemistry.



125 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)

(Isotant or reagent)
(prepn. of amiloripride derivs. useful for the treatment of cognitive failure)
RN 664761-42-6 CAPLUS
CN 2-Morpholinemetanediol, ω -[(5-fluoro-2-hydroxyphenyl)methyl]- α -phenyl-, (4*S*,2*S*)-rel- (CA INDEX NAME)

Absolute stereochemistry.



L25 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 ACCESSION NUMBER: 20051451370 CAPLUS
 DOCUMENT NUMBER: 142480271
 TITLE: Preparation of morpholine derivatives as norasophrine reuptake inhibitors
 INVENTOR(S): Campbell, Gordon Stacy; Casse-Thomas, Marcell Javiera;
 Mar, Teresa; Matos, John Joseph; Rody, Helene
 Catherine; Rospene, Walter; Neuma Wilheim
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 113 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO. KIND DATE APPLICATION NO. DATE
 MO 0605041272 A1 200505050 MO 2004-0832771 20041009
 M1 A2, A3, A4, A5, A6, A7, A8, A9, B1, B2, B3, B4, B5, B6, B7, B8, C1, C2,
 C3, C4, C5, C6, C7, C8, C9, D1, D2, D3, D4, D5, D6, D7, D8, D9, E1, E2, E3,
 E4, E5, E6, E7, E8, E9, F1, F2, F3, F4, F5, F6, F7, F8, F9, G1, G2, G3,
 G4, G5, G6, G7, G8, G9, H1, H2, H3, H4, H5, H6, H7, H8, H9, I1, I2, I3, I4,
 I5, I6, I7, I8, I9, J1, J2, J3, J4, J5, J6, J7, J8, J9, K1, K2, K3, K4, K5, K6,
 K7, K8, K9, L1, L2, L3, L4, L5, L6, L7, L8, L9, M1, M2, M3, M4, M5, M6, M7, M8,
 M9, N1, N2, N3, N4, N5, N6, N7, N8, N9, O1, O2, O3, O4, O5, O6, O7, O8, O9,
 P1, P2, P3, P4, P5, P6, P7, P8, P9, Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, Q9, R1, R2,
 R3, R4, R5, R6, R7, R8, R9, S1, S2, S3, S4, S5, S6, S7, S8, S9, T1, T2, T3, T4,
 T5, T6, T7, T8, T9, U1, U2, U3, U4, U5, U6, U7, U8, U9, V1, V2, V3, V4, V5, V6,
 V7, V8, V9, W1, W2, W3, W4, W5, W6, W7, W8, W9, X1, X2, X3, X4, X5, X6, X7, X8,
 X9, Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Z1, Z2, Z3, Z4, Z5, Z6, Z7, Z8, Z9,
 AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AM, AN, AO, AP, AQ, AR, AS, AT,
 AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM,
 BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BX, BY, BZ, CA, CB, CC, CD, CE, CF, CG,
 CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DA,
 DB, DC, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT,
 DU, DV, DW, DX, DY, DZ
 AP 2004039616 A1 200405050 AU 2004-289616 20041009
 CA 2544649 A1 200505050 CA 2004-2544649 20041009
 EP 1645523 A1 200407026 EP 2004-794209 20041009
 KR 200400726 A1 200407026 KR 2004-00726 20041009
 ES 1819762 A 20041213 CA 2004-0023115 20041009
 JP 2004015273 A 20041213 JP 2004-15273 20041009
 JP 2005107320 A 200510426 JP 2005-379482 20041009
 US 2005030406 A1 200504150 US 2005-578841 20040428
 MX 2004020226 A 200407026 MX 2004-07026 20040509
 KR 783585 NL 20021310 KN 2006-708989 20040509
 MO 200402760 A 200409008 MO 2004-2760 20040612
 PRIORITY APPL. INFO. A 2003-26148 A 20031110
 US 2004-535459 P 20040109
 WO 2004-0532771 P 20041009

OTHER SOURCE(S): CASREACT 142480271; MEDPAT 142480271
 GI

L25 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)

Relative stereochemistry.

 RU 852236-38-1 CAPLUS
 RU 2-Morpholinomethanol, α -[2-methoxyphenyl)methyl]- α -[1-methyl-ethyl]-, (1R,2S)-rel-1 (CA INDEX NAME)

Relative stereochemistry.

 RU 852236-38-1 CAPLUS
 RU 2-Morpholinomethanol, α -[2-methoxyphenyl)methyl]- α -[1-methyl-ethyl]-, (1R,2S)-rel-1 (CA INDEX NAME)

Relative stereochemistry.

 RU 852236-42-1 CAPLUS
 RU 2-Morpholinomethanol, α -[2-methoxyphenyl)methyl]- α -[1-methyl-ethyl]-, (1R,2S)-rel-1 (CA INDEX NAME)

Relative stereochemistry.

 RU 852236-42-1 CAPLUS
 RU 2-Morpholinomethanol, α -[2-methoxyphenyl)methyl]- α -[1-methyl-ethyl]-, (1R,2S)-rel-1 (CA INDEX NAME)

Relative stereochemistry.

 RU 852236-42-1 CAPLUS
 RU 2-Morpholinomethanol, α -[2-methoxyphenyl)methyl]- α -[1-methyl-ethyl]-, (1R,2S)-rel-1 (CA INDEX NAME)

Relative stereochemistry.

 RU 852236-42-1 CAPLUS
 RU 2-Morpholinomethanol, α -[2-methoxyphenyl)methyl]- α -[1-methyl-ethyl]-, (1R,2S)-rel-1 (CA INDEX NAME)

Relative stereochemistry.

 RU 852236-42-1 CAPLUS
 RU 2-Morpholinomethanol, α -[2-methoxyphenyl)methyl]- α -[1-methyl-ethyl]-, (1R,2S)-rel-1 (CA INDEX NAME)

Relative stereochemistry.

 RU 852236-42-1 CAPLUS
 RU 2-Morpholinomethanol, α -[2-methoxyphenyl)methyl]- α -[1-methyl-ethyl]-, (1R,2S)-rel-1 (CA INDEX NAME)




AB Title compds. 1 (X = OH, alkoxy, H₂O, etc.; R independently = H, alkyl, with provisions); R¹ = (un)substituted-alkyl, -alkoxy, CN, etc.; R² = H, alkyl; R³ = H, alkyl; Ar = (un)substituted-Ph, -5- to 6-membered heterocyl and their pharmaceutically acceptable salts, are prepared and disclosed as norasophrine reuptake inhibitors. Thus, e.g., II was prepared by conversion of 6-methyl-morpholine-3-carboxamide into the reasp. carboxylic ester followed by oxidation with N,N-dimethylhydrazine and subsequent dehydrated reactions with Me magnesium bromide and 2-phenylmethyl magnesium bromide followed by deacetylation and conversion into the RCT salt. The activity of I was evaluated in a CYP2D6 inhibition assay and preferred compds. of the invent exhibited an IC50 higher than 6 μ M. I as norasophrine reuptake inhibitors should prove useful in the treatment of disorders that are associated with norasophrine dysfunction. Pharmaceutical compds. comprising I are disclosed.

RU 852236-37-4P 852236-38-5P 852236-42-1P
 RU 852236-42-1P
 RU RAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reaction); STM (Synthetic preparation); THU (Therapeutic use); ROL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 Preparation of morpholine derivs. as norasophrine reuptake inhibitors)
 RU 852236-37-4 CAPLUS
 CN 2-Morpholinomethanol, α -[2-methoxyphenyl)methyl]- α -[1-methyl-ethyl]-, (1R,2S)-rel-1 (CA INDEX NAME)

L25 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)

RU 852236-60-3P 852237-02-4P
 RU RAC (Pharmacological activity); RCT (Reactant); STM (Synthetic preparation); THU (Therapeutic use); ROL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 Preparation of morpholine derivs. as norasophrine reuptake inhibitors)
 RU 852236-60-3 CAPLUS
 CN 2-Morpholinomethanol, α -[1,1'-biphenyl]-2-ylmethyl)- α -[2-methyl-propyl]-, (1R,2S)-rel-1 (CA INDEX NAME)



RU 852236-37-3P 852236-39-4P 852236-31-4P
 RU 852236-39-4P 852236-35-2P 852236-39-4P
 RU 852236-40-4P 852236-44-3P 852236-45-4P
 RU 852236-47-4P 852236-48-4P 852236-41-2P
 RU 852236-50-4P 852236-58-4P 852236-54-7P
 RU 852236-55-4P 852236-54-4P 852236-55-4P
 RU 852236-59-2P 852236-59-4P 852236-97-4P
 RU 852236-59-4P 852237-01-5P 852237-14-4P
 RU 852237-01-5P 852237-23-3P 852237-27-5P
 RU 852237-23-3P
 RU RAC (Pharmacological activity); STM (Synthetic preparation); THU (Therapeutic use); ROL (Biological study); PREP (Preparation); USES (Uses)
 Preparation of morpholine derivs. as norasophrine reuptake inhibitors)
 RU 852236-27-2 CAPLUS
 CN 2-Morpholinomethanol, α -[1,1'-biphenyl]-2-ylmethyl)- α -methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

HN 852236-29-4 CAPLUS
CN 2-Morpholinomethanol, 4-methyl-4-[(5-fluoro-2-methoxyphenyl)methyl]-, hydrochloride (HCl) (CA INDEX NAME)



● HCl

HN 852236-31-8 CAPLUS
CN 2-Morpholinomethanol, 4-methyl-4-[(2-trifluoromethoxyphenyl)methyl]-, hydrochloride (HCl) (CA INDEX NAME)



● HCl

HN 852236-33-0 CAPLUS
CN 2-Morpholinomethanol, 4-methyl-4-[(1-methyl-2-ylmethyl)-2-ylmethyl]-4-ethyl-, hydrochloride (HCl) (CA INDEX NAME)



● HCl


HN 852236-35-2 CAPLUS
CN 2-Morpholinomethanol, 4-methyl-4-[(5-fluoro-2-methoxyphenyl)methyl]-, hydrochloride (HCl) (CA INDEX NAME)



● HCl

HN 852236-39-8 CAPLUS
CN 2-Morpholinomethanol, 4-methyl-4-[(2-methoxyphenyl)methyl]-4-ethyl-, hydrochloride (HCl) (CA INDEX NAME)


Relative stereochemistry.



● HCl

HN 852236-40-9 CAPLUS
CN 2-Morpholinomethanol, 4-methyl-4-[(2-methoxyphenyl)methyl]-4-ethyl-, hydrochloride (HCl) (CA INDEX NAME)


Relative stereochemistry.



● HCl

HN 852236-44-3 CAPLUS
CN 2-Morpholinomethanol, 4-methyl-4-[(2-ethoxyphenyl)methyl]-4-ethyl-, hydrochloride (HCl) (CA INDEX NAME)


Relative stereochemistry.



● HCl

HN 852236-48-4 CAPLUS
CN 2-Morpholinomethanol, 4-methyl-4-[(2-ethoxyphenyl)methyl]-4-ethyl-, hydrochloride (HCl) (CA INDEX NAME)

Relative stereochemistry.



● HCl

HN 852236-47-6 CAPLUS
CN 2-Morpholinomethanol, 4-methyl-4-[(2-ethoxyphenyl)methyl]-4-ethyl-, hydrochloride (HCl) (CA INDEX NAME)



● HCl

HN 852236-49-8 CAPLUS
CN 2-Morpholinomethanol, 4-methyl-4-[(2-ethoxyphenyl)methyl]-4-ethyl-, hydrochloride (HCl) (CA INDEX NAME)



● HCl

HN 852236-51-2 CAPLUS
CN 2-Morpholinomethanol, 4-methyl-4-[(4-fluoro-1,1'-biphenyl)-2-ylmethyl]-4-ethyl-, hydrochloride (HCl) (CA INDEX NAME)



● HCl


HN 852236-53-4 CAPLUS
CN 2-Morpholinomethanol, 4-methyl-4-[(5-fluoro-2-methoxyphenyl)methyl]-4-ethyl-, hydrochloride (HCl) (CA INDEX NAME)



● HCl


XN 852236-55-6 CAPLUS
CN 2-Morpholinemetanol, w-([2-methoxyphenyl]methyl)-w-(2-methylpropyl)-, (4a,5b)-diol- (CA INDEX NAME)

Relative stereochemistry.




XN 852236-56-7 CAPLUS
CN 2-Morpholinemetanol, w-([2-methoxyphenyl]methyl)-w-(2-methylpropyl)-, (4a,5b)-diol- (CA INDEX NAME)

Relative stereochemistry.




XN 852236-58-9 CAPLUS
CN 2-Morpholinemetanol, w-([2-methylpropyl]-w-([2-(trifluoromethoxy)phenyl]methyl))-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

XN 852236-95-4 CAPLUS
CN 2-Morpholinemetanol, w-([2-(trifluoromethoxy)phenyl]methyl)-w-([3,3,3-trifluoropropyl])-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

XN 852236-97-6 CAPLUS
CN 2-Morpholinemetanol, w-([1,1'-biphenyl]-2-ylmethyl)-w-(3,3,3-trifluoropropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

XN 852236-99-8 CAPLUS
CN 2-Morpholinemetanol, w-([4-fluoro-2-methoxyphenyl]methyl)-w-(4,4,4-trifluorodethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

XN 852236-63-6 CAPLUS
CN 2-Morpholinemetanol, w-([1,1'-biphenyl]-2-ylmethyl)-w-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

XN 852236-65-8 CAPLUS
CN 2-Morpholinemetanol, w-([4-fluoro[1,1'-biphenyl]-2-yl]methyl)-w-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

XN 852236-93-2 CAPLUS
CN 2-Morpholinemetanol, w-([5-fluoro-2-methoxyphenyl]methyl)-w-(3,3,3-trifluoropropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

XN 852237-01-5 CAPLUS
CN 2-Morpholinemetanol, w-([1,1'-biphenyl]-2-ylmethyl)-w-(4,4,4-trifluorobutyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

XN 852237-14-0 CAPLUS
CN 2-Morpholinemetanol, w-w-bis([2-methoxyphenyl]methyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

XN 852237-21-9 CAPLUS
CN 2-Morpholinemetanol, w-butyl-w-([2-methoxyphenyl]methyl)-, hydrochloride (9CI) (CA INDEX NAME)




● RC1

RI 85227-21-1 CAPLUS
 CH 2-Morpholinomethanol, 1-((2-methoxyphenyl)methyl)-, hydrochloride (RC1) (CA INDEX NAME)



● RC1

RI 85227-21-5 CAPLUS
 CH 2-Morpholinomethanol, 1-((2-chloro-6-(4-fluorophenyl)methyl)-4-(2-methylpropyl))-, hydrochloride (RC1) (CA INDEX NAME)



● RC1

RI 85237-28-7 CAPLUS
 CH 2-Morpholinomethanol, 1-((2-chloro-6-(4-fluorophenyl)methyl)-4-(2-methylpropyl))-, hydrochloride (RC1) (CA INDEX NAME)

ACCESSION NUMBER: 2005128719 CAPLUS
 DOCUMENT NUMBER: 14129416
 TITLE: Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
 INVENTOR(S): Melvyn Douglas Kenneth
 PATENT ASSIGNOR(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 299 pp.
 COUNTRY: PAKISTAN
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005021095	A2	20050310	WO 2004-082593	20040825
WO 2005021095	A3	20050609		
US 6,400,000	A1	20010310	US 2001-0310	20010310
US 6,400,000	A2	20010310	US 2001-0310	20010310
US 6,400,000	A3	20010310	US 2001-0310	20010310
US 6,400,000	A4	20010310	US 2001-0310	20010310
US 6,400,000	A5	20010310	US 2001-0310	20010310
US 6,400,000	A6	20010310	US 2001-0310	20010310
US 6,400,000	A7	20010310	US 2001-0310	20010310
US 6,400,000	A8	20010310	US 2001-0310	20010310
US 6,400,000	A9	20010310	US 2001-0310	20010310
US 6,400,000	A10	20010310	US 2001-0310	20010310
US 6,400,000	A11	20010310	US 2001-0310	20010310
US 6,400,000	A12	20010310	US 2001-0310	20010310
US 6,400,000	A13	20010310	US 2001-0310	20010310
US 6,400,000	A14	20010310	US 2001-0310	20010310
US 6,400,000	A15	20010310	US 2001-0310	20010310
US 6,400,000	A16	20010310	US 2001-0310	20010310
US 6,400,000	A17	20010310	US 2001-0310	20010310
US 6,400,000	A18	20010310	US 2001-0310	20010310
US 6,400,000	A19	20010310	US 2001-0310	20010310
US 6,400,000	A20	20010310	US 2001-0310	20010310
US 6,400,000	A21	20010310	US 2001-0310	20010310
US 6,400,000	A22	20010310	US 2001-0310	20010310
US 6,400,000	A23	20010310	US 2001-0310	20010310
US 6,400,000	A24	20010310	US 2001-0310	20010310
US 6,400,000	A25	20010310	US 2001-0310	20010310
US 6,400,000	A26	20010310	US 2001-0310	20010310
US 6,400,000	A27	20010310	US 2001-0310	20010310
US 6,400,000	A28	20010310	US 2001-0310	20010310
US 6,400,000	A29	20010310	US 2001-0310	20010310
US 6,400,000	A30	20010310	US 2001-0310	20010310
US 6,400,000	A31	20010310	US 2001-0310	20010310
US 6,400,000	A32	20010310	US 2001-0310	20010310
US 6,400,000	A33	20010310	US 2001-0310	20010310
US 6,400,000	A34	20010310	US 2001-0310	20010310
US 6,400,000	A35	20010310	US 2001-0310	20010310
US 6,400,000	A36	20010310	US 2001-0310	20010310
US 6,400,000	A37	20010310	US 2001-0310	20010310
US 6,400,000	A38	20010310	US 2001-0310	20010310
US 6,400,000	A39	20010310	US 2001-0310	20010310
US 6,400,000	A40	20010310	US 2001-0310	20010310
US 6,400,000	A41	20010310	US 2001-0310	20010310
US 6,400,000	A42	20010310	US 2001-0310	20010310
US 6,400,000	A43	20010310	US 2001-0310	20010310
US 6,400,000	A44	20010310	US 2001-0310	20010310
US 6,400,000	A45	20010310	US 2001-0310	20010310
US 6,400,000	A46	20010310	US 2001-0310	20010310
US 6,400,000	A47	20010310	US 2001-0310	20010310
US 6,400,000	A48	20010310	US 2001-0310	20010310
US 6,400,000	A49	20010310	US 2001-0310	20010310
US 6,400,000	A50	20010310	US 2001-0310	20010310
US 6,400,000	A51	20010310	US 2001-0310	20010310
US 6,400,000	A52	20010310	US 2001-0310	20010310
US 6,400,000	A53	20010310	US 2001-0310	20010310
US 6,400,000	A54	20010310	US 2001-0310	20010310
US 6,400,000	A55	20010310	US 2001-0310	20010310
US 6,400,000	A56	20010310	US 2001-0310	20010310
US 6,400,000	A57	20010310	US 2001-0310	20010310
US 6,400,000	A58	20010310	US 2001-0310	20010310
US 6,400,000	A59	20010310	US 2001-0310	20010310
US 6,400,000	A60	20010310	US 2001-0310	20010310
US 6,400,000	A61	20010310	US 2001-0310	20010310
US 6,400,000	A62	20010310	US 2001-0310	20010310
US 6,400,000	A63	20010310	US 2001-0310	20010310
US 6,400,000	A64	20010310	US 2001-0310	20010310
US 6,400,000	A65	20010310	US 2001-0310	20010310
US 6,400,000	A66	20010310	US 2001-0310	20010310
US 6,400,000	A67	20010310	US 2001-0310	20010310
US 6,400,000	A68	20010310	US 2001-0310	20010310
US 6,400,000	A69	20010310	US 2001-0310	20010310
US 6,400,000	A70	20010310	US 2001-0310	20010310
US 6,400,000	A71	20010310	US 2001-0310	20010310
US 6,400,000	A72	20010310	US 2001-0310	20010310
US 6,400,000	A73	20010310	US 2001-0310	20010310
US 6,400,000	A74	20010310	US 2001-0310	20010310
US 6,400,000	A75	20010310	US 2001-0310	20010310
US 6,400,000	A76	20010310	US 2001-0310	20010310
US 6,400,000	A77	20010310	US 2001-0310	20010310
US 6,400,000	A78	20010310	US 2001-0310	20010310
US 6,400,000	A79	20010310	US 2001-0310	20010310
US 6,400,000	A80	20010310	US 2001-0310	20010310
US 6,400,000	A81	20010310	US 2001-0310	20010310
US 6,400,000	A82	20010310	US 2001-0310	20010310
US 6,400,000	A83	20010310	US 2001-0310	20010310
US 6,400,000	A84	20010310	US 2001-0310	20010310
US 6,400,000	A85	20010310	US 2001-0310	20010310
US 6,400,000	A86	20010310	US 2001-0310	20010310
US 6,400,000	A87	20010310	US 2001-0310	20010310
US 6,400,000	A88	20010310	US 2001-0310	20010310
US 6,400,000	A89	20010310	US 2001-0310	20010310
US 6,400,000	A90	20010310	US 2001-0310	20010310
US 6,400,000	A91	20010310	US 2001-0310	20010310
US 6,400,000	A92	20010310	US 2001-0310	20010310
US 6,400,000	A93	20010310	US 2001-0310	20010310
US 6,400,000	A94	20010310	US 2001-0310	20010310
US 6,400,000	A95	20010310	US 2001-0310	20010310
US 6,400,000	A96	20010310	US 2001-0310	20010310
US 6,400,000	A97	20010310	US 2001-0310	20010310
US 6,400,000	A98	20010310	US 2001-0310	20010310
US 6,400,000	A99	20010310	US 2001-0310	20010310
US 6,400,000	A100	20010310	US 2001-0310	20010310

OTHER SOURCE(S):
 01




● RC1

IT 85227-66-99
 RI: RCT (Reactant); SPM (Synthetic preparation); FRP (Preparation); PCT (Preparation of reagent)
 Preparation of morpholine derivative as norepinephrine reuptake inhibitor
 RI 85227-66-9 CAPLUS
 CH 2-Morpholinomethanol, 1-((4-fluorophenyl)-2-yl)methyl)-, hydrochloride (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE AS

FORMAT



21

AB Provided are methods and medicaments for treating stuttering or another communication disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor. The invention discloses the use of atomoxetine, racemic reboxetine, (S,S)-reboxetine, and compounds of formula I (wherein X = alkylthio and Y = alkyl) as described in U.S. patent Number 5,781,624), as well as their pharmaceutically acceptable salts, as the norepinephrine reuptake inhibitors described for treatment purposes. The invention further discloses the preparation of additional heterocyclic derivs. (as well as


their pharmaceutically acceptable salts) that possess ability to serve as norepinephrine reuptake inhibitors. For instance, morpholine derivative I (wherein X = alkylthio and Y = alkyl) was prepared via alkylation of (4-methylmorpholin-2-yl)phenylmethanone with 2-chloro-6-fluorobenzylmagnesium chloride and subsequent H-debenzylation. The preferred invention compounds exhibited pK values of less than 5.00 mM at the norepinephrine transporter

incubation (pH 7.4) assay:
 IT 64360-72-9P 64360-73-9P 64360-74-9P
 64360-75-9P 64360-76-9P 64360-77-9P
 64360-78-9P 64360-79-9P 64360-80-9P
 64360-81-9P 64360-82-9P 64360-83-9P
 64360-84-9P 64360-85-9P 64360-86-9P
 64360-87-9P 64360-88-9P 64360-89-9P
 64360-90-9P 64360-91-9P 64360-92-9P
 64360-93-9P 64360-94-9P 64360-95-9P
 64360-96-9P 64360-97-9P 64360-98-9P
 64360-99-9P 64361-00-9P 64361-01-9P
 64361-02-9P 64361-03-9P 64361-04-9P
 64361-05-9P 64361-06-9P 64361-07-9P
 64361-08-9P 64361-09-9P 64361-10-9P
 RI: PCT (Pharmacological activity); SPM (Synthetic preparation); THO

125 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 (Therapeutic use); BIO (Biological study); PREP (Preparation); USES
 (Uses)
 [prep. of heterocyclic compds. useful as norepinephrine reuptake
 inhibitors]

BN 664360-72-9 CAPLUS
 CH 2-Morpholinomethanol, ω -[2-methoxyphenylmethyl]- α -phenyl-,
 hydrochloride, (4*S*,2*S*)- (PC1) (CA INDEX NAME)


Absolute stereochemistry.



● RC1

BN 664360-73-0 CAPLUS
 CH 2-Morpholinomethanol, ω -[2-ethoxyphenylmethyl]- α -phenyl-,
 hydrochloride, (4*S*,2*S*)- (PC1) (CA INDEX NAME)

Absolute stereochemistry.




● RC1

BN 664360-74-1 CAPLUS
 CH 2-Morpholinomethanol, ω -[2-[1-methylethoxyphenylmethyl]- α -
 phenyl-, hydrochloride, (4*S*,2*S*)- (PC1) (CA INDEX NAME)

Absolute stereochemistry.


125 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



● RC1

BN 664360-77-4 CAPLUS
 CH 2-Morpholinomethanol, ω -[1,1'-biphenyl]-2-ylmethyl]- α -phenyl-,
 hydrochloride, (4*S*,2*S*)- (PC1) (CA INDEX NAME)


Absolute stereochemistry.



● RC1

BN 664360-78-5 CAPLUS
 CH 2-Morpholinomethanol, ω -[2-(chlorophenyl)methyl]- α -phenyl-,
 hydrochloride, (4*S*,2*S*)- (PC1) (CA INDEX NAME)


Absolute stereochemistry.



● RC1

BN 664360-78-6 CAPLUS
 CH 2-Morpholinomethanol, ω -[5-fluoro-2-methoxyphenylmethyl]- α -
 phenyl-, hydrochloride, (4*S*,2*S*)- (PC1) (CA INDEX NAME)


125 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



● RC1

BN 664360-75-2 CAPLUS
 CH 2-Morpholinomethanol, ω -[2-(4-fluorophenyl)- α -[2-
 methoxyphenylmethyl]-, hydrochloride, (4*S*,2*S*)- (PC1) (CA INDEX
 NAME)

Absolute stereochemistry.




● RC1

BN 664360-76-3 CAPLUS
 CH 2-Morpholinomethanol, ω -phenyl- α -[2-
 (trifluoromethyl)phenylmethyl]-, hydrochloride, (4*S*,2*S*)- (PC1)
 (CA INDEX NAME)

Absolute stereochemistry.



125 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)




● RC1

BN 664360-81-0 CAPLUS
 CH 2-Morpholinomethanol, ω -phenyl- α -[2-
 (trifluoromethylthio)phenylmethyl]-, (4*S*,2*S*)-, acetate (salt)
 (PC1) (CA INDEX NAME)

CH 1

CHI 664360-80-9
 CHP C19 H20 F3 N O2 S

Absolute stereochemistry.




CH 2

CHI 64-19-7
 CHP C2 H4 O2




BN 664360-82-3 CAPLUS
 CH 2-Morpholinomethanol, ω -phenyl- α -[2-
 (trifluoromethyl)phenylmethyl]-, (4*S*,2*S*)- (CA INDEX NAME)

Absolute stereochemistry.



20 664360-83-2 CAPLOS
CN 2-Morpholinemethanol, 4-([2-chlorophenyl]methyl)-1,3-fluorophenyl-2-hydrochloride, (aR,2S)- (PC1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


20 664360-84-3 CAPLOS
CN 2-Morpholinemethanol, 4-([2-methylphenyl]methyl)-1,3-phenyl-2-hydrochloride, (aR,2S)- (PC1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


20 664360-85-4 CAPLOS
CN 2-Morpholinemethanol, 4-phenyl-1,3-phenylmethyl-2-hydrochloride, (aR,2S)- (PC1) (CA INDEX NAME)



● HCl

20 664360-89-8 CAPLOS
CN 2-Morpholinemethanol, 4-([5-fluoro-2-hydroxyphenyl]methyl)-1,3-phenyl-2-hydrochloride, (aR,2S)- (PC1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

20 664360-92-1 CAPLOS
CN 2-Morpholinemethanol, 4-([2-chloro-6-fluorophenyl]methyl)-1,3-phenyl-2-hydrochloride, (aR,2S)- (PC1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


Absolute stereochemistry.



● HCl

20 664360-86-5 CAPLOS
CN 2-Morpholinemethanol, 4-([2-fluorophenyl]methyl)-1,3-phenyl-2-hydrochloride, (aR,2S)- (PC1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

20 664360-87-6 CAPLOS
CN 2-Morpholinemethanol, 4-([2-bromophenyl]methyl)-1,3-phenyl-2-hydrochloride, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




20 664360-88-7 CAPLOS
CN 2-Morpholinemethanol, 4-([2'-chloro[1,1'-biphenyl]-2-yl]methyl)-1,3-phenyl-2-hydrochloride, (aR,2S)- (PC1) (CA INDEX NAME)

Absolute stereochemistry.



20 664360-91-2 CAPLOS
CN 2-Morpholinemethanol, 4-([2,5-dimethoxyphenyl]methyl)-1,3-phenyl-2-hydrochloride, (aR,2S)- (PC1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

20 664360-92-3 CAPLOS
CN 2-Morpholinemethanol, 4-([2,4-difluorophenyl]methyl)-1,3-phenyl-2-hydrochloride, (aR,2S)- (PC1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

20 664360-93-4 CAPLOS
CN 2-Morpholinemethanol, 4-([2,6-dichlorophenyl]methyl)-1,3-phenyl-2-hydrochloride, (aR,2S)- (PC1) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

320 664760-94-5 CAPLUS
CN 2-Morpholinomethyl, 4-chlorophenyl, hydrochloride, (4S,2S)- (9C1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


320 664760-95-6 CAPLUS
CN 2-Morpholinomethyl, 4-chlorophenyl, hydrochloride, (4S,2S)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

320 664760-96-7 CAPLUS




320 664760-99-0 CAPLUS
CN 2-Morpholinomethyl, 4-chlorophenyl, hydrochloride, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.




320 664761-02-6 CAPLUS
CN 2-Morpholinomethyl, 4-chlorophenyl, hydrochloride, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



320 664761-01-7 CAPLUS
CN 2-Morpholinomethyl, 4-chlorophenyl, hydrochloride, (4S,2S)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl

320 664760-97-8 CAPLUS
CN 2-Morpholinomethyl, 4-chlorophenyl, hydrochloride, (4S,2S)- (CA INDEX NAME)


Absolute stereochemistry.



320 664760-98-9 CAPLUS
CN 2-Morpholinomethyl, 4-chlorophenyl, hydrochloride, (4S,2S)- (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




320 664761-02-8 CAPLUS
CN 2-Morpholinomethyl, 4-chlorophenyl, hydrochloride, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.




320 664761-03-9 CAPLUS
CN 2-Morpholinomethyl, 4-chlorophenyl, hydrochloride, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.




320 664761-04-0 CAPLUS
CN 2-Morpholinomethyl, 4-chlorophenyl, hydrochloride, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RI 644361-05-1 CAPLUS
 CH 2-Morpholinomethanol, w-([2',4'-dichloro[1,1'-biphenyl]-2-yl)methyl)-
 w-phenyl-, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RI 644361-06-2 CAPLUS
 CH 2-Morpholinomethanol, w-([2',4'-dimethoxy[1,1'-biphenyl]-2-
 yl)methyl)-w-phenyl-, (4S,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RI 644361-07-3 CAPLUS
 CH 2-Morpholinomethanol, w-([2'-fluoro-2-hydroxyphenyl)methyl)-
 w-phenyl-, (4S,2S)- (CA INDEX NAME)




Absolute stereochemistry.




RI 644361-08-4 CAPLUS
 CH 2-Morpholinomethanol, w-([2-(3-thienylphenyl)methyl]-
 w-phenyl-, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RI 644361-09-5 CAPLUS
 CH 2-Morpholinomethanol, w-([3',4'-dichloro[1,1'-biphenyl]-2-yl)methyl)-
 w-phenyl-, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RI 644361-42-6 CAPLUS
 CH 2-Morpholinomethanol, w-([3-fluoro-2-hydroxyphenyl)methyl)-
 w-phenyl-, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.








L25 ANSWER 10 OF 14		CAPLUS COPYRIGHT 2008 ACS on STN			
ACCESSION NUMBER:		2005-216669		CAPLUS	
DOCUMENT NUMBER:		142-291415		Treatment of pervasive development disorders	
TITLE:		employing		norepinephrine reuptake inhibitors	
INVENTOR(S):		Allen, Albert John; Easley, Douglas Kenneth			
PATENT ASSIGNOR(S):		Eli Lilly and Company, USA			
SOURCE:		PCT Int. Appl., 2004 pp.			
DOCUMENT TYPE:		Patent			
LANGUAGE:		English			
FAMILY ACC. NUM. COUNTRY:		1			
PATENT INFORMATION:					
PATENT NO.		KIND		DATE	
WO 2005020976		A2		20050310	
WO 2005020976		A2		20050616	
WO 2005020976		A2		20050616	
CA 2536161		A1		20050310	
EP 160065		A2		20060531	
US 200421185		A1		20040305	
PRIORITY AFFILI. INFO.:		WO 2004-0825593		P 20030927	
OTHER SOURCE(S):		CASREACT 142-291415; NMRPAT 142-291415			
GI		WO 2004-0825593		P 20040825	



125 ABSTRACT 10 QY 1 CAMPUS COPYRIGHT 1989 ACS ON STM (Continued)
an effective act of a selective morphopneumate reuptake inhibitor. The invention discloses the use of atomoxetine, racemic reboxetine, (S,S)-reboxetine, and compds. of formula I (wherein X = alythoxy and Y = alythoxy), as described in U.S. patent No. 5,358,426; and as their pharmaceutically acceptable salts. The invention discloses morphopneumate inhibitors described for treatment purposes. The invention further discloses the prepn. of admtl. heterocyclic derivs. (as well as their pharmaceutically acceptable salts) that possess ability to serve as morphopneumate inhibitors. The inhibitory activity of the morphopneumate 11- β -CD (15) H₂O was prepd. via alylation of 4-benzyl-morpholine-2-yl phenylthiomethoxy by 2-chloro-6-fluorobenzylmagnesium chloride and

subsequent N-debenzoylation of the obtained acid 7 (100 nm). The inversion couplet, exhibited Ki values of less than 10 nM at the neurokinin B transport-linked inhibition proximity assay).

IT 664360-75 75 664360-81 75 664360-82 75 664360-83 75 664360-84 75 664360-85 75 664360-86 75 664360-87 75 664360-88 75 664360-89 75 664360-90 75 664360-91 75 664360-92 75 664360-93 75 664360-94 75 664360-95 75 664360-96 75 664360-97 75 664360-98 75 664360-99 75 664360-100 75 664360-101 75 664360-102 75 664360-103 75 664360-104 75 664360-105 75 664360-106 75 664360-107 75 664360-108 75 664360-109 75 664360-110 75 664360-111 75 664360-112 75 664360-113 75 664360-114 75 664360-115 75 664360-116 75 664360-117 75 664360-118 75 664360-119 75 664360-120 75 664360-121 75 664360-122 75 664360-123 75 664360-124 75 664360-125 75 664360-126 75 664360-127 75 664360-128 75 664360-129 75 664360-130 75 664360-131 75 664360-132 75 664360-133 75 664360-134 75 664360-135 75 664360-136 75 664360-137 75 664360-138 75 664360-139 75 664360-140 75 664360-141 75 664360-142 75 664360-143 75 664360-144 75 664360-145 75 664360-146 75 664360-147 75 664360-148 75 664360-149 75 664360-150 75 664360-151 75 664360-152 75 664360-153 75 664360-154 75 664360-155 75 664360-156 75 664360-157 75 664360-158 75 664360-159 75 664360-160 75 664360-161 75 664360-162 75 664360-163 75 664360-164 75 664360-165 75 664360-166 75 664360-167 75 664360-168 75 664360-169 75 664360-170 75 664360-171 75 664360-172 75 664360-173 75 664360-174 75 664360-175 75 664360-176 75 664360-177 75 664360-178 75 664360-179 75 664360-180 75 664360-181 75 664360-182 75 664360-183 75 664360-184 75 664360-185 75 664360-186 75 664360-187 75 664360-188 75 664360-189 75 664360-190 75 664360-191 75 664360-192 75 664360-193 75 664360-194 75 664360-195 75 664360-196 75 664360-197 75 664360-198 75 664360-199 75 664360-200 75 664360-201 75 664360-202 75 664360-203 75 664360-204 75 664360-205 75 664360-206 75 664360-207 75 664360-208 75 664360-209 75 664360-210 75 664360-211 75 664360-212 75 664360-213 75 664360-214 75 664360-215 75 664360-216 75 664360-217 75 664360-218 75 664360-219 75 664360-220 75 664360-221 75 664360-222 75 664360-223 75 664360-224 75 664360-225 75 664360-226 75 664360-227 75 664360-228 75 664360-229 75 664360-230 75 664360-231 75 664360-232 75 664360-233 75 664360-234 75 664360-235 75 664360-236 75 664360-237 75 664360-238 75 664360-239 75 664360-240 75 664360-241 75 664360-242 75 664360-243 75 664360-244 75 664360-245 75 664360-246 75 664360-247 75 664360-248 75 664360-249 75 664360-250 75 664360-251 75 664360-252 75 664360-253 75 664360-254 75 664360-255 75 664360-256 75 664360-257 75 664360-258 75 664360-259 75 664360-260 75 664360-261 75 664360-262 75 664360-263 75 664360-264 75 664360-265 75 664360-266 75 664360-267 75 664360-268 75 664360-269 75 664360-270 75 664360-271 75 664360-272 75 664360-273 75 664360-274 75 664360-275 75 664360-276 75 664360-277 75 664360-278 75 664360-279 75 664360-280 75 664360-281 75 664360-282 75 664360-283 75 664360-284 75 664360-285 75 664360-286 75 664360-287 75 664360-288 75 664360-289 75 664360-290 75 664360-291 75 664360-292 75 664360-293 75 664360-294 75 664360-295 75 664360-296 75 664360-297 75 664360-298 75 664360-299 75 664360-300 75 664360-301 75 664360-302 75 664360-303 75 664360-304 75 664360-305 75 664360-306 75 664360-307 75 664360-308 75 664360-309 75 664360-310 75 664360-311 75 664360-312 75 664360-313 75 664360-314 75 664360-315 75 664360-316 75 664360-317 75 664360-318 75 664360-319 75 664360-320 75 664360-321 75 664360-322 75 664360-323 75 664360-324 75 664360-325 75 664360-326 75 664360-327 75 664360-328 75 664360-329 75 664360-330 75 664360-331 75 664360-332 75 664360-333 75 664360-334 75 664360-335 75 664360-336 75 664360-337 75 664360-338 75 664360-339 75 664360-340 75 664360-341 75 664360-342 75 664360-343 75 664360-344 75 664360-345 75 664360-346 75 664360-347 75 664360-348 75 664360-349 75 664360-350 75 664360-351 75 664360-352 75 664360-353 75 664360-354 75 664360-355 75 664360-356 75 664360-357 75 664360-358 75 664360-359 75 664360-360 75 664360-361 75 664360-362 75 664360-363 75 664360-364 75 664360-365 75 664360-366 75 664360-367 75 664360-368 75 664360-369 75




CH 2

CH 64-19-7
OH C2 H4 O2




ZN 664360-82-1 CAPLOS
CH 2-Morpholinemetanol, α -phenyl- α -[2-(trifluoromethyl)phenyl]methyl-, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



ZN 664360-83-2 CAPLOS
CH 2-Morpholinemetanol, α -[2-(chlorophenyl)methyl]- α -[2-(fluorophenyl)-], hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

ZN 664360-84-3 CAPLOS
CH 2-Morpholinemetanol, α -[2-(methylphenyl)methyl]- α -phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.



ZN 664360-88-7 CAPLOS
CH 2-Morpholinemetanol, α -[2-(2-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


ZN 664360-89-8 CAPLOS
CH 2-Morpholinemetanol, α -[2-(5-fluoro-2-hydroxyphenyl)methyl]- α -phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

ZN 664360-90-1 CAPLOS
CH 2-Morpholinemetanol, α -[2-(2-chloro-6-fluorophenyl)methyl]- α -phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)



● HCl

ZN 664360-95-4 CAPLOS
CH 2-Morpholinemetanol, α -phenyl- α -(phenylmethyl)-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

ZN 664360-96-5 CAPLOS
CH 2-Morpholinemetanol, α -[2-(2-fluorophenyl)methyl]- α -phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

ZN 664360-97-6 CAPLOS
CH 2-Morpholinemetanol, α -[2-(3-bromophenyl)methyl]- α -phenyl-, (4S,2S)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl

ZN 664360-93-2 CAPLOS
CH 2-Morpholinemetanol, α -[2-(2,3-dimethoxyphenyl)methyl]- α -phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

ZN 664360-92-3 CAPLOS
CH 2-Morpholinemetanol, α -[2-(2,4-difluorophenyl)methyl]- α -phenyl-, hydrochloride, (4S,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

125 ANSWER 10 OF 14 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

HN 664360-93-4 CAPLOS
CN 2-Morpholinemetanol, α -[(2,6-dichlorophenyl)methyl]- ω -phenyl-, hydrochloride, (aR,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



• HCl

HN 664760-94-5 CAPLOS
CN 2-Morpholinemetanol, α -[(2,3-dichlorophenyl)methyl]- ω -phenyl-, hydrochloride, (aR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



• HCl


HN 664760-95-6 CAPLOS
CN 2-Morpholinemetanol, α -[(2,3-difluorophenyl)methyl]- ω -phenyl-, hydrochloride, (aR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

125 ANSWER 10 OF 14 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)


CN 2-Morpholinemetanol, α -[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




HN 664360-99-0 CAPLOS
CN 2-Morpholinemetanol, α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




HN 664363-02-6 CAPLOS
CN 2-Morpholinemetanol, α -[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




125 ANSWER 10 OF 14 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)



• HCl

HN 664360-96-7 CAPLOS
CN 2-Morpholinemetanol, α -[(4'-fluoro[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, hydrochloride, (aR,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



• HCl

HN 664760-97-8 CAPLOS
CN 2-Morpholinemetanol, α -[(4'-methyl[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




HN 664360-98-9 CAPLOS

125 ANSWER 10 OF 14 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)


HN 664363-02-7 CAPLOS
CN 2-Morpholinemetanol, α -[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




HN 664363-02-8 CAPLOS
CN 2-Morpholinemetanol, α -[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.



HN 664363-02-9 CAPLOS
CN 2-Morpholinemetanol, α -[(3'-methyl[1,1'-biphenyl]-2-yl)methyl]- ω -phenyl-, (aR,2S)- (CA INDEX NAME)


Absolute stereochemistry.



HN 664363-04-0 CAPLOS


L25 ANWEX 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN 2-Morpholinemetanol, ω -[3',5'-dichloro[1,1'-biphenyl]-2-ylmethyl]-
 α -phenyl-, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.




BN 664361-05-1 CAPLUS
 CN 2-Morpholinemetanol, ω -[2',4'-dimethoxy[1,1'-biphenyl]-2-ylmethyl]-
 α -phenyl-, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.




BN 664361-06-2 CAPLUS
 CN 2-Morpholinemetanol, ω -[2',4'-dimethoxy[1,1'-biphenyl]-2-
 ylmethyl]- α -phenyl-, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



L25 ANWEX 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 phonyl-, (4S,2S)- (CA INDEX NAME)


Absolute stereochemistry.



L25 ANWEX 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


BN 664361-07-3 CAPLUS
 CN 2-Morpholinemetanol, α -phenyl- ω -[2-[3-
 pyridinyl]phenyl]methyl-, (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.




BN 664361-08-4 CAPLUS
 CN 2-Morpholinemetanol, α -phenyl- ω -[2-[3-thienyl]phenyl]methyl-,
 (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



BN 664361-09-5 CAPLUS
 CN 2-Morpholinemetanol, α -phenyl- ω -[2-[3-thienyl]phenyl]methyl-,
 (4S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



BN 664361-42-6 CAPLUS
 CN 2-Morpholinemetanol, ω -[15-fluoro-2-hydroxyphenyl]methyl-, α -

L25 ANWEX 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005-216659 CAPLUS
 DOCUMENT NUMBER: 142721414
 TITLE: Treatment of learning disabilities and motor skills
 disorder with norepinephrine reuptake inhibitors
 SUMMARY: Calixto Russell
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 704 pp.
 CODES: P14X2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020975	A2	20050310	WO 2004-082592	20040825
WO 2005020975	A3	20050602		
W1	AB, AD, AL, AN, AT, AU, AZ, BA, BB, BG, BR, BS, BW, BY, BE, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, ES, EC, EG, EP, FI, GB, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KR, KZ, LC, LI, LU, LV, LY, MA, MD, MG, MK, MN, MU, MW, MY, NZ, PA, PE, PG, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, SL, SV, TH, TM, TR, TT, TZ, UA, UG, US, VC, VE, VN, ZA, ZM, ZW			
W4	AW, GW, GR, EE, LS, MG, ME, MH, SD, SL, SE, TG, UG, ZM, ZW, AM, AS, AY, AU, BE, BG, BR, BY, CA, CH, CY, CZ, DE, DK, DM, ES, FI, FR, GB, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KR, KZ, LC, LI, LU, LV, LY, MA, MD, MG, MK, MN, MU, MW, MY, NZ, PA, PE, PG, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, SL, SV, TH, TM, TR, TT, TZ, UA, UG, US, VC, VE, VN, ZA, ZM, ZW			
CA 2530014	A1	20050310	CA 2004-2530014	20040825
EP 1660064	A2	20060311	EP 2004-789100	20060311
R1	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, TR, SI, FI, NO, CY, TR, BG, CZ, SK, HU, PL, BG			
US 2007105960	A1	20070510	US 2004-568244	20060214
PRIORITY APPL. INFO.:			US 2003-499019P	P 20030827
			WO 2004-082592	W 20040825

OTHER SOURCE(S): M3P47 142:291414

L25 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I




II

AB Provided are methods and medicaments for treating a learning disability
 or a motor skills disorder, comprising administering to a patient in need of
 such treatment an effective amount of a selective norepinephrine reuptake
 inhibitor. The invention discloses the use of atomoxetine, racemic
 reboxetine, (S)-reboxetine, and compounds of formula I (wherein X =
 allylphenyl and Y = allyl); as described in U.S. patent Number 5,281,624),
 as well as their pharmaceutically acceptable salts, as the norepinephrine
 reuptake inhibitor described for treatment purposes. The invention
 further discloses the preparation of adducts, heterocyclic deriva- (as
 well as

their pharmaceutically acceptable salts) that possess ability to serve as
 norepinephrine reuptake inhibitors. For instance, morpholine derivative
 IIAE1 was prepared via alkylation of (4-benzyl-morpholin-2-
 yl)phenylmethanone with 2-chloro-4-[[2-(benzyl)imipazine ethoxide
 and subsequent N-benzylation. The preferred invention compounds exhibited KI
 values of less than 500 nM at the norepinephrine transporter
 (scintillation proximity assay).
 IT 664362-72-3P 664362-73-2P 664362-74-1P
 664362-75-2P 664362-76-3P 664362-77-4P
 664362-78-5P 664362-79-6P 664362-80-7P
 664362-82-1P 664362-83-2P 664362-84-3P
 664362-85-4P 664362-86-5P 664362-87-6P
 664362-88-7P 664362-89-8P 664362-90-1P
 664362-91-2P 664362-92-3P 664362-93-4P
 664362-94-5P 664362-95-6P 664362-96-7P
 664362-97-8P 664362-98-9P 664362-99-0P
 664362-00-1P 664362-01-2P 664362-02-3P
 664362-03-4P 664362-04-5P 664362-05-6P
 664362-06-7P 664362-07-8P 664362-08-9P
 664362-09-0P 664362-10-1P


L25 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● RCI

RI 664362-75-2 CAPLUS
 CI 2-Morpholinemetanol, α-[(3-fluorophenyl)-α-[(2-
 methoxyphenyl)methyl]-, hydrochloride, (aR,2S)- (PCI) (CA INDEX
 NAME)

Absolute stereochemistry.



● RCI

RI 664362-75-3 CAPLUS
 CI 2-Morpholinemetanol, α-phenyl-α-[(2-
 (1,1,1-trifluoro-2-methoxyphenyl)methyl]-, hydrochloride, (aR,2S)- (PCI)
 (CA INDEX NAME)


Absolute stereochemistry.

L25 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RI: PIC (Pharmacological activity); STN (Synthetic preparation); THO
 (Therapeutic use); BIOG (Biological study); PREP (Preparation); USES
 (Uses)

RI 664362-72-9 CAPLUS
 CI 2-Morpholinemetanol, α-[(2-methoxyphenyl)methyl]-α-phenyl-,
 hydrochloride, (aR,2S)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● RCI

RI 664362-73-0 CAPLUS
 CI 2-Morpholinemetanol, α-[(2-ethoxyphenyl)methyl]-α-phenyl-,
 hydrochloride, (aR,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.




● RCI

RI 664362-74-1 CAPLUS
 CI 2-Morpholinemetanol, α-[(2-(1-methylethoxyphenyl)methyl)-α-
 phenyl]-, hydrochloride, (aR,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.


L25 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● RCI

RI 664362-77-4 CAPLUS
 CI 2-Morpholinemetanol, α-[(1,1'-biphenyl)-2-ylmethyl]-α-phenyl-,
 hydrochloride, (aR,2S)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● RCI

RI 664362-78-5 CAPLUS
 CI 2-Morpholinemetanol, α-[(2-chlorophenyl)methyl]-α-phenyl-,
 hydrochloride, (aR,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.




● RCI

RI 664362-79-6 CAPLUS
 CI 2-Morpholinemetanol, α-[(5-fluoro-2-methoxyphenyl)methyl]-α-
 phenyl-, hydrochloride, (aR,2S)- (PCI) (CA INDEX NAME)

125 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RU 664360-91-2 CAPLUS
 CH 2-Morpholinemetanol, ω -[(2,5-dimethoxyphenyl)methyl]- α -phenyl-, hydrochloride, (4*S*,2*S*)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RU 664360-92-3 CAPLUS
 CH 2-Morpholinemetanol, ω -[(2,4-difluorophenyl)methyl]- α -phenyl-, hydrochloride, (4*S*,2*S*)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RU 664360-91-4 CAPLUS
 CH 2-Morpholinemetanol, ω -[(2,6-dichlorophenyl)methyl]- α -phenyl-, hydrochloride, (4*S*,2*S*)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


125 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RU 664360-94-5 CAPLUS
 CH 2-Morpholinemetanol, ω -[(2,5-dichlorophenyl)methyl]- α -phenyl-, hydrochloride, (4*S*,2*S*)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RU 664360-95-6 CAPLUS
 CH 2-Morpholinemetanol, ω -[(2,5-difluorophenyl)methyl]- α -phenyl-, hydrochloride, (4*S*,2*S*)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RU 664360-96-7 CAPLUS

125 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CH 2-Morpholinemetanol, ω -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (4*S*,2*S*)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RU 664360-97-8 CAPLUS
 CH 2-Morpholinemetanol, ω -[[4'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (4*S*,2*S*)- (CA INDEX NAME)


Absolute stereochemistry.



RU 664360-98-9 CAPLUS
 CH 2-Morpholinemetanol, ω -[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (4*S*,2*S*)- (CA INDEX NAME)


Absolute stereochemistry.

125 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RU 664360-99-0 CAPLUS
 CH 2-Morpholinemetanol, ω -[[4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (4*S*,2*S*)- (CA INDEX NAME)

Absolute stereochemistry.




RU 664360-98-6 CAPLUS
 CH 2-Morpholinemetanol, ω -[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (4*S*,2*S*)- (CA INDEX NAME)

Absolute stereochemistry.




RU 664360-93-7 CAPLUS
 CH 2-Morpholinemetanol, ω -[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (4*S*,2*S*)- (CA INDEX NAME)

Absolute stereochemistry.




2N 664361-01-8 CAPLUS
CN 2-Morpholinomethyl, 4-chlorobiphenyl-1-ylmethylether, (4R,1S)- (CA INDEX NAME)

Absolute stereochemistry.



2N 664361-01-9 CAPLUS
CN 2-Morpholinomethyl, 4-methoxybiphenyl-1-ylmethylether, (4R,1S)- (CA INDEX NAME)


Absolute stereochemistry.



2N 664361-04-0 CAPLUS
CN 2-Morpholinomethyl, 4,4'-dichlorobiphenyl-1-ylmethylether, (4R,1S)- (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




2N 664361-08-4 CAPLUS
CN 2-Morpholinomethyl, 4-thienylbiphenyl-1-ylmethylether, (4R,1S)- (CA INDEX NAME)

Absolute stereochemistry.




2N 664361-08-5 CAPLUS
CN 2-Morpholinomethyl, 4,4'-dichlorobiphenyl-1-ylmethylether, (4R,1S)- (CA INDEX NAME)

Absolute stereochemistry.




2N 664361-42-6 CAPLUS
CN 2-Morpholinomethyl, 4-(5-fluoro-2-hydroxyphenyl)methyl-1-phenyl-, (4R,1S)- (CA INDEX NAME)

Absolute stereochemistry.




2N 664361-02-1 CAPLUS
CN 2-Morpholinomethyl, 4,4'-dimethylbiphenyl-1-ylmethylether, (4R,1S)- (CA INDEX NAME)

Absolute stereochemistry.




2N 664361-06-2 CAPLUS
CN 2-Morpholinomethyl, 4,4'-dimethylbiphenyl-1-ylmethylether, (4R,1S)- (CA INDEX NAME)

Absolute stereochemistry.



2N 664361-07-3 CAPLUS
CN 2-Morpholinomethyl, 4-phenyl-1-pyridinylbiphenyl-1-ylmethylether, (4R,1S)- (CA INDEX NAME)



125 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

ACCESSION NUMBER: 2004103691 CAPLUS

DOCUMENT NUMBER: 14216941

TITLE: Treatment of emotional dysregulation

INVENTOR(S): Allen, Albert John; Cloutier, Kathleen Ann;

Michaelson,

PATENT ASSIGNER(S): David; Rainberry, Frederick William

SOURCE: Kili Lilly and Company, USA

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION(S):

PATENT NO.	KIND	DATA	APPLICATION NO.	DATA
MO 2004103556	A2	20041102	MO 2004-051005	20040511
MO 2004103556	A3	20050315		

W: At, Ag, Al, Am, Ar, As, Av, Bb, Bc, Bd, Bf, Bg, Bh, Bi, Bk, Bl, Bm, Bn, Bo, Bp, Bq, Br, Bs, Bt, Bv, Bw, Bx, By, Bz, Ca, Cb, Cc, Cd, Ce, Cf, Cg, Ch, Ci, Cj, Ck, Cl, Cm, Cn, Co, Cp, Cq, Cr, Cs, Ct, Cu, Cv, Cw, Cx, Cy, Cz, Dd, Df, Dg, Dh, Di, Dj, Dk, Dl, Dm, Dn, Do, Dp, Dq, Dr, Ds, Dt, Du, Dv, Dw, Dx, Dy, Dz, Ee, Ef, Eg, Eh, Ei, Ej, Ek, El, Em, En, Eo, Ep, Eq, Er, Es, Et, Eu, Ev, Ew, Ex, Ey, Ez, Ff, Fg, Fh, Fi, Fj, Fk, Fl, Fm, Fn, Fo, Fp, Fq, Fr, Fs, Ft, Fu, Fv, Fw, Fx, Fy, Fz, Gg, Gh, Gi, Gj, Gk, Gl, Gm, Gn, Go, Gp, Gq, Gr, Gs, Gt, Gu, Gv, Gw, Gx, Gy, Gz, Hh, Hi, Hj, Hk, Hl, Hm, Hn, Ho, Hp, Hq, Hr, Hs, Ht, Hu, Hv, Hw, Hx, Hy, Hz, Ii, Ij, Ik, Il, Im, In, Io, Ip, Iq, Ir, Is, It, Iu, Iv, Iw, Ix, Iy, Iz, Jj, Jk, Jl, Jm, Jn, Jo, Jp, Jq, Jr, Js, Jt, Ju, Jv, Jw, Jx, Jy, Jz, Kk, Kl, Km, Kn, Ko, Kp, Kq, Kr, Ks, Kt, Ku, Kv, Kw, Kx, Ky, Kz, Ll, Lm, Ln, Lo, Lp, Lq, Lr, Ls, Lt, Lu, Lv, Lw, Lx, Ly, Lz, Mm, Mn, Mo, Mp, Mq, Mr, Ms, Mt, Mu, Mv, Mw, Mx, My, Mz, Nn, No, Np, Nq, Nr, Ns, Nt, Nu, Nv, Nw, Nx, Ny, Nz, Oo, Op, Oq, Or, Os, Ot, Ou, Ov, Ow, Ox, Oy, Oz, Pp, Pq, Pr, Ps, Pt, Pv, Pw, Px, Py, Pz, Qq, Qr, Qs, Qt, Qu, Qv, Qw, Qx, Qy, Qz, Rr, Rs, Rt, Ru, Rv, Rw, Rx, Ry, Rz, Ss, St, Su, Sv, Sw, Sx, Sy, Sz, Tt, Tu, Tv, Tw, Tx, Ty, Tz, Uu, Uv, Uw, Ux, Uy, Uz, Vv, Vw, Vx, Vy, Vz, Ww, Wx, Wy, Wz, Xx, Xy, Xz, Yy, Yz, Zz.

FIGURE 1 APPL. INFO. 05 2003-470752P F 20030515

CHEM SUBC(S):

AB Provided is a method of treating emotional dysregulation comprising administering to a patient in need of such treatment a selective norepinephrine reuptake inhibitor.

IT 664360-72-3P 664360-73-2P 664360-74-1P 664360-75-2P 664360-76-3P 664360-77-4P 664360-78-5P 664360-79-6P 664360-80-9P 664360-81-0P 664360-82-1P 664360-83-2P 664360-84-3P

84. 88 (Synthesis preparation) PREP (Preparation)

treatment of emotional dysregulation)


88 664360-72-3 CAPLUS

CH 2-Morpholinemetanol, α -([2-methoxyphenyl]methyl)- α -phenyl-, hydrochloride, (4b,25)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.

125 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)


Absolute stereochemistry.



88 664360-77-4 CAPLUS

CH 2-Morpholinemetanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -phenyl-, hydrochloride, (4b,25)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



88 664360-78-5 CAPLUS

CH 2-Morpholinemetanol, α -([2-chlorophenyl]methyl)- α -phenyl-, hydrochloride, (4b,25)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



88 664360-79-6 CAPLUS

CH 2-Morpholinemetanol, α -([5-fluoro-2-methoxyphenyl]methyl)- α -phenyl-, hydrochloride, (4b,25)- (PCI) (CA INDEX NAME)


125 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



88 664360-73-0 CAPLUS

CH 2-Morpholinemetanol, α -([2-ethoxyphenyl]methyl)- α -phenyl-, hydrochloride, (4b,25)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



88 664360-74-1 CAPLUS

CH 2-Morpholinemetanol, α -([2-(1-methylethoxy)phenyl]methyl)- α -phenyl-, hydrochloride, (4b,25)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.




88 664360-76-3 CAPLUS

CH 2-Morpholinemetanol, α -phenyl- α -([2-(trifluoromethyl)phenyl]methyl)-, hydrochloride, (4b,28)- (PCI) (CA INDEX NAME)

125 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

Absolute stereochemistry.



88 664360-81-0 CAPLUS


CH 2-Morpholinemetanol, α -phenyl- α -([2-(trifluoromethylthio)phenyl]methyl)-, (4b,28)-, acetate (salt) (PCI) (CA INDEX NAME)

CH 1

CHN 664360-80-9

CHP C19 H20 F3 N O2 S

Absolute stereochemistry.



CH 2

64-19.7

CHP C2 H4 O2


HO-C-C-CH3

88 664360-82-1 CAPLUS

CH 2-Morpholinemetanol, α -phenyl- α -([2-(trifluoromethyl)phenyl]methyl)-, (4b,28)- (CA INDEX NAME)


Absolute stereochemistry.

L25 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RU 664360-81-2 CAPLUS
CN 2-Morpholinomethanol, 4-([2-chlorophenyl]methyl)-4-(3-fluorophenyl)-, hydrochloride, (4a,2S) - (1C1) (CA INDEX NAME)


Absolute stereochemistry.



● 1C1

RU 664360-84-3 CAPLUS
CN 2-Morpholinomethanol, 4-([2-methylphenyl]methyl)-4-phenyl-, hydrochloride, (4a,2S) - (1C1) (CA INDEX NAME)

Absolute stereochemistry.



● 1C1

L25 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)


AS Morpholine deriva. of formula 2 [R = independently H, alkyl, R1 = H, alkyl; Y = OR, alkoxyl; Ar1, Ar2 = (substituted) Ph, (substituted) heterocyl] are prepared. The compds. are selective inhibitors of the reuptake of norepinephrine. Thus, IT-823 was prepared from (4-benzylmorpholin-2-yl)-phenylmethanone (preparation given) and 2-(trifluoromethyl)benzoyl bromide. The compd. had R1 values less than 500 nM at the norepinephrine transporter in a sensitization proximity assay.

IT 664360-97-8P 664360-98-3P 664360-99-0P
664360-00-0P 664360-01-7P 664360-02-8P
664360-03-9P 664360-04-0P 664360-05-1P
664360-06-2P 664360-07-3P 664360-08-4P
664360-09-5P

RI, CPU (Combinatorial preparation); PAC (Pharmacological activity); TEU (Therapeutic use); BCU (Biological study); CMI (Combinatorial study); PMP (Preparation); USES (Uses);
[Preparation of aryl and heterocyl morpholine deriva. as norepinephrine reuptake inhibitors]

RU 664360-97-8 CAPLUS
CN 2-Morpholinomethanol, 4-([4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-4-phenyl-, (4a,2S) - (CA INDEX NAME)

Absolute stereochemistry.



RU 664360-98-9 CAPLUS
CN 2-Morpholinomethanol, 4-([4'-chloro[1,1'-biphenyl]-2-yl)methyl]-4-phenyl-, (4a,2S) - (CA INDEX NAME)

Absolute stereochemistry.


L25 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

ACCESSION NUMBER: 2004182855 CAPLUS
DOCUMENT NUMBER: 140-027649
TITLE: Preparation of aryl and heterocyl morpholine derivatives as norepinephrine reuptake inhibitors
Gans-Thomae, Marcel Jansen, Hapthone, Helen Janssen, Lamas-Potencia, Carlos, Ouwertker-Maldonado, Olivi, Maters, John, Jiangyong Simmonds, Robin, Gentry, Judy, Helene Catherine Ekenberry Walter, Magnus Wilhelm Eli Lilly and Company, USA
PCT Int. Appl., 82 pp.
CIS/INT PCT/US
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.		KIND DATE		APPLICATION NO.		DATE	
WO 2004018441		AL		20040304		2003-05-20 70	
M1	AL	AL	AL	AL	AL	AL	AL
	AM	AM	AM	AM	AM	AM	AM
	AR	AR	AR	AR	AR	AR	AR
	AT	AT	AT	AT	AT	AT	AT
	AU	AU	AU	AU	AU	AU	AU
	BE	BE	BE	BE	BE	BE	BE
	BR	BR	BR	BR	BR	BR	BR
	CA	CA	CA	CA	CA	CA	CA
	CH	CH	CH	CH	CH	CH	CH
	CL	CL	CL	CL	CL	CL	CL
CO	CO	CO	CO	CO	CO	CO	
DE	DE	DE	DE	DE	DE	DE	
DK	DK	DK	DK	DK	DK	DK	
EE	EE	EE	EE	EE	EE	EE	
ES	ES	ES	ES	ES	ES	ES	
FI	FI	FI	FI	FI	FI	FI	
FR	FR	FR	FR	FR	FR	FR	
GB	GB	GB	GB	GB	GB	GB	
GR	GR	GR	GR	GR	GR	GR	
HN	HN	HN	HN	HN	HN	HN	
IE	IE	IE	IE	IE	IE	IE	
IL	IL	IL	IL	IL	IL	IL	
IN	IN	IN	IN	IN	IN	IN	
JP	JP	JP	JP	JP	JP	JP	
KE	KE	KE	KE	KE	KE	KE	
KR	KR	KR	KR	KR	KR	KR	
LT	LT	LT	LT	LT	LT	LT	
LU	LU	LU	LU	LU	LU	LU	
LV	LV	LV	LV	LV	LV	LV	
MC	MC	MC	MC	MC	MC	MC	
MD	MD	MD	MD	MD	MD	MD	
ME	ME	ME	ME	ME	ME	ME	
MG	MG	MG	MG	MG	MG	MG	
MI	MI	MI	MI	MI	MI	MI	
ML	ML	ML	ML	ML	ML	ML	
MM	MM	MM	MM	MM	MM	MM	
MN	MN	MN	MN	MN	MN	MN	
MO	MO	MO	MO	MO	MO	MO	
MP	MP	MP	MP	MP	MP	MP	
MR	MR	MR	MR	MR	MR	MR	
MT	MT	MT	MT	MT	MT	MT	
MU	MU	MU	MU	MU	MU	MU	
MV	MV	MV	MV	MV	MV	MV	
MW	MW	MW	MW	MW	MW	MW	
MY	MY	MY	MY	MY	MY	MY	
MZ	MZ	MZ	MZ	MZ	MZ	MZ	
NA	NA	NA	NA	NA	NA	NA	
NE	NE	NE	NE	NE	NE	NE	
NG	NG	NG	NG	NG	NG	NG	
NL	NL	NL	NL	NL	NL	NL	
NZ	NZ	NZ	NZ	NZ	NZ	NZ	
OM	OM	OM	OM	OM	OM	OM	
PA	PA	PA	PA	PA	PA	PA	
PE	PE	PE	PE	PE	PE	PE	
PG	PG	PG	PG	PG	PG	PG	
PH	PH	PH	PH	PH	PH	PH	
PK	PK	PK	PK	PK	PK	PK	
PL	PL	PL	PL	PL	PL	PL	
PT	PT	PT	PT	PT	PT	PT	
PY	PY	PY	PY	PY	PY	PY	
QA	QA	QA	QA	QA	QA	QA	
RO	RO	RO	RO	RO	RO	RO	
RU	RU	RU	RU	RU	RU	RU	
SA	SA	SA	SA	SA	SA	SA	
SE	SE	SE	SE	SE	SE	SE	
SG	SG	SG	SG	SG	SG	SG	
SI	SI	SI	SI	SI	SI	SI	
SK	SK	SK	SK	SK	SK	SK	
SL	SL	SL	SL	SL	SL	SL	
SM	SM	SM	SM	SM	SM	SM	
SN	SN	SN	SN	SN	SN	SN	
SR	SR	SR	SR	SR	SR	SR	
SS	SS	SS	SS	SS	SS	SS	
ST	ST	ST	ST	ST	ST	ST	
SV	SV	SV	SV	SV	SV	SV	
SW	SW	SW	SW	SW	SW	SW	
SY	SY	SY	SY	SY	SY	SY	
TD	TD	TD	TD	TD	TD	TD	
TE	TE	TE	TE	TE	TE	TE	
TH	TH	TH	TH	TH	TH	TH	
TJ	TJ	TJ	TJ	TJ	TJ	TJ	
TM	TM	TM	TM	TM	TM	TM	
TN	TN	TN	TN	TN	TN	TN	
TO	TO	TO	TO	TO	TO	TO	
TR	TR	TR	TR	TR	TR	TR	
TT	TT	TT	TT	TT	TT	TT	
TU	TU	TU	TU	TU	TU	TU	
TV	TV	TV	TV	TV	TV	TV	
TW	TW	TW	TW	TW	TW	TW	
UA	UA	UA	UA	UA	UA	UA	
UG	UG	UG	UG	UG	UG	UG	
US	US	US	US	US	US	US	
UY	UY	UY	UY	UY	UY	UY	
UZ	UZ	UZ	UZ	UZ	UZ	UZ	
VE	VE	VE	VE	VE	VE	VE	
VN	VN	VN	VN	VN	VN	VN	
VO	VO	VO	VO	VO	VO	VO	
WA	WA	WA	WA	WA	WA	WA	
WI	WI	WI	WI	WI	WI	WI	
WO	WO	WO	WO	WO	WO	WO	
WS	WS	WS	WS	WS	WS	WS	
ZA	ZA	ZA	ZA	ZA	ZA	ZA	
ZB	ZB	ZB	ZB	ZB	ZB	ZB	
ZD	ZD	ZD	ZD	ZD	ZD	ZD	
ZG	ZG	ZG	ZG	ZG	ZG	ZG	
ZH	ZH	ZH	ZH	ZH	ZH	ZH	
ZI	ZI	ZI	ZI	ZI	ZI	ZI	
ZJ	ZJ	ZJ	ZJ	ZJ	ZJ	ZJ	
ZK	ZK	ZK	ZK	ZK	ZK	ZK	
ZL	ZL	ZL	ZL	ZL	ZL	ZL	
ZM	ZM	ZM	ZM	ZM	ZM	ZM	
ZN	ZN	ZN	ZN	ZN	ZN	ZN	
ZO	ZO	ZO	ZO	ZO	ZO	ZO	
ZP	ZP	ZP	ZP	ZP	ZP	ZP	
ZQ	ZQ	ZQ	ZQ	ZQ	ZQ	ZQ	
ZR	ZR	ZR	ZR	ZR	ZR	ZR	
ZS	ZS	ZS	ZS	ZS	ZS	ZS	
ZT	ZT	ZT	ZT	ZT	ZT	ZT	
ZU	ZU	ZU	ZU	ZU	ZU	ZU	
ZV	ZV	ZV	ZV	ZV	ZV	ZV	
ZW	ZW	ZW	ZW	ZW	ZW	ZW	
ZX	ZX	ZX	ZX	ZX	ZX	ZX	
ZY	ZY	ZY	ZY	ZY	ZY	ZY	
ZZ	ZZ	ZZ	ZZ	ZZ	ZZ	ZZ	
PRIORITY APPAR. INFO.				US 2003-05-20 70 A 2004-03-04			


125 NUMBER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)

Absolute stereochemistry




322 664361-02-8 CAPLUS
CN 2-Morpholinomethanol, α -([3'-methoxy(1,1'-biphenyl)-2-yl)methyl]-
 α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



F01 664361-03-9 CAPLUS
 CN 2-Morpholinomethanol, α -[(3'-methyl[1,1'-biphenyl]-2-yl)methyl]-
 α -phenyl-, (2R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




IN 664361-04-0 CAPLOS
 CN 2-Morpholinomethanol, α -[(3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]-
 α -phenyl-, (4R,2S)- (CA INDEX NAME)

Absolute stereochemistry.

125 ANSWER 13 OF 14 CAPLOS COPYRIGHT 2008 ACS on STM (Continued)

Absolute stereochemistry.




```

NN  664361-00-4  CAPLOS
CN  2-Morpholinemethanol, o-phenyl-o-[2-(3-thienyl)phenyl]methyl-
    , (aR,2S)- (CA INDEX NAME)


```

Absolute stereochemistry



IN 664361-09-5 CAPLUS
 CN 2-Morpholinomethanol, α -([3',4'-dichloro[1,1'-biphenyl]-2-yl)methyl)-
 α -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry.



```


IT 664360-87-6P
RL: CAT (Combinatorial reactant); PAC (Pharmacological activity); RCT
(Ractant); SPN (Synthetic preparation); THU (Therapeutic use); BIOG
(Biological study); CHR1 (Combinatorial study); PREP (Preparation); RACT
(Reactant or reagent); USSS (Uses)
[preparation of aryl and heteroaryl morpholine derivs. as
norepinephrine

```

125 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)


RN 664361-05-1 CASREG
 CN 2-Morpholinomethanol, α -[(2',4'-dimethyl[1,1'-biphenyl]-2-yl)methyl]-
 ω -phenyl-, (S,2S)- (CA INDEX NAME)

Absolute stereochemistry



323 664361-06-2 CAPLUS
 CN 2-Morpholinemethanol, α -[2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (aR,2S)- (CA INDEX NAME)

Absolute stereochemistry



RN 664361-07-3 CAPLOS
 CN 2-Morpholinemethanol, α -phenyl- α -[2-(2-pyridinyl)phenyl]methyl-, (aR,2R)- (CA INDEX NAME)


125 ANSWER 13 OF 14 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)

```

      reuptake inhibitors)
NN      664360-87-6  CAPLUS
CN      2-Morpholinemethanol, m-[(2-bromophenyl)methyl]-m-phenyl-,
      (aR,2S)- (CA INDEX NAME)

```


Absolute stereochemistry



IT 664361-41-5P
 RL: PWC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); ECOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 [Preparation of aryl and heteroaryl morpholine derivs. as

RE	664361-41-5	CAPLUS	
CM	2-Morpholinomethanol, o-phenyl- α -[2-(trifluoromethyl)phenyl]methyl]-, (4R,2S)-rel- (CA INDEX NAME)		

Relative stereochemistry.




IT 664360-82-1P
 RL: PNC (Pharmacological activity); PUR (Purification or recovery); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)

```


norepinephrine
  reuptake inhibitors)
RN  664360-82-1  CAPLUS
CN  2-Morpholinomethanol, o-phenyl-o-(2-
    (trifluoromethyl)phenyl)methyl-, (9E,25)-  ICA INDEX NAME

```

Absolute stereochemistry.




IT 664362-79-6P 664362-42-6P
 RI: PAC (Pharmacological activity); RCT (Reactant); SPH (Synthetic preparation); THO (Therapeutic use); BIOG (Biological study); PREP (Preparation); RAC (Reactant or reagent); USEG (Name)
 [Preparation of aryl and heteroaryl morpholine derivs. as morpholine reuptake inhibitors]
 RH 664362-79-6 CAPLUS
 CH 2-Morpholinemetanol, ω -[5-(4-fluorophenyl)methyl]- ω -phenyl-, hydrochloride, (aR,2S)- (PCI) (CA INDEX NAME)
 Absolute stereochemistry.




● HCI

RH 664363-42-6 CAPLUS
 CH 2-Morpholinemetanol, ω -[5-(5-oxo-2-hydroxyphenyl)methyl]- ω -phenyl-, (aR,2S)- (CA INDEX NAME)
 Absolute stereochemistry.




IT 664362-73-3P 664362-73-6P 664362-74-1P
 664362-75-3P 664362-76-3P 664362-77-4P
 664362-78-3P 664362-81-3P 664362-82-2P
 664362-84-3P 664362-85-6P 664362-86-5P



● HCI

RH 664362-75-2 CAPLUS
 CH 2-Morpholinemetanol, ω -[3-(4-fluorophenyl)- ω -[2-(4-methoxyphenyl)methyl]-, hydrochloride, (aR,2S)- (PCI) (CA INDEX NAME)
 Absolute stereochemistry.



● HCI


RH 664362-75-3 CAPLUS
 CH 2-Morpholinemetanol, ω -phenyl- ω -[2-[[trifluoromethyl]thio]phenyl]methyl]-, hydrochloride, (aR,2S)- (PCI) (CA INDEX NAME)
 Absolute stereochemistry.



664362-88-7P 664362-89-8P 664362-90-1P
 664362-91-2P 664362-92-3P 664362-93-4P
 664362-94-5P 664362-95-6P 664362-96-7P
 664361-97-9P 664361-98-0P 664361-99-1P
 664361-40-4P


RI: PAC (Pharmacological activity); SPH (Synthetic preparation); THO (Therapeutic use); BIOG (Biological study); PREP (Preparation); USEG (Name)
 [Prep. of aryl and heteroaryl morpholine derivs. as morpholine reuptake inhibitors]

RH 664362-72-9 CAPLUS
 CH 2-Morpholinemetanol, ω -[2-(4-methoxyphenyl)methyl]- ω -phenyl-, hydrochloride, (aR,2S)- (PCI) (CA INDEX NAME)
 Absolute stereochemistry.




● HCI

RH 664362-73-2 CAPLUS
 CH 2-Morpholinemetanol, ω -[2-(4-methoxyphenyl)methyl]- ω -phenyl-, hydrochloride, (aR,2S)- (PCI) (CA INDEX NAME)
 Absolute stereochemistry.




● HCI

RH 664362-74-1 CAPLUS
 CH 2-Morpholinemetanol, ω -[2-(1-methylethoxyphenyl)methyl]- ω -phenyl-, hydrochloride, (aR,2S)- (PCI) (CA INDEX NAME)
 Absolute stereochemistry.




● HCI

RH 664362-77-4 CAPLUS
 CH 2-Morpholinemetanol, ω -[1,1'-biphenyl]-2-ylmethyl]- ω -phenyl-, hydrochloride, (aR,2S)- (PCI) (CA INDEX NAME)
 Absolute stereochemistry.



● HCI

RH 664362-78-5 CAPLUS
 CH 2-Morpholinemetanol, ω -[2-(4-chlorophenyl)methyl]- ω -phenyl-, hydrochloride, (aR,2S)- (PCI) (CA INDEX NAME)
 Absolute stereochemistry.




● HCI

RH 664362-81-0 CAPLUS
 CH 2-Morpholinemetanol, ω -phenyl- ω -[2-[[trifluoromethyl]thio]phenyl]methyl]-, (aR,2S)-, acetate (salt) (PCI) (CA INDEX NAME)

CM 1

CH 64360-30-9
CM C19 R22 F3 N O2 S

Absolute stereochemistry.




CM 2

CH 64-19-7
CM C2 R4 O2



HN 64430-81-2 CAPLUS
CH 2-Morpholinomethyl, 4-phenyl-1,1'-biphenyl-2-ylmethanol, (4S,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.




● HCL

HN 64430-84-3 CAPLUS
CH 2-Morpholinomethyl, 4-phenyl-1,1'-biphenyl-2-ylmethanol, (4S,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



● HCL

HN 64430-89-8 CAPLUS
CH 2-Morpholinomethyl, 4-phenyl-1,1'-biphenyl-2-ylmethanol, (4S,2S)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● HCL

HN 64430-92-1 CAPLUS
CH 2-Morpholinomethyl, 4-phenyl-1,1'-biphenyl-2-ylmethanol, (4S,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.



● HCL

HN 64430-95-4 CAPLUS
CH 2-Morpholinomethyl, 4-phenyl-1,1'-biphenyl-2-ylmethanol, (4S,2S)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● HCL


HN 64430-96-5 CAPLUS
CH 2-Morpholinomethyl, 4-phenyl-1,1'-biphenyl-2-ylmethanol, (4S,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.



● HCL


HN 64430-98-7 CAPLUS
CH 2-Morpholinomethyl, 4-phenyl-1,1'-biphenyl-2-ylmethanol, (4S,2S)- (PCI) (CA INDEX NAME)



● HCL

HN 64430-91-2 CAPLUS
CH 2-Morpholinomethyl, 4-phenyl-1,1'-biphenyl-2-ylmethanol, (4S,2S)- (PCI) (CA INDEX NAME)


Absolute stereochemistry.



● HCL

HN 64430-93-3 CAPLUS
CH 2-Morpholinomethyl, 4-phenyl-1,1'-biphenyl-2-ylmethanol, (4S,2S)- (PCI) (CA INDEX NAME)

Absolute stereochemistry.




● HCL

HN 64430-93-4 CAPLUS

L25 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN 2-Morpholinemetancl, ω -[2,6-dichlorophenyl]methyl]- ω -phenyl-, hydrochloride, (wh,25)- (PC1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-94-5 CAPLUS
 CN 2-Morpholinemetancl, ω -[2,5-dichlorophenyl]methyl]- ω -phenyl-, hydrochloride, (wh,25)- (PC1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-95-6 CAPLUS
 CN 2-Morpholinemetancl, ω -[2,5-difluorophenyl]methyl]- ω -phenyl-, hydrochloride, (wh,25)- (PC1) (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 664361-39-1 CAPLUS
 CN 2-Morpholinemetancl, ω -[5-fluoro-2-methoxyphenyl]methyl]- ω -phenyl-, (wh,25)- (CA INDEX NAME)



RN 664361-40-4 CAPLUS
 CN 2-Morpholinemetancl, ω -[5-fluoro-2-methoxyphenyl]methyl]- ω -phenyl-, (wh,25)- (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L25 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl


RN 664360-96-7 CAPLUS
 CN 2-Morpholinemetancl, ω -[4-fluoro[1,1'-biphenyl]-2-yl]methyl]- ω -phenyl-, hydrochloride, (wh,25)- (PC1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 664361-37-9 CAPLUS
 CN 2-Morpholinemetancl, ω -phenyl- ω -[2-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 664361-38-0 CAPLUS
 CN 2-Morpholinemetancl, ω -phenyl- ω -[2-(trifluoromethoxy)phenyl]methyl]-, (wh,25)- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1985:24500 CAPLUS
 DOCUMENT NUMBER: 102:24500
 ORIGINAL REFERENCE NO.: 102:40514, 4054a
 TITLE: Potential antidepressant agents. ω -Aryloxy-benzyl derivatives of morpholine and morpholine
 Meloni, Piero; Carniel, Giovanni; Della Torre, Arturo; Ronzani, Alberto; Ronzani, Melina; Rossi, Ottavio; Ronzani, Sante; Rossi, Alessandro C.
 Farnitalia C. Ebe S.p.A., Milan, 20159, Italy
 SOURCE: European Journal of Medicinal Chemistry (1984), 19(1), 235-42
 CODEN: EJMC5J; ISSN: 0223-5224
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 102:24500
 CI



AB The title compounds I and II (R = Me, H, Cl, MeO, methylenedioxy; R1 = H, Me, R2 = H, MeO, Cl; R3 = H, Me, MeCO; R4, R5 = H, Me, R6 = H, Me, Me, MeO, etc.; S = O, CMe, MeO) were prepared as antidepressants from phenylacetates III (R7 = R8). Thus, III (R = 2-MeO, R1 = R2 = R3 = R4 = R5 = R6 = R7 = R8) was treated with carbonyldiimidazole and nitromethane sodium salt to give the nitro emolate, which was reduced by H2/PdO2 to give 2 diastereoisomers of I (R = 2-MeO, R1-R5 = H). II (R = 2-EtO, R1 = R2 = R3 = R4 = R5 = R6 = R7 = R8) showed antidepressant activity in the antidepressant test when compared with Imipramine, Desipramine and Viloxazine.
 TY 93852-76-7
 RI: RAC (Biological activity or effector, except adverse); BDU (Biological study, unclassified); THU (Therapeutic use); BGL (Biological study); (Rac)
 (antidepressant activity of)
 RN 93852-76-7 CAPLUS



25 33811-95-TP
 2L1 BAC (Biological activity or effector, except Adverse); RSO
 (Radioisotope)
 at02Z, unclassified); SPM (Synthetic preparation); TSO (Therapeutic use);
 R10L (Radioisotope study); FRIP (Preparation); USES (Uses)
 (Preparation and antidepressant activity of)
 308 33811-95-9 CAPLUS
 CH Morpholine, 2-[1-(2-methoxyphenoxy)-1-phenylethyl]-, hydrochloride (HCl)
 (CA INDEX NAME)



● HCl

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

76.78

1213.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-11.20

-22.40

STN INTERNATIONAL LOGOFF AT 12:23:58 ON 14 FEB 2008